raw_dataset_id
int64 0
15
| answer
stringclasses 103
values | inputs
stringlengths 43
59.7k
| prompt_template
stringclasses 160
values | prompt
stringlengths 46
29.9k
| task
stringclasses 160
values |
|---|---|---|---|---|---|
6 | Yes | {'bill_summary': 'Medicare Negotiation and Competitive Licensing Act of 2019\n\nThis bill requires the Centers for Medicare & Medicaid Services (CMS) to negotiate with pharmaceutical companies regarding prices for drugs covered under the Medicare prescription drug benefit. (Current law prohibits the CMS from doing so.)\n\nThe CMS must take certain factors into account during negotiations, including the clinical- and cost-effectiveness of the drug, the financial burden on patients, and unmet patient needs. If the CMS is unable to negotiate the price of a drug, such drug is subject to competitive licensing in order to further its sale under Medicare, notwithstanding existing government-granted exclusivities.\n\nAdditionally, for one year after a drug is provided under a competitive license, such drug is also subject to specified price limitations; if the drug is not offered at such prices, the drug is\xa0subject to additional licensing that furthers its sale under any federal program (e.g., Medicaid).', 'bill_title': 'To amend title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate prices of prescription drugs furnished under part D of the Medicare program.', 'company_description': 'Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to research, develop and commercialize, both with partners and on its own, pharmaceutical products that are designed to address unmet medical needs of patients in major therapeutic areas. Alkermes has a diversified portfolio of marketed drug products and a clinical pipeline of products that address central nervous system ("CNS") disorders such as schizophrenia, depression, addiction and multiple sclerosis ("MS"). Headquartered in Dublin, Ireland, Alkermes has a research and development ("R & D") center in Waltham, Massachusetts; an R & D and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. The key marketed products discussed below are expected to generate significant revenues for us. None Commercialized by Alkermes in the U.S. Alcohol dependence and Opioid dependence Russia and Commonwealth of Independent States ("CIS") 5 Summary information regarding products that use our proprietary technologies: Product Indication(s) Treatment to improve walking in patients with MS, as demonstrated by an increase in walking speed We develop and commercialize products designed to address the unmet needs of patients suffering from addiction and schizophrenia. ARISTADA ARISTADA (aripiprazole lauroxil) is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia. ARISTADA is the first of our products to utilize our proprietary LinkeRx technology. ARISTADA is a prodrug; once in the body, ARISTADA is likely converted by enzyme-mediated hydrolysis to N-hydroxymethyl aripiprazole, which is then hydrolyzed to aripiprazole. ARISTADA is the first atypical antipsychotic with once-monthly, once-every-six-weeks and once-every-two-months dosing options to deliver and maintain therapeutic levels of medication in the body. ARISTADA has four dosing options (441 mg, 662 mg, 882 mg and 1064 mg) and is packaged in a ready-to-use, pre-filled product format. ARISTADA 1064 mg, our two-month dosing option, was approved by the U.S. Food and Drug Administration (the "FDA") in June 2017. We developed ARISTADA and manufacture and commercialize it in the U.S. Schizophrenia is a chronic, severe and disabling brain disorder. The disease is marked by positive symptoms (hallucinations and delusions) and negative symptoms (depression, blunted emotions and social withdrawal), as well as by disorganized thinking. An estimated 2.4 million Americans over the age of 18 have schizophrenia in a given year, with men and women affected equally. Worldwide, it is estimated that one person in every 100 develops schizophrenia. Studies have demonstrated that as many as 75% of patients with schizophrenia have difficulty taking their oral medication on a regular basis, which can lead to worsening of symptoms. VIVITROL VIVITROL (naltrexone for extended-release injectable suspension) is a once-monthly, non-narcotic, injectable medication approved in the U.S., Russia and certain countries of the CIS for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. VIVITROL uses our polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through one intramuscular injection every four weeks. We developed and exclusively manufacture VIVITROL. What are opioid dependence and alcohol dependence? Opioid dependence is a serious and chronic brain disease characterized by compulsive, prolonged self-administration of opioid substances that are not used for a medical purpose.', 'company_name': 'Alkermes Plc', 'index': '6'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: To amend title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate prices of prescription drugs furnished under part D of the Medicare program.
Official summary of bill: Medicare Negotiation and Competitive Licensing Act of 2019
Additionally, for one year after a drug is provided under a competitive license, such drug is also subject to specified price limitations; if the drug is not offered at such prices, the drug is subject to additional licensing that furthers its sale under any federal program (e.g., Medicaid).
Company name: Alkermes Plc
Company business description: Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to research, develop and commercialize, both with partners and on its own, pharmaceutical products that are designed to address unmet medical needs of patients in major therapeutic areas. Alkermes has a diversified portfolio of marketed drug products and a clinical pipeline of products that address central nervous system ("CNS") disorders such as schizophrenia, depression, addiction and multiple sclerosis ("MS"). Headquartered in Dublin, Ireland, Alkermes has a research and development ("R & D") center in Waltham, Massachusetts; an R & D and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. The key marketed products discussed below are expected to generate significant revenues for us. None Commercialized by Alkermes in the U.S. Alcohol dependence and Opioid dependence Russia and Commonwealth of Independent States ("CIS") 5 Summary information regarding products that use our proprietary technologies: Product Indication(s) Treatment to improve walking in patients with MS, as demonstrated by an increase in walking speed We develop and commercialize products designed to address the unmet needs of patients suffering from addiction and schizophrenia. ARISTADA ARISTADA (aripiprazole lauroxil) is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia. ARISTADA is the first of our products to utilize our proprietary LinkeRx technology. ARISTADA is a prodrug; once in the body, ARISTADA is likely converted by enzyme-mediated hydrolysis to N-hydroxymethyl aripiprazole, which is then hydrolyzed to aripiprazole. ARISTADA is the first atypical antipsychotic with once-monthly, once-every-six-weeks and once-every-two-months dosing options to deliver and maintain therapeutic levels of medication in the body. ARISTADA has four dosing options (441 mg, 662 mg, 882 mg and 1064 mg) and is packaged in a ready-to-use, pre-filled product format. ARISTADA 1064 mg, our two-month dosing option, was approved by the U.S. Food and Drug Administration (the "FDA") in June 2017. We developed ARISTADA and manufacture and commercialize it in the U.S. Schizophrenia is a chronic, severe and disabling brain disorder. The disease is marked by positive symptoms (hallucinations and delusions) and negative symptoms (depression, blunted emotions and social withdrawal), as well as by disorganized thinking. An estimated 2.4 million Americans over the age of 18 have schizophrenia in a given year, with men and women affected equally. Worldwide, it is estimated that one person in every 100 develops schizophrenia. Studies have demonstrated that as many as 75% of patients with schizophrenia have difficulty taking their oral medication on a regular basis, which can lead to worsening of symptoms. VIVITROL VIVITROL (naltrexone for extended-release injectable suspension) is a once-monthly, non-narcotic, injectable medication approved in the U.S., Russia and certain countries of the CIS for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. VIVITROL uses our polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through one intramuscular injection every four weeks. We developed and exclusively manufacture VIVITROL. What are opioid dependence and alcohol dependence? Opioid dependence is a serious and chronic brain disease characterized by compulsive, prolonged self-administration of opioid substances that are not used for a medical purpose.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
3 | No | {'bill_summary': 'Advancing Human Spaceflight Act\n\nThis bill addresses the establishment of U.S. policy, programs, and activities pertaining to human presence in space.\n\nThe bill declares that it is U.S. policy to permanently establish a human presence in low-Earth orbit and that such capability shall\n\n maintain U.S. global leadership and relations with partners and allies, contribute to the general welfare of the United States, and be affordable so as to not preclude a robust portfolio of other human space exploration activities. The National Aeronautics and Space Administration (NASA) shall ensure that the International Space Station (ISS) remains a viable and productive facility capable of potential U.S. use through at least FY2030.\n\nNASA must submit a strategy that includes how it will transition to a successor platform to the ISS.\n\nThe bill expands the objectives of NASA to include the expansion of permanent human presence beyond Earth in a way that enables human space settlement and a thriving space economy.\n\nNASA shall establish a program of developing space suits and associated technologies.', 'bill_title': 'A bill to extend the commitment of the United States to the International Space Station, to develop advanced space suits, and to enable human space settlement, and for other purposes.', 'company_description': 'Our mission is to improve lives by eliminating the back row in higher education. We are a global leader in education technology. For more than a decade, we have been improving lives by powering world-class digital education. As a trusted partner and brand steward of great universities, we build, deliver, and support online graduate programs and certificates for working adults. Our industry-leading short courses, offered by GetSmarter, are designed to equip life-long learners with in-demand career skills. Over the past decade, we have developed new and innovative tools within our platform to enhance the effectiveness of instructional methods and improve student outcomes and the student experience. During that time, we have also improved our data-driven digital marketing capabilities across our ecosystem of offerings to generate increased student enrollments in a cost effective manner. As a result, demand for our comprehensive platform of integrated technology and services has increased significantly. When 2U was formed in 2008, we had one university client and one 2U-powered graduate program. Today, our university client base has grown to 35, our platform powers 49 graduate programs and over 90 short courses, and from inception to date we have enrolled over 44,000 students in 2U-powered graduate programs and over 86,000 students in our short courses. Our core strategy is to launch graduate programs and short courses with new and existing university clients, to increase student enrollments and graduations across our portfolio of offerings and to expand our non-degree offerings across the career curriculum continuum. We are also committed to continuously improving our platform to deliver high-quality university and student experiences and outcomes at scale. In our Short Course Segment, we target working professionals seeking career advancement through skills attainment. Our Graduate Program Segment derives revenue primarily from a contractually specified percentage of the amounts our university clients receive from their students in the 2U-enabled graduate program for tuition and fees, less credit card fees and other specified charges we have agreed to exclude in certain of our universicty client contracts. The Short Course Segment derives revenue directly from students for the tuition and fees paid to enroll in and progress through our short courses. We share a contractually specified percentage of the tuition and fees received from students in each course with the relevant university client. Our platform, which we refer to as the 2U Operating System, or 2UOS, consists of a seamlessly integrated ecosystem of technology, people and data. Through 2UOS, we provide our university clients with front-end and back-end cloud-based SaaS technology and technology-enabled services. These two components are tightly integrated and optimized with data analysis and machine learning techniques. 2UOS delivers technology with a human touch and is the keystone of our commitment to provide our university clients the tools they need to lead the digital transformation in education. 2UOS provides the following front-end technology and services to students enrolled in our offerings and to faculty members and university administrators supporting our offerings: Our online learning platform is a cohesive end-to-end learning and teaching platform, where our university clients can reliably deliver their high-quality educational content to students. For our Graduate Program Segment, our online learning platform replicates an intimate and live classroom environment and is accessible through proprietary web, mobile and TV applications as well as in an offline mode for convenient consumption of asynchronous coursework. With the recent integration of stem-based education tools and collaborative annotation technology and an improved data-driven user experience, we have significantly enhanced the learning experience for students in 2U-powered graduate programs and instruction capabilities for faculty. Our short course offerings are delivered through a separate proprietary learning platform that shares many of the core features of our Graduate Program Segment learning platform, with some exceptions, such as the enhanced features that facilitate the live classroom environment in our graduate program leaning platform. ', 'company_name': '2U, Inc.', 'index': '3'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: A bill to extend the commitment of the United States to the International Space Station, to develop advanced space suits, and to enable human space settlement, and for other purposes.
Official summary of bill: Advancing Human Spaceflight Act
NASA shall establish a program of developing space suits and associated technologies.
Company name: 2U, Inc.
Company business description: Our mission is to improve lives by eliminating the back row in higher education. We are a global leader in education technology. For more than a decade, we have been improving lives by powering world-class digital education. As a trusted partner and brand steward of great universities, we build, deliver, and support online graduate programs and certificates for working adults. Our industry-leading short courses, offered by GetSmarter, are designed to equip life-long learners with in-demand career skills. Over the past decade, we have developed new and innovative tools within our platform to enhance the effectiveness of instructional methods and improve student outcomes and the student experience. During that time, we have also improved our data-driven digital marketing capabilities across our ecosystem of offerings to generate increased student enrollments in a cost effective manner. As a result, demand for our comprehensive platform of integrated technology and services has increased significantly. When 2U was formed in 2008, we had one university client and one 2U-powered graduate program. Today, our university client base has grown to 35, our platform powers 49 graduate programs and over 90 short courses, and from inception to date we have enrolled over 44,000 students in 2U-powered graduate programs and over 86,000 students in our short courses. Our core strategy is to launch graduate programs and short courses with new and existing university clients, to increase student enrollments and graduations across our portfolio of offerings and to expand our non-degree offerings across the career curriculum continuum. We are also committed to continuously improving our platform to deliver high-quality university and student experiences and outcomes at scale. In our Short Course Segment, we target working professionals seeking career advancement through skills attainment. Our Graduate Program Segment derives revenue primarily from a contractually specified percentage of the amounts our university clients receive from their students in the 2U-enabled graduate program for tuition and fees, less credit card fees and other specified charges we have agreed to exclude in certain of our universicty client contracts. The Short Course Segment derives revenue directly from students for the tuition and fees paid to enroll in and progress through our short courses. We share a contractually specified percentage of the tuition and fees received from students in each course with the relevant university client. Our platform, which we refer to as the 2U Operating System, or 2UOS, consists of a seamlessly integrated ecosystem of technology, people and data. Through 2UOS, we provide our university clients with front-end and back-end cloud-based SaaS technology and technology-enabled services. These two components are tightly integrated and optimized with data analysis and machine learning techniques. 2UOS delivers technology with a human touch and is the keystone of our commitment to provide our university clients the tools they need to lead the digital transformation in education. 2UOS provides the following front-end technology and services to students enrolled in our offerings and to faculty members and university administrators supporting our offerings: Our online learning platform is a cohesive end-to-end learning and teaching platform, where our university clients can reliably deliver their high-quality educational content to students. For our Graduate Program Segment, our online learning platform replicates an intimate and live classroom environment and is accessible through proprietary web, mobile and TV applications as well as in an offline mode for convenient consumption of asynchronous coursework. With the recent integration of stem-based education tools and collaborative annotation technology and an improved data-driven user experience, we have significantly enhanced the learning experience for students in 2U-powered graduate programs and instruction capabilities for faculty. Our short course offerings are delivered through a separate proprietary learning platform that shares many of the core features of our Graduate Program Segment learning platform, with some exceptions, such as the enhanced features that facilitate the live classroom environment in our graduate program leaning platform.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
12 | No | {'bill_summary': " This bill requires federal courts to make remote access to certain criminal court proceedings available for victims of the bombing of Pan American Flight 103 over Lockerbie, Scotland, on December 21, 1988.\n\nSpecifically, federal courts must make remote access available to the proceedings in the criminal case against Abu Agila Mohammed Mas'ud Kheir Al-Marimi and against any co-conspirator subsequently charged and prosecuted in federal court for crimes related to the bombing of Pan American Flight 103.", 'bill_title': ' S.3250 - A bill to provide remote access to court proceedings for victims of the 1988 Bombing of Pan Am Flight 103 over Lockerbie, Scotland.', 'company_description': ' \nFeeding America’s story began in the late 1960s when a mother visiting a local meal program suggested there should be a place where food could be stored for people to pick up rather than being thrown away. With that, food banking was born.\n\nSince then, Feeding America has become the leading voice on ending hunger in America.\n\n \nToday, we’re part of a nationwide network that includes food banks, food pantries, and local meal programs. \n\nWe’re committed to listening to the tens of millions of people who experience food insecurity and working together to help the communities most impacted by hunger get the food and resources they need to thrive. We advocate for policies that address the root causes of hunger and continue to innovate solutions that increase equitable access to nutritious food.', 'company_name': ' Feeding America', 'index': 13} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: S.3250 - A bill to provide remote access to court proceedings for victims of the 1988 Bombing of Pan Am Flight 103 over Lockerbie, Scotland.
Official summary of bill: This bill requires federal courts to make remote access to certain criminal court proceedings available for victims of the bombing of Pan American Flight 103 over Lockerbie, Scotland, on December 21, 1988.
We’re committed to listening to the tens of millions of people who experience food insecurity and working together to help the communities most impacted by hunger get the food and resources they need to thrive. We advocate for policies that address the root causes of hunger and continue to innovate solutions that increase equitable access to nutritious food.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
10 | Yes | {'bill_summary': '\nThis bill provides FY2024 supplemental appropriations for federal departments and agencies to respond to the conflict in Ukraine. The bill designates the funding as emergency spending, which is exempt from discretionary spending limits.\n\nSpecifically, the bill provides appropriations to the\n\nDepartment of Defense (DOD),\nDepartment of Energy science programs,\nthe National Nuclear Security Administration,\nthe Administration for Children and Families,\nthe Department of State, and\nthe U.S. Agency for International Development.\nThe funding is provided for purposes such as\n\nsupporting current U.S. military operations in the region,\nthe Ukraine Security Assistance Initiative,\nreplacing defense articles that were provided to Ukraine,\nreimbursing DOD for defense services and training provided to Ukraine,\nthe Foreign Military Financing Program,\neconomic support for Ukraine,\nrefugee and entrant assistance,\ninternational narcotics control and law enforcement, and\nthe development and production of isotopes.\nThe bill also includes provisions that\n\nexpand the authorities of the President to transfer defense articles and services from DOD to foreign countries or international organizations,\nrequire the President to transfer long-range Army Tactical Missile Systems to Ukraine,\nrequire the President to enter into an agreement with Ukraine regarding repaying the United States for the economic assistance it has provided to Ukraine,\nrequire certain funds that are provided for Ukraine to be matched by other donors, and\nestablish various oversight and reporting requirements for assistance provided to Ukraine.\n', 'bill_title': 'H.R.8035 - Ukraine Security Supplemental Appropriations Act, 2024. A bill for making emergency supplemental appropriations to respond to the situation in Ukraine and for related expenses for the fiscal year ending September 30, 2024, and for other purposes.', 'company_description': 'U.S. Bancorp, with more than 70,000 employees and $663 billion in assets as of December 31, 2023, is the\nparent company of U.S. Bank National Association. Headquartered in Minneapolis, the company serves millions\nof customers locally, nationally and globally through a diversified mix of businesses including consumer banking,\nbusiness banking, commercial banking, institutional banking, payments and wealth management. U.S. Bancorp\nhas been recognized for its approach to digital innovation, community partnerships and customer service,\nincluding being named one of the 2023 World’s Most Ethical Companies and Fortune’s most admired superregional\nbank. ', 'company_name': 'U.S. Bancorp ', 'index': 10} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: H.R.8035 - Ukraine Security Supplemental Appropriations Act, 2024. A bill for making emergency supplemental appropriations to respond to the situation in Ukraine and for related expenses for the fiscal year ending September 30, 2024, and for other purposes.
Official summary of bill:
This bill provides FY2024 supplemental appropriations for federal departments and agencies to respond to the conflict in Ukraine. The bill designates the funding as emergency spending, which is exempt from discretionary spending limits.
Company name: U.S. Bancorp
Company business description: U.S. Bancorp, with more than 70,000 employees and $663 billion in assets as of December 31, 2023, is the
parent company of U.S. Bank National Association. Headquartered in Minneapolis, the company serves millions
of customers locally, nationally and globally through a diversified mix of businesses including consumer banking,
business banking, commercial banking, institutional banking, payments and wealth management. U.S. Bancorp
has been recognized for its approach to digital innovation, community partnerships and customer service,
including being named one of the 2023 World’s Most Ethical Companies and Fortune’s most admired superregional
bank.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
7 | No | {'bill_summary': 'Disability Integration Act of 2019\n\nThis bill prohibits government entities and insurance providers from denying community-based services to individuals with disabilities that require long-term service or support that would enable such individuals to live in the community and lead an independent life.\n\nSpecifically, these entities may not discriminate against such individuals in the provision of community-based services by such actions as imposing prohibited eligibility criteria, cost caps, or waiting lists or failing to provide a specific community-based service. Additionally, community-based services must be offered to individuals with such disabilities prior to institutionalization. Institutionalized individuals must be notified regularly of community-based alternatives.\n\nThe bill requires the Department of Justice and the Department of Health and Human Services (HHS) to issue regulations requiring government entities and insurance providers to offer community-based long-term services to individuals with such disabilities who would otherwise qualify for institutional placement. Government entities must ensure sufficient availability of affordable, accessible, and integrated housing that is not a disability-specific residential setting or a setting where services are tied to tenancy.\n\nRegulations shall also (1) require government entities and insurance providers to perform self-evaluation on current services, policies, and practices and concerning compliance with requirements of this bill; and (2) require government entities to submit a transition plan. HHS must determine annually whether each government entity is complying with the transition plan and must increase funding for those in compliance.\n\nThe bill allows civil actions by individuals subjected to, or about to be subjected to, a violation of its requirements.', 'bill_title': 'To prohibit discrimination against individuals with disabilities who need long-term services and supports, and for other purposes.', 'company_description': 'We are a leading manufacturer, marketer and distributor of high-quality, branded food products in North America, with annual net sales of approximately $3.1 billion in fiscal 2017. Our brand portfolio enjoys strong household penetration in the United States ("U.S."), where our products can be found in over 85% of U.S. households. Our products are sold through supermarkets, grocery wholesalers and distributors, mass merchandisers, super centers, convenience stores, dollar stores, natural and organic food stores, drug stores, e-commerce websites and warehouse clubs in the United States and Canada, as well as in military channels and foodservice locations. Pinnacle Foods Inc. is a holding company whose sole asset is 100% ownership of Peak Finance Holdings LLC ("PFH"). PFH is a holding company whose sole asset is 100% ownership of Pinnacle Foods Finance LLC. The Company\'s business is organized into the following four reportable segments: The Frozen segment, The Grocery segment, The Boulder segment and The Specialty segment Frozen Segment Birds Eye is the largest brand in the $3.3 billion frozen vegetables category, with a 31.9% market share. Government programs, such as the USDA\'s My Plate program, and nutrition and health professionals continue to identify increased vegetable consumption as a key to better health. We believe that enhancing the taste of vegetables and making them exceptionally convenient are keys to driving more vegetable consumption. Birds Eye has taken a leadership role in increasing vegetable consumption, including encouraging children to eat more vegetables. We are supporters of the USDA\'s My Plate program and have engaged in breakthrough marketing efforts with major multi-media family entertainment partners to encourage children to eat more vegetables. We also compete in the frozen complete bagged meals category with our Birds Eye Voila! frozen bagged meals provide consumers with a high quality complete meal, including protein, starch, and vegetables, that can be prepared in a skillet in just minutes. Our Frozen segment also includes Hungry-Man frozen entrées, Van de Kamp\'s and frozen prepared seafood, Lender\'s frozen and refrigerated bagels and Celeste frozen pizza. Grocery Segment Included in the Grocery segment is our Duncan Hines portfolio, which includes cake mixes, ready-to-serve frostings, brownie mixes, and cookie mixes. In addition to our traditional cake mix offerings, our cake mix portfolio also includes premium offerings under the Duncan Hines Decadent and Duncan Hines Perfect Size brands. Duncan Hines is the #2 brand with a 28.9% market share in the $1.1 billion cake/brownie mix and frostings We compete in the shelf-stable salad dressings category with our Wish-Bone and Western brands, including our Wish-Bone E.V.O.O., Wish-Bone Ristorante Italiano and Wish-Bone Avocado Oil lines. We hold the #4 position in the $2.0 billion salad dressings category, with a combined share of 11.0%, and Wish-Bone holds the #1 position in the branded Italian segment of the category. Our Grocery segment also includes Armour, Nalley and Brooks canned meat, Mrs. Butterworth\'s and Log Cabin table syrups, Smart Balance premium margarine/spread, Comstock and Wilderness pie and pastry fruit fillings and Open Pit barbecue sauce. The Grocery segment also includes a diversified portfolio of shelf-stable and refrigerated products including a complete line of shelf-stable pickle products, primarily under the nationally-distributed Vlasic brand, and the regional brands under the Milwaukee\'s and Wiejske Wyroby brands. Our Vlasic brand, represented by its trademark Vlasic stork, has the highest consumer awareness and quality ratings in the pickle category. Vlasic is the #1 brand in the $790 million shelf-stable pickle category and Pinnacle pickle brands collectively hold a 34.3% market share. We offer a portfolio of gluten-free products under the ', 'company_name': 'Pinnacle Foods, Inc.', 'index': '7'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: To prohibit discrimination against individuals with disabilities who need long-term services and supports, and for other purposes.
Official summary of bill: Disability Integration Act of 2019
The bill allows civil actions by individuals subjected to, or about to be subjected to, a violation of its requirements.
Company name: Pinnacle Foods, Inc.
Company business description: We are a leading manufacturer, marketer and distributor of high-quality, branded food products in North America, with annual net sales of approximately $3.1 billion in fiscal 2017. Our brand portfolio enjoys strong household penetration in the United States ("U.S."), where our products can be found in over 85% of U.S. households. Our products are sold through supermarkets, grocery wholesalers and distributors, mass merchandisers, super centers, convenience stores, dollar stores, natural and organic food stores, drug stores, e-commerce websites and warehouse clubs in the United States and Canada, as well as in military channels and foodservice locations. Pinnacle Foods Inc. is a holding company whose sole asset is 100% ownership of Peak Finance Holdings LLC ("PFH"). PFH is a holding company whose sole asset is 100% ownership of Pinnacle Foods Finance LLC. The Company's business is organized into the following four reportable segments: The Frozen segment, The Grocery segment, The Boulder segment and The Specialty segment Frozen Segment Birds Eye is the largest brand in the $3.3 billion frozen vegetables category, with a 31.9% market share. Government programs, such as the USDA's My Plate program, and nutrition and health professionals continue to identify increased vegetable consumption as a key to better health. We believe that enhancing the taste of vegetables and making them exceptionally convenient are keys to driving more vegetable consumption. Birds Eye has taken a leadership role in increasing vegetable consumption, including encouraging children to eat more vegetables. We are supporters of the USDA's My Plate program and have engaged in breakthrough marketing efforts with major multi-media family entertainment partners to encourage children to eat more vegetables. We also compete in the frozen complete bagged meals category with our Birds Eye Voila! frozen bagged meals provide consumers with a high quality complete meal, including protein, starch, and vegetables, that can be prepared in a skillet in just minutes. Our Frozen segment also includes Hungry-Man frozen entrées, Van de Kamp's and frozen prepared seafood, Lender's frozen and refrigerated bagels and Celeste frozen pizza. Grocery Segment Included in the Grocery segment is our Duncan Hines portfolio, which includes cake mixes, ready-to-serve frostings, brownie mixes, and cookie mixes. In addition to our traditional cake mix offerings, our cake mix portfolio also includes premium offerings under the Duncan Hines Decadent and Duncan Hines Perfect Size brands. Duncan Hines is the #2 brand with a 28.9% market share in the $1.1 billion cake/brownie mix and frostings We compete in the shelf-stable salad dressings category with our Wish-Bone and Western brands, including our Wish-Bone E.V.O.O., Wish-Bone Ristorante Italiano and Wish-Bone Avocado Oil lines. We hold the #4 position in the $2.0 billion salad dressings category, with a combined share of 11.0%, and Wish-Bone holds the #1 position in the branded Italian segment of the category. Our Grocery segment also includes Armour, Nalley and Brooks canned meat, Mrs. Butterworth's and Log Cabin table syrups, Smart Balance premium margarine/spread, Comstock and Wilderness pie and pastry fruit fillings and Open Pit barbecue sauce. The Grocery segment also includes a diversified portfolio of shelf-stable and refrigerated products including a complete line of shelf-stable pickle products, primarily under the nationally-distributed Vlasic brand, and the regional brands under the Milwaukee's and Wiejske Wyroby brands. Our Vlasic brand, represented by its trademark Vlasic stork, has the highest consumer awareness and quality ratings in the pickle category. Vlasic is the #1 brand in the $790 million shelf-stable pickle category and Pinnacle pickle brands collectively hold a 34.3% market share. We offer a portfolio of gluten-free products under the
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
12 | No | {'bill_summary': " This bill requires federal courts to make remote access to certain criminal court proceedings available for victims of the bombing of Pan American Flight 103 over Lockerbie, Scotland, on December 21, 1988.\n\nSpecifically, federal courts must make remote access available to the proceedings in the criminal case against Abu Agila Mohammed Mas'ud Kheir Al-Marimi and against any co-conspirator subsequently charged and prosecuted in federal court for crimes related to the bombing of Pan American Flight 103.", 'bill_title': ' S.3250 - A bill to provide remote access to court proceedings for victims of the 1988 Bombing of Pan Am Flight 103 over Lockerbie, Scotland.', 'company_description': ' \nFeeding America’s story began in the late 1960s when a mother visiting a local meal program suggested there should be a place where food could be stored for people to pick up rather than being thrown away. With that, food banking was born.\n\nSince then, Feeding America has become the leading voice on ending hunger in America.\n\n \nToday, we’re part of a nationwide network that includes food banks, food pantries, and local meal programs. \n\nWe’re committed to listening to the tens of millions of people who experience food insecurity and working together to help the communities most impacted by hunger get the food and resources they need to thrive. We advocate for policies that address the root causes of hunger and continue to innovate solutions that increase equitable access to nutritious food.', 'company_name': ' Feeding America', 'index': 13} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: S.3250 - A bill to provide remote access to court proceedings for victims of the 1988 Bombing of Pan Am Flight 103 over Lockerbie, Scotland.
Official summary of bill: This bill requires federal courts to make remote access to certain criminal court proceedings available for victims of the bombing of Pan American Flight 103 over Lockerbie, Scotland, on December 21, 1988.
We’re committed to listening to the tens of millions of people who experience food insecurity and working together to help the communities most impacted by hunger get the food and resources they need to thrive. We advocate for policies that address the root causes of hunger and continue to innovate solutions that increase equitable access to nutritious food.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
4 | No | {'bill_summary': 'Federal Register Modernization Act\n\nThis bill revises provisions regarding the Federal Register or the Code of Federal Regulations, including to replace requirements that the documents be printed with requirements that the documents be published.\n\nThe bill provides that in a continuity of operations event in which the Government Publishing Office (GPO) does not fulfill its publication requirements, the Office of the Federal Register may establish a website to publish the Federal Register until such time that GPO resumes publication.', 'bill_title': 'A bill to amend title 44, United States Code, to modernize the Federal Register, and for other purposes.', 'company_description': '"us" or the "Parent Company") is a leading provider of financial products to middle-income households in the United States and Canada with 130,736 licensed sales representatives as of December 31, 2018. This network of independent contractor sales representatives ("sales representatives" or "sales force") assists our clients in meeting their needs for term life insurance, which we underwrite, and mutual funds, annuities, managed investments and other financial products, which we distribute primarily on behalf of third parties. Licensed sales representatives primarily use our proprietary financial needs analysis tool ("FNA") and an educational approach to demonstrate how our product offerings can assist clients to provide financial protection for their families, save for their retirement and other needs, and manage their debt. Typically, our clients are the friends, family members and personal acquaintances of sales representatives. We provide an entrepreneurial business opportunity for individuals to distribute financial products. Low entry fees as well as the ability to select their own schedules and time commitments allow sales representatives to supplement their income by starting their own independent businesses without leaving their current jobs. Our unique compensation structure, technology, sales support and back-office processing are designed to enable sales representatives to successfully grow their independent businesses. We believe there is significant opportunity to meet the increasing array of financial services needs of our clients. We intend to leverage the sales force to meet such client needs, which will drive long-term value for all of our stakeholders. • Broadening and strengthening our protection product portfolio; • Providing offerings that enhance our Investment and Savings Products ("ISP") business; and • Developing digital capabilities to deepen our client relationships. Primerica Life Insurance Company ("Primerica Life"), our principal life insurance underwriting company; and • ("PFS Investments"), our investment and savings products company, broker-dealer and registered investment advisor. Primerica Life is domiciled in Tennessee, and its wholly owned subsidiary, National Benefit Life Insurance Company ("NBLIC"), is a New York-domiciled life insurance underwriting company. Primerica Life Insurance Company of Canada ("Primerica Life Canada"), our Canadian life insurance underwriting company; • ("PFSL Investments Canada"), our Canadian licensed mutual fund dealer; and • ("PFSL Fund Management"), our Canadian investment funds manager. Our clients are generally middle-income consumers, which we define as households with $30,000 to $100,000 of annual income. According to the 2017 U.S. Census Bureau Current Population Survey, the latest period for which data is available, almost 50% of U.S. households fall in this range. Many have inadequate or no life insurance coverage. Individual life insurance sales in the United States declined from 12.5 million policy sales in 1975 to 9.8 million policy sales in 2017, the latest period for which data is available, according to the Life Insurance Marketing and Research Association International, Inc. ("LIMRA"), a worldwide association of insurance and financial services companies. We believe that term life insurance, which we have provided to middle-income clients for many years, is generally the best option for them to meet their life insurance needs. Many need help saving for retirement and other personal goals.', 'company_name': 'Primerica, Inc.', 'index': '4'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: A bill to amend title 44, United States Code, to modernize the Federal Register, and for other purposes.
Official summary of bill: Federal Register Modernization Act
The bill provides that in a continuity of operations event in which the Government Publishing Office (GPO) does not fulfill its publication requirements, the Office of the Federal Register may establish a website to publish the Federal Register until such time that GPO resumes publication.
Company name: Primerica, Inc.
Company business description: "us" or the "Parent Company") is a leading provider of financial products to middle-income households in the United States and Canada with 130,736 licensed sales representatives as of December 31, 2018. This network of independent contractor sales representatives ("sales representatives" or "sales force") assists our clients in meeting their needs for term life insurance, which we underwrite, and mutual funds, annuities, managed investments and other financial products, which we distribute primarily on behalf of third parties. Licensed sales representatives primarily use our proprietary financial needs analysis tool ("FNA") and an educational approach to demonstrate how our product offerings can assist clients to provide financial protection for their families, save for their retirement and other needs, and manage their debt. Typically, our clients are the friends, family members and personal acquaintances of sales representatives. We provide an entrepreneurial business opportunity for individuals to distribute financial products. Low entry fees as well as the ability to select their own schedules and time commitments allow sales representatives to supplement their income by starting their own independent businesses without leaving their current jobs. Our unique compensation structure, technology, sales support and back-office processing are designed to enable sales representatives to successfully grow their independent businesses. We believe there is significant opportunity to meet the increasing array of financial services needs of our clients. We intend to leverage the sales force to meet such client needs, which will drive long-term value for all of our stakeholders. • Broadening and strengthening our protection product portfolio; • Providing offerings that enhance our Investment and Savings Products ("ISP") business; and • Developing digital capabilities to deepen our client relationships. Primerica Life Insurance Company ("Primerica Life"), our principal life insurance underwriting company; and • ("PFS Investments"), our investment and savings products company, broker-dealer and registered investment advisor. Primerica Life is domiciled in Tennessee, and its wholly owned subsidiary, National Benefit Life Insurance Company ("NBLIC"), is a New York-domiciled life insurance underwriting company. Primerica Life Insurance Company of Canada ("Primerica Life Canada"), our Canadian life insurance underwriting company; • ("PFSL Investments Canada"), our Canadian licensed mutual fund dealer; and • ("PFSL Fund Management"), our Canadian investment funds manager. Our clients are generally middle-income consumers, which we define as households with $30,000 to $100,000 of annual income. According to the 2017 U.S. Census Bureau Current Population Survey, the latest period for which data is available, almost 50% of U.S. households fall in this range. Many have inadequate or no life insurance coverage. Individual life insurance sales in the United States declined from 12.5 million policy sales in 1975 to 9.8 million policy sales in 2017, the latest period for which data is available, according to the Life Insurance Marketing and Research Association International, Inc. ("LIMRA"), a worldwide association of insurance and financial services companies. We believe that term life insurance, which we have provided to middle-income clients for many years, is generally the best option for them to meet their life insurance needs. Many need help saving for retirement and other personal goals.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
6 | Yes | {'bill_summary': 'Medicare Negotiation and Competitive Licensing Act of 2019\n\nThis bill requires the Centers for Medicare & Medicaid Services (CMS) to negotiate with pharmaceutical companies regarding prices for drugs covered under the Medicare prescription drug benefit. (Current law prohibits the CMS from doing so.)\n\nThe CMS must take certain factors into account during negotiations, including the clinical- and cost-effectiveness of the drug, the financial burden on patients, and unmet patient needs. If the CMS is unable to negotiate the price of a drug, such drug is subject to competitive licensing in order to further its sale under Medicare, notwithstanding existing government-granted exclusivities.\n\nAdditionally, for one year after a drug is provided under a competitive license, such drug is also subject to specified price limitations; if the drug is not offered at such prices, the drug is\xa0subject to additional licensing that furthers its sale under any federal program (e.g., Medicaid).', 'bill_title': 'To amend title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate prices of prescription drugs furnished under part D of the Medicare program.', 'company_description': 'Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to research, develop and commercialize, both with partners and on its own, pharmaceutical products that are designed to address unmet medical needs of patients in major therapeutic areas. Alkermes has a diversified portfolio of marketed drug products and a clinical pipeline of products that address central nervous system ("CNS") disorders such as schizophrenia, depression, addiction and multiple sclerosis ("MS"). Headquartered in Dublin, Ireland, Alkermes has a research and development ("R & D") center in Waltham, Massachusetts; an R & D and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. The key marketed products discussed below are expected to generate significant revenues for us. None Commercialized by Alkermes in the U.S. Alcohol dependence and Opioid dependence Russia and Commonwealth of Independent States ("CIS") 5 Summary information regarding products that use our proprietary technologies: Product Indication(s) Treatment to improve walking in patients with MS, as demonstrated by an increase in walking speed We develop and commercialize products designed to address the unmet needs of patients suffering from addiction and schizophrenia. ARISTADA ARISTADA (aripiprazole lauroxil) is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia. ARISTADA is the first of our products to utilize our proprietary LinkeRx technology. ARISTADA is a prodrug; once in the body, ARISTADA is likely converted by enzyme-mediated hydrolysis to N-hydroxymethyl aripiprazole, which is then hydrolyzed to aripiprazole. ARISTADA is the first atypical antipsychotic with once-monthly, once-every-six-weeks and once-every-two-months dosing options to deliver and maintain therapeutic levels of medication in the body. ARISTADA has four dosing options (441 mg, 662 mg, 882 mg and 1064 mg) and is packaged in a ready-to-use, pre-filled product format. ARISTADA 1064 mg, our two-month dosing option, was approved by the U.S. Food and Drug Administration (the "FDA") in June 2017. We developed ARISTADA and manufacture and commercialize it in the U.S. Schizophrenia is a chronic, severe and disabling brain disorder. The disease is marked by positive symptoms (hallucinations and delusions) and negative symptoms (depression, blunted emotions and social withdrawal), as well as by disorganized thinking. An estimated 2.4 million Americans over the age of 18 have schizophrenia in a given year, with men and women affected equally. Worldwide, it is estimated that one person in every 100 develops schizophrenia. Studies have demonstrated that as many as 75% of patients with schizophrenia have difficulty taking their oral medication on a regular basis, which can lead to worsening of symptoms. VIVITROL VIVITROL (naltrexone for extended-release injectable suspension) is a once-monthly, non-narcotic, injectable medication approved in the U.S., Russia and certain countries of the CIS for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. VIVITROL uses our polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through one intramuscular injection every four weeks. We developed and exclusively manufacture VIVITROL. What are opioid dependence and alcohol dependence? Opioid dependence is a serious and chronic brain disease characterized by compulsive, prolonged self-administration of opioid substances that are not used for a medical purpose.', 'company_name': 'Alkermes Plc', 'index': '6'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: To amend title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate prices of prescription drugs furnished under part D of the Medicare program.
Official summary of bill: Medicare Negotiation and Competitive Licensing Act of 2019
Additionally, for one year after a drug is provided under a competitive license, such drug is also subject to specified price limitations; if the drug is not offered at such prices, the drug is subject to additional licensing that furthers its sale under any federal program (e.g., Medicaid).
Company name: Alkermes Plc
Company business description: Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to research, develop and commercialize, both with partners and on its own, pharmaceutical products that are designed to address unmet medical needs of patients in major therapeutic areas. Alkermes has a diversified portfolio of marketed drug products and a clinical pipeline of products that address central nervous system ("CNS") disorders such as schizophrenia, depression, addiction and multiple sclerosis ("MS"). Headquartered in Dublin, Ireland, Alkermes has a research and development ("R & D") center in Waltham, Massachusetts; an R & D and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. The key marketed products discussed below are expected to generate significant revenues for us. None Commercialized by Alkermes in the U.S. Alcohol dependence and Opioid dependence Russia and Commonwealth of Independent States ("CIS") 5 Summary information regarding products that use our proprietary technologies: Product Indication(s) Treatment to improve walking in patients with MS, as demonstrated by an increase in walking speed We develop and commercialize products designed to address the unmet needs of patients suffering from addiction and schizophrenia. ARISTADA ARISTADA (aripiprazole lauroxil) is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia. ARISTADA is the first of our products to utilize our proprietary LinkeRx technology. ARISTADA is a prodrug; once in the body, ARISTADA is likely converted by enzyme-mediated hydrolysis to N-hydroxymethyl aripiprazole, which is then hydrolyzed to aripiprazole. ARISTADA is the first atypical antipsychotic with once-monthly, once-every-six-weeks and once-every-two-months dosing options to deliver and maintain therapeutic levels of medication in the body. ARISTADA has four dosing options (441 mg, 662 mg, 882 mg and 1064 mg) and is packaged in a ready-to-use, pre-filled product format. ARISTADA 1064 mg, our two-month dosing option, was approved by the U.S. Food and Drug Administration (the "FDA") in June 2017. We developed ARISTADA and manufacture and commercialize it in the U.S. Schizophrenia is a chronic, severe and disabling brain disorder. The disease is marked by positive symptoms (hallucinations and delusions) and negative symptoms (depression, blunted emotions and social withdrawal), as well as by disorganized thinking. An estimated 2.4 million Americans over the age of 18 have schizophrenia in a given year, with men and women affected equally. Worldwide, it is estimated that one person in every 100 develops schizophrenia. Studies have demonstrated that as many as 75% of patients with schizophrenia have difficulty taking their oral medication on a regular basis, which can lead to worsening of symptoms. VIVITROL VIVITROL (naltrexone for extended-release injectable suspension) is a once-monthly, non-narcotic, injectable medication approved in the U.S., Russia and certain countries of the CIS for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. VIVITROL uses our polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through one intramuscular injection every four weeks. We developed and exclusively manufacture VIVITROL. What are opioid dependence and alcohol dependence? Opioid dependence is a serious and chronic brain disease characterized by compulsive, prolonged self-administration of opioid substances that are not used for a medical purpose.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
9 | Yes | {'bill_summary': "Move America Act of 2019\n\nThis bill allows tax-exempt Move America bonds and Move America tax credits to be used for certain infrastructure projects.\n\nA Move America bond is treated as a tax-exempt private facility bond with certain exceptions. At least 95% of the net proceeds from the issuance of the bond must be used for infrastructure projects, including\n\n airports; docks and wharves; mass commuting facilities; facilities for the furnishing of water; sewage facilities; railroads; certain surface transportation projects eligible for federal assistance, projects for an international bridge or tunnel, or facilities for transferring freight from truck to rail or rail to truck; flood diversions; inland waterways; or rural broadband service infrastructure. The bill specifies exceptions and modifications to existing rules for bonds regarding land acquisition, government ownership, rehabilitation expenditures, and the alternative minimum tax.\n\nThe bonds are subject to a volume cap equal to 50% of a state's current private activity bond volume cap. States may exchange all or a portion of the volume cap for Move America tax credits to be allocated to taxpayers. The credits include (1) an equity credit for a portion of the basis of each qualified facility; and (2) an infrastructure fund credit for investments in qualified infrastructure funds, including a state infrastructure bank, a water pollution control revolving fund, or a drinking water treatment revolving loan fund.", 'bill_title': 'A bill to amend the Internal Revenue Code of 1986 to provide for Move America bonds and Move America credits.', 'company_description': 'We acquire, develop, own and operate self-storage facilities , which offer storage spaces for lease on a month-to-month basis, for personal and business use. We are the largest owner and operator of self-storage facilities in the U.S. We have direct and indirect equity interests in 2,3 8 6 self-storage facilities that we consolidate (an aggregate of 15 9 million net rentable square feet of space) located in 38 states within the U.S. operating under the "Public Storage" brand name. We also own one self -storage facility in London, England which is managed by Shurgard Europe (defined below). Ancillary Operations : We reinsure policies against losses to goods stored by customers in our self-storage facilities and sell merchandise, primarily locks and cardboard boxes, at our self-storage facilities. Inc. ("PSB"), a publicly held REIT that owns, operates, acquires and develops commercial properties, primarily multi-tenant flex, office, and industrial parks. 0 million rentable square feet of commercial space. Shurgard Self Storage Europe Limited ("Shurgard Europe") which owns 221 self-storage facilities (twelve million net rentable square feet) located in seven countries in Western Europe operated under the "Shurgard" brand name. We believe Shurgard Europe is the largest owner and operator of self-storage facilities in Western Europe. We also manage approximately 27 self-storage facilities for third parties . We are seeking to expand our third-party management operations to further increase our economies of scale and leverage our brand; however, there is no assurance that we will be able to do so. We also own 0.9 million net rentable square feet of commercial space which is managed primarily by PSB . For all periods presented herein, we have elected to be treated as a REIT, as defined in the Internal Revenue Code of 1986, as amended (the "Code") . and we expect to continue to elect and qualify as a REIT. We believe that our customers generally store their goods within a five mile radius of their home or business . Our facilities compete with nearby self-storage facilities owned by other operators using marketing channels similar to ours , including Internet advertising, signage, and banners and offer services similar to ours . A s a result, competition is significant and affects the occupancy levels, rental rates, rental income and operating expenses of our facilities. There has been an increase in supply of newly constructed self-storage facilities in several of our markets, most notably Atlanta, Austin, Charlotte, Chicago, Dallas, Denver, Houston, and New York. Ownership and operation of self- storage facilities is highly fragmented. As the largest owner of self-storage facilities, we believe that we own approximately 7 % of the self-storage square footage in the U.S. and that collectively the five largest self-storage owners in the U.S. own approximately 15 %, with the remaining 8 5 % owned by numerous regional and local operators. We believe that we have significant market share and concentration in major metropolitan centers, with approximately 71 % of our 201 7 same-store revenues generated in the 20 Metropolitan Statistical Areas (each, an "MSA", as defined by the U.S. Census Bureau) with the highest population levels. Industry fragmentation also provides opportunities for us to acquire additional facilities; however, we compete with a wide variety of institutions and other investors who also view self-storage facilities as attractive investments. The amount of capital available for real estate investments greatly influences the competition for ownership interests in facilities and, by extension, the yields that we can achieve on newly acquired investments. a s well as analyze customer data and quickly change each of our individual properties \' pricing and promotion s on an automated basis. ', 'company_name': 'Public Storage', 'index': '9'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: A bill to amend the Internal Revenue Code of 1986 to provide for Move America bonds and Move America credits.
Official summary of bill: Move America Act of 2019
The bonds are subject to a volume cap equal to 50% of a state's current private activity bond volume cap. States may exchange all or a portion of the volume cap for Move America tax credits to be allocated to taxpayers. The credits include (1) an equity credit for a portion of the basis of each qualified facility; and (2) an infrastructure fund credit for investments in qualified infrastructure funds, including a state infrastructure bank, a water pollution control revolving fund, or a drinking water treatment revolving loan fund.
Company name: Public Storage
Company business description: We acquire, develop, own and operate self-storage facilities , which offer storage spaces for lease on a month-to-month basis, for personal and business use. We are the largest owner and operator of self-storage facilities in the U.S. We have direct and indirect equity interests in 2,3 8 6 self-storage facilities that we consolidate (an aggregate of 15 9 million net rentable square feet of space) located in 38 states within the U.S. operating under the "Public Storage" brand name. We also own one self -storage facility in London, England which is managed by Shurgard Europe (defined below). Ancillary Operations : We reinsure policies against losses to goods stored by customers in our self-storage facilities and sell merchandise, primarily locks and cardboard boxes, at our self-storage facilities. Inc. ("PSB"), a publicly held REIT that owns, operates, acquires and develops commercial properties, primarily multi-tenant flex, office, and industrial parks. 0 million rentable square feet of commercial space. Shurgard Self Storage Europe Limited ("Shurgard Europe") which owns 221 self-storage facilities (twelve million net rentable square feet) located in seven countries in Western Europe operated under the "Shurgard" brand name. We believe Shurgard Europe is the largest owner and operator of self-storage facilities in Western Europe. We also manage approximately 27 self-storage facilities for third parties . We are seeking to expand our third-party management operations to further increase our economies of scale and leverage our brand; however, there is no assurance that we will be able to do so. We also own 0.9 million net rentable square feet of commercial space which is managed primarily by PSB . For all periods presented herein, we have elected to be treated as a REIT, as defined in the Internal Revenue Code of 1986, as amended (the "Code") . and we expect to continue to elect and qualify as a REIT. We believe that our customers generally store their goods within a five mile radius of their home or business . Our facilities compete with nearby self-storage facilities owned by other operators using marketing channels similar to ours , including Internet advertising, signage, and banners and offer services similar to ours . A s a result, competition is significant and affects the occupancy levels, rental rates, rental income and operating expenses of our facilities. There has been an increase in supply of newly constructed self-storage facilities in several of our markets, most notably Atlanta, Austin, Charlotte, Chicago, Dallas, Denver, Houston, and New York. Ownership and operation of self- storage facilities is highly fragmented. As the largest owner of self-storage facilities, we believe that we own approximately 7 % of the self-storage square footage in the U.S. and that collectively the five largest self-storage owners in the U.S. own approximately 15 %, with the remaining 8 5 % owned by numerous regional and local operators. We believe that we have significant market share and concentration in major metropolitan centers, with approximately 71 % of our 201 7 same-store revenues generated in the 20 Metropolitan Statistical Areas (each, an "MSA", as defined by the U.S. Census Bureau) with the highest population levels. Industry fragmentation also provides opportunities for us to acquire additional facilities; however, we compete with a wide variety of institutions and other investors who also view self-storage facilities as attractive investments. The amount of capital available for real estate investments greatly influences the competition for ownership interests in facilities and, by extension, the yields that we can achieve on newly acquired investments. a s well as analyze customer data and quickly change each of our individual properties ' pricing and promotion s on an automated basis.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
2 | No | {'bill_summary': 'Violence Against Women Reauthorization Act of 2019\n\nThis bill modifies and reauthorizes through FY2024 programs and activities under the Violence Against Women Act that seek to prevent and respond to domestic violence, sexual assault, dating violence, and stalking.\n\nAmong other things, the bill also authorizes new programs, makes changes to federal firearms laws, and establishes new protections to promote housing stability and economic security for victims of domestic violence, sexual assault, dating violence, and stalking.', 'bill_title': 'To reauthorize the Violence Against Women Act of 1994, and for other purposes.', 'company_description': 'Our mission is to improve lives by eliminating the back row in higher education. We are a global leader in education technology. For more than a decade, we have been improving lives by powering world-class digital education. As a trusted partner and brand steward of great universities, we build, deliver, and support online graduate programs and certificates for working adults. Our industry-leading short courses, offered by GetSmarter, are designed to equip life-long learners with in-demand career skills. Over the past decade, we have developed new and innovative tools within our platform to enhance the effectiveness of instructional methods and improve student outcomes and the student experience. During that time, we have also improved our data-driven digital marketing capabilities across our ecosystem of offerings to generate increased student enrollments in a cost effective manner. As a result, demand for our comprehensive platform of integrated technology and services has increased significantly. When 2U was formed in 2008, we had one university client and one 2U-powered graduate program. Today, our university client base has grown to 35, our platform powers 49 graduate programs and over 90 short courses, and from inception to date we have enrolled over 44,000 students in 2U-powered graduate programs and over 86,000 students in our short courses. Our core strategy is to launch graduate programs and short courses with new and existing university clients, to increase student enrollments and graduations across our portfolio of offerings and to expand our non-degree offerings across the career curriculum continuum. We are also committed to continuously improving our platform to deliver high-quality university and student experiences and outcomes at scale. In our Short Course Segment, we target working professionals seeking career advancement through skills attainment. Our Graduate Program Segment derives revenue primarily from a contractually specified percentage of the amounts our university clients receive from their students in the 2U-enabled graduate program for tuition and fees, less credit card fees and other specified charges we have agreed to exclude in certain of our universicty client contracts. The Short Course Segment derives revenue directly from students for the tuition and fees paid to enroll in and progress through our short courses. We share a contractually specified percentage of the tuition and fees received from students in each course with the relevant university client. Our platform, which we refer to as the 2U Operating System, or 2UOS, consists of a seamlessly integrated ecosystem of technology, people and data. Through 2UOS, we provide our university clients with front-end and back-end cloud-based SaaS technology and technology-enabled services. These two components are tightly integrated and optimized with data analysis and machine learning techniques. 2UOS delivers technology with a human touch and is the keystone of our commitment to provide our university clients the tools they need to lead the digital transformation in education. 2UOS provides the following front-end technology and services to students enrolled in our offerings and to faculty members and university administrators supporting our offerings: Our online learning platform is a cohesive end-to-end learning and teaching platform, where our university clients can reliably deliver their high-quality educational content to students. For our Graduate Program Segment, our online learning platform replicates an intimate and live classroom environment and is accessible through proprietary web, mobile and TV applications as well as in an offline mode for convenient consumption of asynchronous coursework. With the recent integration of stem-based education tools and collaborative annotation technology and an improved data-driven user experience, we have significantly enhanced the learning experience for students in 2U-powered graduate programs and instruction capabilities for faculty. Our short course offerings are delivered through a separate proprietary learning platform that shares many of the core features of our Graduate Program Segment learning platform, with some exceptions, such as the enhanced features that facilitate the live classroom environment in our graduate program leaning platform. ', 'company_name': '2U, Inc.', 'index': '2'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: To reauthorize the Violence Against Women Act of 1994, and for other purposes.
Official summary of bill: Violence Against Women Reauthorization Act of 2019
Among other things, the bill also authorizes new programs, makes changes to federal firearms laws, and establishes new protections to promote housing stability and economic security for victims of domestic violence, sexual assault, dating violence, and stalking.
Company name: 2U, Inc.
Company business description: Our mission is to improve lives by eliminating the back row in higher education. We are a global leader in education technology. For more than a decade, we have been improving lives by powering world-class digital education. As a trusted partner and brand steward of great universities, we build, deliver, and support online graduate programs and certificates for working adults. Our industry-leading short courses, offered by GetSmarter, are designed to equip life-long learners with in-demand career skills. Over the past decade, we have developed new and innovative tools within our platform to enhance the effectiveness of instructional methods and improve student outcomes and the student experience. During that time, we have also improved our data-driven digital marketing capabilities across our ecosystem of offerings to generate increased student enrollments in a cost effective manner. As a result, demand for our comprehensive platform of integrated technology and services has increased significantly. When 2U was formed in 2008, we had one university client and one 2U-powered graduate program. Today, our university client base has grown to 35, our platform powers 49 graduate programs and over 90 short courses, and from inception to date we have enrolled over 44,000 students in 2U-powered graduate programs and over 86,000 students in our short courses. Our core strategy is to launch graduate programs and short courses with new and existing university clients, to increase student enrollments and graduations across our portfolio of offerings and to expand our non-degree offerings across the career curriculum continuum. We are also committed to continuously improving our platform to deliver high-quality university and student experiences and outcomes at scale. In our Short Course Segment, we target working professionals seeking career advancement through skills attainment. Our Graduate Program Segment derives revenue primarily from a contractually specified percentage of the amounts our university clients receive from their students in the 2U-enabled graduate program for tuition and fees, less credit card fees and other specified charges we have agreed to exclude in certain of our universicty client contracts. The Short Course Segment derives revenue directly from students for the tuition and fees paid to enroll in and progress through our short courses. We share a contractually specified percentage of the tuition and fees received from students in each course with the relevant university client. Our platform, which we refer to as the 2U Operating System, or 2UOS, consists of a seamlessly integrated ecosystem of technology, people and data. Through 2UOS, we provide our university clients with front-end and back-end cloud-based SaaS technology and technology-enabled services. These two components are tightly integrated and optimized with data analysis and machine learning techniques. 2UOS delivers technology with a human touch and is the keystone of our commitment to provide our university clients the tools they need to lead the digital transformation in education. 2UOS provides the following front-end technology and services to students enrolled in our offerings and to faculty members and university administrators supporting our offerings: Our online learning platform is a cohesive end-to-end learning and teaching platform, where our university clients can reliably deliver their high-quality educational content to students. For our Graduate Program Segment, our online learning platform replicates an intimate and live classroom environment and is accessible through proprietary web, mobile and TV applications as well as in an offline mode for convenient consumption of asynchronous coursework. With the recent integration of stem-based education tools and collaborative annotation technology and an improved data-driven user experience, we have significantly enhanced the learning experience for students in 2U-powered graduate programs and instruction capabilities for faculty. Our short course offerings are delivered through a separate proprietary learning platform that shares many of the core features of our Graduate Program Segment learning platform, with some exceptions, such as the enhanced features that facilitate the live classroom environment in our graduate program leaning platform.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
6 | Yes | {'bill_summary': 'Medicare Negotiation and Competitive Licensing Act of 2019\n\nThis bill requires the Centers for Medicare & Medicaid Services (CMS) to negotiate with pharmaceutical companies regarding prices for drugs covered under the Medicare prescription drug benefit. (Current law prohibits the CMS from doing so.)\n\nThe CMS must take certain factors into account during negotiations, including the clinical- and cost-effectiveness of the drug, the financial burden on patients, and unmet patient needs. If the CMS is unable to negotiate the price of a drug, such drug is subject to competitive licensing in order to further its sale under Medicare, notwithstanding existing government-granted exclusivities.\n\nAdditionally, for one year after a drug is provided under a competitive license, such drug is also subject to specified price limitations; if the drug is not offered at such prices, the drug is\xa0subject to additional licensing that furthers its sale under any federal program (e.g., Medicaid).', 'bill_title': 'To amend title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate prices of prescription drugs furnished under part D of the Medicare program.', 'company_description': 'Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to research, develop and commercialize, both with partners and on its own, pharmaceutical products that are designed to address unmet medical needs of patients in major therapeutic areas. Alkermes has a diversified portfolio of marketed drug products and a clinical pipeline of products that address central nervous system ("CNS") disorders such as schizophrenia, depression, addiction and multiple sclerosis ("MS"). Headquartered in Dublin, Ireland, Alkermes has a research and development ("R & D") center in Waltham, Massachusetts; an R & D and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. The key marketed products discussed below are expected to generate significant revenues for us. None Commercialized by Alkermes in the U.S. Alcohol dependence and Opioid dependence Russia and Commonwealth of Independent States ("CIS") 5 Summary information regarding products that use our proprietary technologies: Product Indication(s) Treatment to improve walking in patients with MS, as demonstrated by an increase in walking speed We develop and commercialize products designed to address the unmet needs of patients suffering from addiction and schizophrenia. ARISTADA ARISTADA (aripiprazole lauroxil) is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia. ARISTADA is the first of our products to utilize our proprietary LinkeRx technology. ARISTADA is a prodrug; once in the body, ARISTADA is likely converted by enzyme-mediated hydrolysis to N-hydroxymethyl aripiprazole, which is then hydrolyzed to aripiprazole. ARISTADA is the first atypical antipsychotic with once-monthly, once-every-six-weeks and once-every-two-months dosing options to deliver and maintain therapeutic levels of medication in the body. ARISTADA has four dosing options (441 mg, 662 mg, 882 mg and 1064 mg) and is packaged in a ready-to-use, pre-filled product format. ARISTADA 1064 mg, our two-month dosing option, was approved by the U.S. Food and Drug Administration (the "FDA") in June 2017. We developed ARISTADA and manufacture and commercialize it in the U.S. Schizophrenia is a chronic, severe and disabling brain disorder. The disease is marked by positive symptoms (hallucinations and delusions) and negative symptoms (depression, blunted emotions and social withdrawal), as well as by disorganized thinking. An estimated 2.4 million Americans over the age of 18 have schizophrenia in a given year, with men and women affected equally. Worldwide, it is estimated that one person in every 100 develops schizophrenia. Studies have demonstrated that as many as 75% of patients with schizophrenia have difficulty taking their oral medication on a regular basis, which can lead to worsening of symptoms. VIVITROL VIVITROL (naltrexone for extended-release injectable suspension) is a once-monthly, non-narcotic, injectable medication approved in the U.S., Russia and certain countries of the CIS for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. VIVITROL uses our polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through one intramuscular injection every four weeks. We developed and exclusively manufacture VIVITROL. What are opioid dependence and alcohol dependence? Opioid dependence is a serious and chronic brain disease characterized by compulsive, prolonged self-administration of opioid substances that are not used for a medical purpose.', 'company_name': 'Alkermes Plc', 'index': '6'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: To amend title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate prices of prescription drugs furnished under part D of the Medicare program.
Official summary of bill: Medicare Negotiation and Competitive Licensing Act of 2019
Additionally, for one year after a drug is provided under a competitive license, such drug is also subject to specified price limitations; if the drug is not offered at such prices, the drug is subject to additional licensing that furthers its sale under any federal program (e.g., Medicaid).
Company name: Alkermes Plc
Company business description: Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to research, develop and commercialize, both with partners and on its own, pharmaceutical products that are designed to address unmet medical needs of patients in major therapeutic areas. Alkermes has a diversified portfolio of marketed drug products and a clinical pipeline of products that address central nervous system ("CNS") disorders such as schizophrenia, depression, addiction and multiple sclerosis ("MS"). Headquartered in Dublin, Ireland, Alkermes has a research and development ("R & D") center in Waltham, Massachusetts; an R & D and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. The key marketed products discussed below are expected to generate significant revenues for us. None Commercialized by Alkermes in the U.S. Alcohol dependence and Opioid dependence Russia and Commonwealth of Independent States ("CIS") 5 Summary information regarding products that use our proprietary technologies: Product Indication(s) Treatment to improve walking in patients with MS, as demonstrated by an increase in walking speed We develop and commercialize products designed to address the unmet needs of patients suffering from addiction and schizophrenia. ARISTADA ARISTADA (aripiprazole lauroxil) is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia. ARISTADA is the first of our products to utilize our proprietary LinkeRx technology. ARISTADA is a prodrug; once in the body, ARISTADA is likely converted by enzyme-mediated hydrolysis to N-hydroxymethyl aripiprazole, which is then hydrolyzed to aripiprazole. ARISTADA is the first atypical antipsychotic with once-monthly, once-every-six-weeks and once-every-two-months dosing options to deliver and maintain therapeutic levels of medication in the body. ARISTADA has four dosing options (441 mg, 662 mg, 882 mg and 1064 mg) and is packaged in a ready-to-use, pre-filled product format. ARISTADA 1064 mg, our two-month dosing option, was approved by the U.S. Food and Drug Administration (the "FDA") in June 2017. We developed ARISTADA and manufacture and commercialize it in the U.S. Schizophrenia is a chronic, severe and disabling brain disorder. The disease is marked by positive symptoms (hallucinations and delusions) and negative symptoms (depression, blunted emotions and social withdrawal), as well as by disorganized thinking. An estimated 2.4 million Americans over the age of 18 have schizophrenia in a given year, with men and women affected equally. Worldwide, it is estimated that one person in every 100 develops schizophrenia. Studies have demonstrated that as many as 75% of patients with schizophrenia have difficulty taking their oral medication on a regular basis, which can lead to worsening of symptoms. VIVITROL VIVITROL (naltrexone for extended-release injectable suspension) is a once-monthly, non-narcotic, injectable medication approved in the U.S., Russia and certain countries of the CIS for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. VIVITROL uses our polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through one intramuscular injection every four weeks. We developed and exclusively manufacture VIVITROL. What are opioid dependence and alcohol dependence? Opioid dependence is a serious and chronic brain disease characterized by compulsive, prolonged self-administration of opioid substances that are not used for a medical purpose.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
10 | Yes | {'bill_summary': '\nThis bill provides FY2024 supplemental appropriations for federal departments and agencies to respond to the conflict in Ukraine. The bill designates the funding as emergency spending, which is exempt from discretionary spending limits.\n\nSpecifically, the bill provides appropriations to the\n\nDepartment of Defense (DOD),\nDepartment of Energy science programs,\nthe National Nuclear Security Administration,\nthe Administration for Children and Families,\nthe Department of State, and\nthe U.S. Agency for International Development.\nThe funding is provided for purposes such as\n\nsupporting current U.S. military operations in the region,\nthe Ukraine Security Assistance Initiative,\nreplacing defense articles that were provided to Ukraine,\nreimbursing DOD for defense services and training provided to Ukraine,\nthe Foreign Military Financing Program,\neconomic support for Ukraine,\nrefugee and entrant assistance,\ninternational narcotics control and law enforcement, and\nthe development and production of isotopes.\nThe bill also includes provisions that\n\nexpand the authorities of the President to transfer defense articles and services from DOD to foreign countries or international organizations,\nrequire the President to transfer long-range Army Tactical Missile Systems to Ukraine,\nrequire the President to enter into an agreement with Ukraine regarding repaying the United States for the economic assistance it has provided to Ukraine,\nrequire certain funds that are provided for Ukraine to be matched by other donors, and\nestablish various oversight and reporting requirements for assistance provided to Ukraine.\n', 'bill_title': 'H.R.8035 - Ukraine Security Supplemental Appropriations Act, 2024. A bill for making emergency supplemental appropriations to respond to the situation in Ukraine and for related expenses for the fiscal year ending September 30, 2024, and for other purposes.', 'company_description': 'U.S. Bancorp, with more than 70,000 employees and $663 billion in assets as of December 31, 2023, is the\nparent company of U.S. Bank National Association. Headquartered in Minneapolis, the company serves millions\nof customers locally, nationally and globally through a diversified mix of businesses including consumer banking,\nbusiness banking, commercial banking, institutional banking, payments and wealth management. U.S. Bancorp\nhas been recognized for its approach to digital innovation, community partnerships and customer service,\nincluding being named one of the 2023 World’s Most Ethical Companies and Fortune’s most admired superregional\nbank. ', 'company_name': 'U.S. Bancorp ', 'index': 10} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: H.R.8035 - Ukraine Security Supplemental Appropriations Act, 2024. A bill for making emergency supplemental appropriations to respond to the situation in Ukraine and for related expenses for the fiscal year ending September 30, 2024, and for other purposes.
Official summary of bill:
This bill provides FY2024 supplemental appropriations for federal departments and agencies to respond to the conflict in Ukraine. The bill designates the funding as emergency spending, which is exempt from discretionary spending limits.
Company name: U.S. Bancorp
Company business description: U.S. Bancorp, with more than 70,000 employees and $663 billion in assets as of December 31, 2023, is the
parent company of U.S. Bank National Association. Headquartered in Minneapolis, the company serves millions
of customers locally, nationally and globally through a diversified mix of businesses including consumer banking,
business banking, commercial banking, institutional banking, payments and wealth management. U.S. Bancorp
has been recognized for its approach to digital innovation, community partnerships and customer service,
including being named one of the 2023 World’s Most Ethical Companies and Fortune’s most admired superregional
bank.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
10 | Yes | {'bill_summary': '\nThis bill provides FY2024 supplemental appropriations for federal departments and agencies to respond to the conflict in Ukraine. The bill designates the funding as emergency spending, which is exempt from discretionary spending limits.\n\nSpecifically, the bill provides appropriations to the\n\nDepartment of Defense (DOD),\nDepartment of Energy science programs,\nthe National Nuclear Security Administration,\nthe Administration for Children and Families,\nthe Department of State, and\nthe U.S. Agency for International Development.\nThe funding is provided for purposes such as\n\nsupporting current U.S. military operations in the region,\nthe Ukraine Security Assistance Initiative,\nreplacing defense articles that were provided to Ukraine,\nreimbursing DOD for defense services and training provided to Ukraine,\nthe Foreign Military Financing Program,\neconomic support for Ukraine,\nrefugee and entrant assistance,\ninternational narcotics control and law enforcement, and\nthe development and production of isotopes.\nThe bill also includes provisions that\n\nexpand the authorities of the President to transfer defense articles and services from DOD to foreign countries or international organizations,\nrequire the President to transfer long-range Army Tactical Missile Systems to Ukraine,\nrequire the President to enter into an agreement with Ukraine regarding repaying the United States for the economic assistance it has provided to Ukraine,\nrequire certain funds that are provided for Ukraine to be matched by other donors, and\nestablish various oversight and reporting requirements for assistance provided to Ukraine.\n', 'bill_title': 'H.R.8035 - Ukraine Security Supplemental Appropriations Act, 2024. A bill for making emergency supplemental appropriations to respond to the situation in Ukraine and for related expenses for the fiscal year ending September 30, 2024, and for other purposes.', 'company_description': 'U.S. Bancorp, with more than 70,000 employees and $663 billion in assets as of December 31, 2023, is the\nparent company of U.S. Bank National Association. Headquartered in Minneapolis, the company serves millions\nof customers locally, nationally and globally through a diversified mix of businesses including consumer banking,\nbusiness banking, commercial banking, institutional banking, payments and wealth management. U.S. Bancorp\nhas been recognized for its approach to digital innovation, community partnerships and customer service,\nincluding being named one of the 2023 World’s Most Ethical Companies and Fortune’s most admired superregional\nbank. ', 'company_name': 'U.S. Bancorp ', 'index': 10} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: H.R.8035 - Ukraine Security Supplemental Appropriations Act, 2024. A bill for making emergency supplemental appropriations to respond to the situation in Ukraine and for related expenses for the fiscal year ending September 30, 2024, and for other purposes.
Official summary of bill:
This bill provides FY2024 supplemental appropriations for federal departments and agencies to respond to the conflict in Ukraine. The bill designates the funding as emergency spending, which is exempt from discretionary spending limits.
Company name: U.S. Bancorp
Company business description: U.S. Bancorp, with more than 70,000 employees and $663 billion in assets as of December 31, 2023, is the
parent company of U.S. Bank National Association. Headquartered in Minneapolis, the company serves millions
of customers locally, nationally and globally through a diversified mix of businesses including consumer banking,
business banking, commercial banking, institutional banking, payments and wealth management. U.S. Bancorp
has been recognized for its approach to digital innovation, community partnerships and customer service,
including being named one of the 2023 World’s Most Ethical Companies and Fortune’s most admired superregional
bank.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
7 | No | {'bill_summary': 'Disability Integration Act of 2019\n\nThis bill prohibits government entities and insurance providers from denying community-based services to individuals with disabilities that require long-term service or support that would enable such individuals to live in the community and lead an independent life.\n\nSpecifically, these entities may not discriminate against such individuals in the provision of community-based services by such actions as imposing prohibited eligibility criteria, cost caps, or waiting lists or failing to provide a specific community-based service. Additionally, community-based services must be offered to individuals with such disabilities prior to institutionalization. Institutionalized individuals must be notified regularly of community-based alternatives.\n\nThe bill requires the Department of Justice and the Department of Health and Human Services (HHS) to issue regulations requiring government entities and insurance providers to offer community-based long-term services to individuals with such disabilities who would otherwise qualify for institutional placement. Government entities must ensure sufficient availability of affordable, accessible, and integrated housing that is not a disability-specific residential setting or a setting where services are tied to tenancy.\n\nRegulations shall also (1) require government entities and insurance providers to perform self-evaluation on current services, policies, and practices and concerning compliance with requirements of this bill; and (2) require government entities to submit a transition plan. HHS must determine annually whether each government entity is complying with the transition plan and must increase funding for those in compliance.\n\nThe bill allows civil actions by individuals subjected to, or about to be subjected to, a violation of its requirements.', 'bill_title': 'To prohibit discrimination against individuals with disabilities who need long-term services and supports, and for other purposes.', 'company_description': 'We are a leading manufacturer, marketer and distributor of high-quality, branded food products in North America, with annual net sales of approximately $3.1 billion in fiscal 2017. Our brand portfolio enjoys strong household penetration in the United States ("U.S."), where our products can be found in over 85% of U.S. households. Our products are sold through supermarkets, grocery wholesalers and distributors, mass merchandisers, super centers, convenience stores, dollar stores, natural and organic food stores, drug stores, e-commerce websites and warehouse clubs in the United States and Canada, as well as in military channels and foodservice locations. Pinnacle Foods Inc. is a holding company whose sole asset is 100% ownership of Peak Finance Holdings LLC ("PFH"). PFH is a holding company whose sole asset is 100% ownership of Pinnacle Foods Finance LLC. The Company\'s business is organized into the following four reportable segments: The Frozen segment, The Grocery segment, The Boulder segment and The Specialty segment Frozen Segment Birds Eye is the largest brand in the $3.3 billion frozen vegetables category, with a 31.9% market share. Government programs, such as the USDA\'s My Plate program, and nutrition and health professionals continue to identify increased vegetable consumption as a key to better health. We believe that enhancing the taste of vegetables and making them exceptionally convenient are keys to driving more vegetable consumption. Birds Eye has taken a leadership role in increasing vegetable consumption, including encouraging children to eat more vegetables. We are supporters of the USDA\'s My Plate program and have engaged in breakthrough marketing efforts with major multi-media family entertainment partners to encourage children to eat more vegetables. We also compete in the frozen complete bagged meals category with our Birds Eye Voila! frozen bagged meals provide consumers with a high quality complete meal, including protein, starch, and vegetables, that can be prepared in a skillet in just minutes. Our Frozen segment also includes Hungry-Man frozen entrées, Van de Kamp\'s and frozen prepared seafood, Lender\'s frozen and refrigerated bagels and Celeste frozen pizza. Grocery Segment Included in the Grocery segment is our Duncan Hines portfolio, which includes cake mixes, ready-to-serve frostings, brownie mixes, and cookie mixes. In addition to our traditional cake mix offerings, our cake mix portfolio also includes premium offerings under the Duncan Hines Decadent and Duncan Hines Perfect Size brands. Duncan Hines is the #2 brand with a 28.9% market share in the $1.1 billion cake/brownie mix and frostings We compete in the shelf-stable salad dressings category with our Wish-Bone and Western brands, including our Wish-Bone E.V.O.O., Wish-Bone Ristorante Italiano and Wish-Bone Avocado Oil lines. We hold the #4 position in the $2.0 billion salad dressings category, with a combined share of 11.0%, and Wish-Bone holds the #1 position in the branded Italian segment of the category. Our Grocery segment also includes Armour, Nalley and Brooks canned meat, Mrs. Butterworth\'s and Log Cabin table syrups, Smart Balance premium margarine/spread, Comstock and Wilderness pie and pastry fruit fillings and Open Pit barbecue sauce. The Grocery segment also includes a diversified portfolio of shelf-stable and refrigerated products including a complete line of shelf-stable pickle products, primarily under the nationally-distributed Vlasic brand, and the regional brands under the Milwaukee\'s and Wiejske Wyroby brands. Our Vlasic brand, represented by its trademark Vlasic stork, has the highest consumer awareness and quality ratings in the pickle category. Vlasic is the #1 brand in the $790 million shelf-stable pickle category and Pinnacle pickle brands collectively hold a 34.3% market share. We offer a portfolio of gluten-free products under the ', 'company_name': 'Pinnacle Foods, Inc.', 'index': '7'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: To prohibit discrimination against individuals with disabilities who need long-term services and supports, and for other purposes.
Official summary of bill: Disability Integration Act of 2019
The bill allows civil actions by individuals subjected to, or about to be subjected to, a violation of its requirements.
Company name: Pinnacle Foods, Inc.
Company business description: We are a leading manufacturer, marketer and distributor of high-quality, branded food products in North America, with annual net sales of approximately $3.1 billion in fiscal 2017. Our brand portfolio enjoys strong household penetration in the United States ("U.S."), where our products can be found in over 85% of U.S. households. Our products are sold through supermarkets, grocery wholesalers and distributors, mass merchandisers, super centers, convenience stores, dollar stores, natural and organic food stores, drug stores, e-commerce websites and warehouse clubs in the United States and Canada, as well as in military channels and foodservice locations. Pinnacle Foods Inc. is a holding company whose sole asset is 100% ownership of Peak Finance Holdings LLC ("PFH"). PFH is a holding company whose sole asset is 100% ownership of Pinnacle Foods Finance LLC. The Company's business is organized into the following four reportable segments: The Frozen segment, The Grocery segment, The Boulder segment and The Specialty segment Frozen Segment Birds Eye is the largest brand in the $3.3 billion frozen vegetables category, with a 31.9% market share. Government programs, such as the USDA's My Plate program, and nutrition and health professionals continue to identify increased vegetable consumption as a key to better health. We believe that enhancing the taste of vegetables and making them exceptionally convenient are keys to driving more vegetable consumption. Birds Eye has taken a leadership role in increasing vegetable consumption, including encouraging children to eat more vegetables. We are supporters of the USDA's My Plate program and have engaged in breakthrough marketing efforts with major multi-media family entertainment partners to encourage children to eat more vegetables. We also compete in the frozen complete bagged meals category with our Birds Eye Voila! frozen bagged meals provide consumers with a high quality complete meal, including protein, starch, and vegetables, that can be prepared in a skillet in just minutes. Our Frozen segment also includes Hungry-Man frozen entrées, Van de Kamp's and frozen prepared seafood, Lender's frozen and refrigerated bagels and Celeste frozen pizza. Grocery Segment Included in the Grocery segment is our Duncan Hines portfolio, which includes cake mixes, ready-to-serve frostings, brownie mixes, and cookie mixes. In addition to our traditional cake mix offerings, our cake mix portfolio also includes premium offerings under the Duncan Hines Decadent and Duncan Hines Perfect Size brands. Duncan Hines is the #2 brand with a 28.9% market share in the $1.1 billion cake/brownie mix and frostings We compete in the shelf-stable salad dressings category with our Wish-Bone and Western brands, including our Wish-Bone E.V.O.O., Wish-Bone Ristorante Italiano and Wish-Bone Avocado Oil lines. We hold the #4 position in the $2.0 billion salad dressings category, with a combined share of 11.0%, and Wish-Bone holds the #1 position in the branded Italian segment of the category. Our Grocery segment also includes Armour, Nalley and Brooks canned meat, Mrs. Butterworth's and Log Cabin table syrups, Smart Balance premium margarine/spread, Comstock and Wilderness pie and pastry fruit fillings and Open Pit barbecue sauce. The Grocery segment also includes a diversified portfolio of shelf-stable and refrigerated products including a complete line of shelf-stable pickle products, primarily under the nationally-distributed Vlasic brand, and the regional brands under the Milwaukee's and Wiejske Wyroby brands. Our Vlasic brand, represented by its trademark Vlasic stork, has the highest consumer awareness and quality ratings in the pickle category. Vlasic is the #1 brand in the $790 million shelf-stable pickle category and Pinnacle pickle brands collectively hold a 34.3% market share. We offer a portfolio of gluten-free products under the
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
4 | No | {'bill_summary': 'Federal Register Modernization Act\n\nThis bill revises provisions regarding the Federal Register or the Code of Federal Regulations, including to replace requirements that the documents be printed with requirements that the documents be published.\n\nThe bill provides that in a continuity of operations event in which the Government Publishing Office (GPO) does not fulfill its publication requirements, the Office of the Federal Register may establish a website to publish the Federal Register until such time that GPO resumes publication.', 'bill_title': 'A bill to amend title 44, United States Code, to modernize the Federal Register, and for other purposes.', 'company_description': '"us" or the "Parent Company") is a leading provider of financial products to middle-income households in the United States and Canada with 130,736 licensed sales representatives as of December 31, 2018. This network of independent contractor sales representatives ("sales representatives" or "sales force") assists our clients in meeting their needs for term life insurance, which we underwrite, and mutual funds, annuities, managed investments and other financial products, which we distribute primarily on behalf of third parties. Licensed sales representatives primarily use our proprietary financial needs analysis tool ("FNA") and an educational approach to demonstrate how our product offerings can assist clients to provide financial protection for their families, save for their retirement and other needs, and manage their debt. Typically, our clients are the friends, family members and personal acquaintances of sales representatives. We provide an entrepreneurial business opportunity for individuals to distribute financial products. Low entry fees as well as the ability to select their own schedules and time commitments allow sales representatives to supplement their income by starting their own independent businesses without leaving their current jobs. Our unique compensation structure, technology, sales support and back-office processing are designed to enable sales representatives to successfully grow their independent businesses. We believe there is significant opportunity to meet the increasing array of financial services needs of our clients. We intend to leverage the sales force to meet such client needs, which will drive long-term value for all of our stakeholders. • Broadening and strengthening our protection product portfolio; • Providing offerings that enhance our Investment and Savings Products ("ISP") business; and • Developing digital capabilities to deepen our client relationships. Primerica Life Insurance Company ("Primerica Life"), our principal life insurance underwriting company; and • ("PFS Investments"), our investment and savings products company, broker-dealer and registered investment advisor. Primerica Life is domiciled in Tennessee, and its wholly owned subsidiary, National Benefit Life Insurance Company ("NBLIC"), is a New York-domiciled life insurance underwriting company. Primerica Life Insurance Company of Canada ("Primerica Life Canada"), our Canadian life insurance underwriting company; • ("PFSL Investments Canada"), our Canadian licensed mutual fund dealer; and • ("PFSL Fund Management"), our Canadian investment funds manager. Our clients are generally middle-income consumers, which we define as households with $30,000 to $100,000 of annual income. According to the 2017 U.S. Census Bureau Current Population Survey, the latest period for which data is available, almost 50% of U.S. households fall in this range. Many have inadequate or no life insurance coverage. Individual life insurance sales in the United States declined from 12.5 million policy sales in 1975 to 9.8 million policy sales in 2017, the latest period for which data is available, according to the Life Insurance Marketing and Research Association International, Inc. ("LIMRA"), a worldwide association of insurance and financial services companies. We believe that term life insurance, which we have provided to middle-income clients for many years, is generally the best option for them to meet their life insurance needs. Many need help saving for retirement and other personal goals.', 'company_name': 'Primerica, Inc.', 'index': '4'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: A bill to amend title 44, United States Code, to modernize the Federal Register, and for other purposes.
Official summary of bill: Federal Register Modernization Act
The bill provides that in a continuity of operations event in which the Government Publishing Office (GPO) does not fulfill its publication requirements, the Office of the Federal Register may establish a website to publish the Federal Register until such time that GPO resumes publication.
Company name: Primerica, Inc.
Company business description: "us" or the "Parent Company") is a leading provider of financial products to middle-income households in the United States and Canada with 130,736 licensed sales representatives as of December 31, 2018. This network of independent contractor sales representatives ("sales representatives" or "sales force") assists our clients in meeting their needs for term life insurance, which we underwrite, and mutual funds, annuities, managed investments and other financial products, which we distribute primarily on behalf of third parties. Licensed sales representatives primarily use our proprietary financial needs analysis tool ("FNA") and an educational approach to demonstrate how our product offerings can assist clients to provide financial protection for their families, save for their retirement and other needs, and manage their debt. Typically, our clients are the friends, family members and personal acquaintances of sales representatives. We provide an entrepreneurial business opportunity for individuals to distribute financial products. Low entry fees as well as the ability to select their own schedules and time commitments allow sales representatives to supplement their income by starting their own independent businesses without leaving their current jobs. Our unique compensation structure, technology, sales support and back-office processing are designed to enable sales representatives to successfully grow their independent businesses. We believe there is significant opportunity to meet the increasing array of financial services needs of our clients. We intend to leverage the sales force to meet such client needs, which will drive long-term value for all of our stakeholders. • Broadening and strengthening our protection product portfolio; • Providing offerings that enhance our Investment and Savings Products ("ISP") business; and • Developing digital capabilities to deepen our client relationships. Primerica Life Insurance Company ("Primerica Life"), our principal life insurance underwriting company; and • ("PFS Investments"), our investment and savings products company, broker-dealer and registered investment advisor. Primerica Life is domiciled in Tennessee, and its wholly owned subsidiary, National Benefit Life Insurance Company ("NBLIC"), is a New York-domiciled life insurance underwriting company. Primerica Life Insurance Company of Canada ("Primerica Life Canada"), our Canadian life insurance underwriting company; • ("PFSL Investments Canada"), our Canadian licensed mutual fund dealer; and • ("PFSL Fund Management"), our Canadian investment funds manager. Our clients are generally middle-income consumers, which we define as households with $30,000 to $100,000 of annual income. According to the 2017 U.S. Census Bureau Current Population Survey, the latest period for which data is available, almost 50% of U.S. households fall in this range. Many have inadequate or no life insurance coverage. Individual life insurance sales in the United States declined from 12.5 million policy sales in 1975 to 9.8 million policy sales in 2017, the latest period for which data is available, according to the Life Insurance Marketing and Research Association International, Inc. ("LIMRA"), a worldwide association of insurance and financial services companies. We believe that term life insurance, which we have provided to middle-income clients for many years, is generally the best option for them to meet their life insurance needs. Many need help saving for retirement and other personal goals.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
3 | No | {'bill_summary': 'Advancing Human Spaceflight Act\n\nThis bill addresses the establishment of U.S. policy, programs, and activities pertaining to human presence in space.\n\nThe bill declares that it is U.S. policy to permanently establish a human presence in low-Earth orbit and that such capability shall\n\n maintain U.S. global leadership and relations with partners and allies, contribute to the general welfare of the United States, and be affordable so as to not preclude a robust portfolio of other human space exploration activities. The National Aeronautics and Space Administration (NASA) shall ensure that the International Space Station (ISS) remains a viable and productive facility capable of potential U.S. use through at least FY2030.\n\nNASA must submit a strategy that includes how it will transition to a successor platform to the ISS.\n\nThe bill expands the objectives of NASA to include the expansion of permanent human presence beyond Earth in a way that enables human space settlement and a thriving space economy.\n\nNASA shall establish a program of developing space suits and associated technologies.', 'bill_title': 'A bill to extend the commitment of the United States to the International Space Station, to develop advanced space suits, and to enable human space settlement, and for other purposes.', 'company_description': 'Our mission is to improve lives by eliminating the back row in higher education. We are a global leader in education technology. For more than a decade, we have been improving lives by powering world-class digital education. As a trusted partner and brand steward of great universities, we build, deliver, and support online graduate programs and certificates for working adults. Our industry-leading short courses, offered by GetSmarter, are designed to equip life-long learners with in-demand career skills. Over the past decade, we have developed new and innovative tools within our platform to enhance the effectiveness of instructional methods and improve student outcomes and the student experience. During that time, we have also improved our data-driven digital marketing capabilities across our ecosystem of offerings to generate increased student enrollments in a cost effective manner. As a result, demand for our comprehensive platform of integrated technology and services has increased significantly. When 2U was formed in 2008, we had one university client and one 2U-powered graduate program. Today, our university client base has grown to 35, our platform powers 49 graduate programs and over 90 short courses, and from inception to date we have enrolled over 44,000 students in 2U-powered graduate programs and over 86,000 students in our short courses. Our core strategy is to launch graduate programs and short courses with new and existing university clients, to increase student enrollments and graduations across our portfolio of offerings and to expand our non-degree offerings across the career curriculum continuum. We are also committed to continuously improving our platform to deliver high-quality university and student experiences and outcomes at scale. In our Short Course Segment, we target working professionals seeking career advancement through skills attainment. Our Graduate Program Segment derives revenue primarily from a contractually specified percentage of the amounts our university clients receive from their students in the 2U-enabled graduate program for tuition and fees, less credit card fees and other specified charges we have agreed to exclude in certain of our universicty client contracts. The Short Course Segment derives revenue directly from students for the tuition and fees paid to enroll in and progress through our short courses. We share a contractually specified percentage of the tuition and fees received from students in each course with the relevant university client. Our platform, which we refer to as the 2U Operating System, or 2UOS, consists of a seamlessly integrated ecosystem of technology, people and data. Through 2UOS, we provide our university clients with front-end and back-end cloud-based SaaS technology and technology-enabled services. These two components are tightly integrated and optimized with data analysis and machine learning techniques. 2UOS delivers technology with a human touch and is the keystone of our commitment to provide our university clients the tools they need to lead the digital transformation in education. 2UOS provides the following front-end technology and services to students enrolled in our offerings and to faculty members and university administrators supporting our offerings: Our online learning platform is a cohesive end-to-end learning and teaching platform, where our university clients can reliably deliver their high-quality educational content to students. For our Graduate Program Segment, our online learning platform replicates an intimate and live classroom environment and is accessible through proprietary web, mobile and TV applications as well as in an offline mode for convenient consumption of asynchronous coursework. With the recent integration of stem-based education tools and collaborative annotation technology and an improved data-driven user experience, we have significantly enhanced the learning experience for students in 2U-powered graduate programs and instruction capabilities for faculty. Our short course offerings are delivered through a separate proprietary learning platform that shares many of the core features of our Graduate Program Segment learning platform, with some exceptions, such as the enhanced features that facilitate the live classroom environment in our graduate program leaning platform. ', 'company_name': '2U, Inc.', 'index': '3'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: A bill to extend the commitment of the United States to the International Space Station, to develop advanced space suits, and to enable human space settlement, and for other purposes.
Official summary of bill: Advancing Human Spaceflight Act
NASA shall establish a program of developing space suits and associated technologies.
Company name: 2U, Inc.
Company business description: Our mission is to improve lives by eliminating the back row in higher education. We are a global leader in education technology. For more than a decade, we have been improving lives by powering world-class digital education. As a trusted partner and brand steward of great universities, we build, deliver, and support online graduate programs and certificates for working adults. Our industry-leading short courses, offered by GetSmarter, are designed to equip life-long learners with in-demand career skills. Over the past decade, we have developed new and innovative tools within our platform to enhance the effectiveness of instructional methods and improve student outcomes and the student experience. During that time, we have also improved our data-driven digital marketing capabilities across our ecosystem of offerings to generate increased student enrollments in a cost effective manner. As a result, demand for our comprehensive platform of integrated technology and services has increased significantly. When 2U was formed in 2008, we had one university client and one 2U-powered graduate program. Today, our university client base has grown to 35, our platform powers 49 graduate programs and over 90 short courses, and from inception to date we have enrolled over 44,000 students in 2U-powered graduate programs and over 86,000 students in our short courses. Our core strategy is to launch graduate programs and short courses with new and existing university clients, to increase student enrollments and graduations across our portfolio of offerings and to expand our non-degree offerings across the career curriculum continuum. We are also committed to continuously improving our platform to deliver high-quality university and student experiences and outcomes at scale. In our Short Course Segment, we target working professionals seeking career advancement through skills attainment. Our Graduate Program Segment derives revenue primarily from a contractually specified percentage of the amounts our university clients receive from their students in the 2U-enabled graduate program for tuition and fees, less credit card fees and other specified charges we have agreed to exclude in certain of our universicty client contracts. The Short Course Segment derives revenue directly from students for the tuition and fees paid to enroll in and progress through our short courses. We share a contractually specified percentage of the tuition and fees received from students in each course with the relevant university client. Our platform, which we refer to as the 2U Operating System, or 2UOS, consists of a seamlessly integrated ecosystem of technology, people and data. Through 2UOS, we provide our university clients with front-end and back-end cloud-based SaaS technology and technology-enabled services. These two components are tightly integrated and optimized with data analysis and machine learning techniques. 2UOS delivers technology with a human touch and is the keystone of our commitment to provide our university clients the tools they need to lead the digital transformation in education. 2UOS provides the following front-end technology and services to students enrolled in our offerings and to faculty members and university administrators supporting our offerings: Our online learning platform is a cohesive end-to-end learning and teaching platform, where our university clients can reliably deliver their high-quality educational content to students. For our Graduate Program Segment, our online learning platform replicates an intimate and live classroom environment and is accessible through proprietary web, mobile and TV applications as well as in an offline mode for convenient consumption of asynchronous coursework. With the recent integration of stem-based education tools and collaborative annotation technology and an improved data-driven user experience, we have significantly enhanced the learning experience for students in 2U-powered graduate programs and instruction capabilities for faculty. Our short course offerings are delivered through a separate proprietary learning platform that shares many of the core features of our Graduate Program Segment learning platform, with some exceptions, such as the enhanced features that facilitate the live classroom environment in our graduate program leaning platform.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
7 | No | {'bill_summary': 'Disability Integration Act of 2019\n\nThis bill prohibits government entities and insurance providers from denying community-based services to individuals with disabilities that require long-term service or support that would enable such individuals to live in the community and lead an independent life.\n\nSpecifically, these entities may not discriminate against such individuals in the provision of community-based services by such actions as imposing prohibited eligibility criteria, cost caps, or waiting lists or failing to provide a specific community-based service. Additionally, community-based services must be offered to individuals with such disabilities prior to institutionalization. Institutionalized individuals must be notified regularly of community-based alternatives.\n\nThe bill requires the Department of Justice and the Department of Health and Human Services (HHS) to issue regulations requiring government entities and insurance providers to offer community-based long-term services to individuals with such disabilities who would otherwise qualify for institutional placement. Government entities must ensure sufficient availability of affordable, accessible, and integrated housing that is not a disability-specific residential setting or a setting where services are tied to tenancy.\n\nRegulations shall also (1) require government entities and insurance providers to perform self-evaluation on current services, policies, and practices and concerning compliance with requirements of this bill; and (2) require government entities to submit a transition plan. HHS must determine annually whether each government entity is complying with the transition plan and must increase funding for those in compliance.\n\nThe bill allows civil actions by individuals subjected to, or about to be subjected to, a violation of its requirements.', 'bill_title': 'To prohibit discrimination against individuals with disabilities who need long-term services and supports, and for other purposes.', 'company_description': 'We are a leading manufacturer, marketer and distributor of high-quality, branded food products in North America, with annual net sales of approximately $3.1 billion in fiscal 2017. Our brand portfolio enjoys strong household penetration in the United States ("U.S."), where our products can be found in over 85% of U.S. households. Our products are sold through supermarkets, grocery wholesalers and distributors, mass merchandisers, super centers, convenience stores, dollar stores, natural and organic food stores, drug stores, e-commerce websites and warehouse clubs in the United States and Canada, as well as in military channels and foodservice locations. Pinnacle Foods Inc. is a holding company whose sole asset is 100% ownership of Peak Finance Holdings LLC ("PFH"). PFH is a holding company whose sole asset is 100% ownership of Pinnacle Foods Finance LLC. The Company\'s business is organized into the following four reportable segments: The Frozen segment, The Grocery segment, The Boulder segment and The Specialty segment Frozen Segment Birds Eye is the largest brand in the $3.3 billion frozen vegetables category, with a 31.9% market share. Government programs, such as the USDA\'s My Plate program, and nutrition and health professionals continue to identify increased vegetable consumption as a key to better health. We believe that enhancing the taste of vegetables and making them exceptionally convenient are keys to driving more vegetable consumption. Birds Eye has taken a leadership role in increasing vegetable consumption, including encouraging children to eat more vegetables. We are supporters of the USDA\'s My Plate program and have engaged in breakthrough marketing efforts with major multi-media family entertainment partners to encourage children to eat more vegetables. We also compete in the frozen complete bagged meals category with our Birds Eye Voila! frozen bagged meals provide consumers with a high quality complete meal, including protein, starch, and vegetables, that can be prepared in a skillet in just minutes. Our Frozen segment also includes Hungry-Man frozen entrées, Van de Kamp\'s and frozen prepared seafood, Lender\'s frozen and refrigerated bagels and Celeste frozen pizza. Grocery Segment Included in the Grocery segment is our Duncan Hines portfolio, which includes cake mixes, ready-to-serve frostings, brownie mixes, and cookie mixes. In addition to our traditional cake mix offerings, our cake mix portfolio also includes premium offerings under the Duncan Hines Decadent and Duncan Hines Perfect Size brands. Duncan Hines is the #2 brand with a 28.9% market share in the $1.1 billion cake/brownie mix and frostings We compete in the shelf-stable salad dressings category with our Wish-Bone and Western brands, including our Wish-Bone E.V.O.O., Wish-Bone Ristorante Italiano and Wish-Bone Avocado Oil lines. We hold the #4 position in the $2.0 billion salad dressings category, with a combined share of 11.0%, and Wish-Bone holds the #1 position in the branded Italian segment of the category. Our Grocery segment also includes Armour, Nalley and Brooks canned meat, Mrs. Butterworth\'s and Log Cabin table syrups, Smart Balance premium margarine/spread, Comstock and Wilderness pie and pastry fruit fillings and Open Pit barbecue sauce. The Grocery segment also includes a diversified portfolio of shelf-stable and refrigerated products including a complete line of shelf-stable pickle products, primarily under the nationally-distributed Vlasic brand, and the regional brands under the Milwaukee\'s and Wiejske Wyroby brands. Our Vlasic brand, represented by its trademark Vlasic stork, has the highest consumer awareness and quality ratings in the pickle category. Vlasic is the #1 brand in the $790 million shelf-stable pickle category and Pinnacle pickle brands collectively hold a 34.3% market share. We offer a portfolio of gluten-free products under the ', 'company_name': 'Pinnacle Foods, Inc.', 'index': '7'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: To prohibit discrimination against individuals with disabilities who need long-term services and supports, and for other purposes.
Official summary of bill: Disability Integration Act of 2019
The bill allows civil actions by individuals subjected to, or about to be subjected to, a violation of its requirements.
Company name: Pinnacle Foods, Inc.
Company business description: We are a leading manufacturer, marketer and distributor of high-quality, branded food products in North America, with annual net sales of approximately $3.1 billion in fiscal 2017. Our brand portfolio enjoys strong household penetration in the United States ("U.S."), where our products can be found in over 85% of U.S. households. Our products are sold through supermarkets, grocery wholesalers and distributors, mass merchandisers, super centers, convenience stores, dollar stores, natural and organic food stores, drug stores, e-commerce websites and warehouse clubs in the United States and Canada, as well as in military channels and foodservice locations. Pinnacle Foods Inc. is a holding company whose sole asset is 100% ownership of Peak Finance Holdings LLC ("PFH"). PFH is a holding company whose sole asset is 100% ownership of Pinnacle Foods Finance LLC. The Company's business is organized into the following four reportable segments: The Frozen segment, The Grocery segment, The Boulder segment and The Specialty segment Frozen Segment Birds Eye is the largest brand in the $3.3 billion frozen vegetables category, with a 31.9% market share. Government programs, such as the USDA's My Plate program, and nutrition and health professionals continue to identify increased vegetable consumption as a key to better health. We believe that enhancing the taste of vegetables and making them exceptionally convenient are keys to driving more vegetable consumption. Birds Eye has taken a leadership role in increasing vegetable consumption, including encouraging children to eat more vegetables. We are supporters of the USDA's My Plate program and have engaged in breakthrough marketing efforts with major multi-media family entertainment partners to encourage children to eat more vegetables. We also compete in the frozen complete bagged meals category with our Birds Eye Voila! frozen bagged meals provide consumers with a high quality complete meal, including protein, starch, and vegetables, that can be prepared in a skillet in just minutes. Our Frozen segment also includes Hungry-Man frozen entrées, Van de Kamp's and frozen prepared seafood, Lender's frozen and refrigerated bagels and Celeste frozen pizza. Grocery Segment Included in the Grocery segment is our Duncan Hines portfolio, which includes cake mixes, ready-to-serve frostings, brownie mixes, and cookie mixes. In addition to our traditional cake mix offerings, our cake mix portfolio also includes premium offerings under the Duncan Hines Decadent and Duncan Hines Perfect Size brands. Duncan Hines is the #2 brand with a 28.9% market share in the $1.1 billion cake/brownie mix and frostings We compete in the shelf-stable salad dressings category with our Wish-Bone and Western brands, including our Wish-Bone E.V.O.O., Wish-Bone Ristorante Italiano and Wish-Bone Avocado Oil lines. We hold the #4 position in the $2.0 billion salad dressings category, with a combined share of 11.0%, and Wish-Bone holds the #1 position in the branded Italian segment of the category. Our Grocery segment also includes Armour, Nalley and Brooks canned meat, Mrs. Butterworth's and Log Cabin table syrups, Smart Balance premium margarine/spread, Comstock and Wilderness pie and pastry fruit fillings and Open Pit barbecue sauce. The Grocery segment also includes a diversified portfolio of shelf-stable and refrigerated products including a complete line of shelf-stable pickle products, primarily under the nationally-distributed Vlasic brand, and the regional brands under the Milwaukee's and Wiejske Wyroby brands. Our Vlasic brand, represented by its trademark Vlasic stork, has the highest consumer awareness and quality ratings in the pickle category. Vlasic is the #1 brand in the $790 million shelf-stable pickle category and Pinnacle pickle brands collectively hold a 34.3% market share. We offer a portfolio of gluten-free products under the
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
7 | No | {'bill_summary': 'Disability Integration Act of 2019\n\nThis bill prohibits government entities and insurance providers from denying community-based services to individuals with disabilities that require long-term service or support that would enable such individuals to live in the community and lead an independent life.\n\nSpecifically, these entities may not discriminate against such individuals in the provision of community-based services by such actions as imposing prohibited eligibility criteria, cost caps, or waiting lists or failing to provide a specific community-based service. Additionally, community-based services must be offered to individuals with such disabilities prior to institutionalization. Institutionalized individuals must be notified regularly of community-based alternatives.\n\nThe bill requires the Department of Justice and the Department of Health and Human Services (HHS) to issue regulations requiring government entities and insurance providers to offer community-based long-term services to individuals with such disabilities who would otherwise qualify for institutional placement. Government entities must ensure sufficient availability of affordable, accessible, and integrated housing that is not a disability-specific residential setting or a setting where services are tied to tenancy.\n\nRegulations shall also (1) require government entities and insurance providers to perform self-evaluation on current services, policies, and practices and concerning compliance with requirements of this bill; and (2) require government entities to submit a transition plan. HHS must determine annually whether each government entity is complying with the transition plan and must increase funding for those in compliance.\n\nThe bill allows civil actions by individuals subjected to, or about to be subjected to, a violation of its requirements.', 'bill_title': 'To prohibit discrimination against individuals with disabilities who need long-term services and supports, and for other purposes.', 'company_description': 'We are a leading manufacturer, marketer and distributor of high-quality, branded food products in North America, with annual net sales of approximately $3.1 billion in fiscal 2017. Our brand portfolio enjoys strong household penetration in the United States ("U.S."), where our products can be found in over 85% of U.S. households. Our products are sold through supermarkets, grocery wholesalers and distributors, mass merchandisers, super centers, convenience stores, dollar stores, natural and organic food stores, drug stores, e-commerce websites and warehouse clubs in the United States and Canada, as well as in military channels and foodservice locations. Pinnacle Foods Inc. is a holding company whose sole asset is 100% ownership of Peak Finance Holdings LLC ("PFH"). PFH is a holding company whose sole asset is 100% ownership of Pinnacle Foods Finance LLC. The Company\'s business is organized into the following four reportable segments: The Frozen segment, The Grocery segment, The Boulder segment and The Specialty segment Frozen Segment Birds Eye is the largest brand in the $3.3 billion frozen vegetables category, with a 31.9% market share. Government programs, such as the USDA\'s My Plate program, and nutrition and health professionals continue to identify increased vegetable consumption as a key to better health. We believe that enhancing the taste of vegetables and making them exceptionally convenient are keys to driving more vegetable consumption. Birds Eye has taken a leadership role in increasing vegetable consumption, including encouraging children to eat more vegetables. We are supporters of the USDA\'s My Plate program and have engaged in breakthrough marketing efforts with major multi-media family entertainment partners to encourage children to eat more vegetables. We also compete in the frozen complete bagged meals category with our Birds Eye Voila! frozen bagged meals provide consumers with a high quality complete meal, including protein, starch, and vegetables, that can be prepared in a skillet in just minutes. Our Frozen segment also includes Hungry-Man frozen entrées, Van de Kamp\'s and frozen prepared seafood, Lender\'s frozen and refrigerated bagels and Celeste frozen pizza. Grocery Segment Included in the Grocery segment is our Duncan Hines portfolio, which includes cake mixes, ready-to-serve frostings, brownie mixes, and cookie mixes. In addition to our traditional cake mix offerings, our cake mix portfolio also includes premium offerings under the Duncan Hines Decadent and Duncan Hines Perfect Size brands. Duncan Hines is the #2 brand with a 28.9% market share in the $1.1 billion cake/brownie mix and frostings We compete in the shelf-stable salad dressings category with our Wish-Bone and Western brands, including our Wish-Bone E.V.O.O., Wish-Bone Ristorante Italiano and Wish-Bone Avocado Oil lines. We hold the #4 position in the $2.0 billion salad dressings category, with a combined share of 11.0%, and Wish-Bone holds the #1 position in the branded Italian segment of the category. Our Grocery segment also includes Armour, Nalley and Brooks canned meat, Mrs. Butterworth\'s and Log Cabin table syrups, Smart Balance premium margarine/spread, Comstock and Wilderness pie and pastry fruit fillings and Open Pit barbecue sauce. The Grocery segment also includes a diversified portfolio of shelf-stable and refrigerated products including a complete line of shelf-stable pickle products, primarily under the nationally-distributed Vlasic brand, and the regional brands under the Milwaukee\'s and Wiejske Wyroby brands. Our Vlasic brand, represented by its trademark Vlasic stork, has the highest consumer awareness and quality ratings in the pickle category. Vlasic is the #1 brand in the $790 million shelf-stable pickle category and Pinnacle pickle brands collectively hold a 34.3% market share. We offer a portfolio of gluten-free products under the ', 'company_name': 'Pinnacle Foods, Inc.', 'index': '7'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: To prohibit discrimination against individuals with disabilities who need long-term services and supports, and for other purposes.
Official summary of bill: Disability Integration Act of 2019
The bill allows civil actions by individuals subjected to, or about to be subjected to, a violation of its requirements.
Company name: Pinnacle Foods, Inc.
Company business description: We are a leading manufacturer, marketer and distributor of high-quality, branded food products in North America, with annual net sales of approximately $3.1 billion in fiscal 2017. Our brand portfolio enjoys strong household penetration in the United States ("U.S."), where our products can be found in over 85% of U.S. households. Our products are sold through supermarkets, grocery wholesalers and distributors, mass merchandisers, super centers, convenience stores, dollar stores, natural and organic food stores, drug stores, e-commerce websites and warehouse clubs in the United States and Canada, as well as in military channels and foodservice locations. Pinnacle Foods Inc. is a holding company whose sole asset is 100% ownership of Peak Finance Holdings LLC ("PFH"). PFH is a holding company whose sole asset is 100% ownership of Pinnacle Foods Finance LLC. The Company's business is organized into the following four reportable segments: The Frozen segment, The Grocery segment, The Boulder segment and The Specialty segment Frozen Segment Birds Eye is the largest brand in the $3.3 billion frozen vegetables category, with a 31.9% market share. Government programs, such as the USDA's My Plate program, and nutrition and health professionals continue to identify increased vegetable consumption as a key to better health. We believe that enhancing the taste of vegetables and making them exceptionally convenient are keys to driving more vegetable consumption. Birds Eye has taken a leadership role in increasing vegetable consumption, including encouraging children to eat more vegetables. We are supporters of the USDA's My Plate program and have engaged in breakthrough marketing efforts with major multi-media family entertainment partners to encourage children to eat more vegetables. We also compete in the frozen complete bagged meals category with our Birds Eye Voila! frozen bagged meals provide consumers with a high quality complete meal, including protein, starch, and vegetables, that can be prepared in a skillet in just minutes. Our Frozen segment also includes Hungry-Man frozen entrées, Van de Kamp's and frozen prepared seafood, Lender's frozen and refrigerated bagels and Celeste frozen pizza. Grocery Segment Included in the Grocery segment is our Duncan Hines portfolio, which includes cake mixes, ready-to-serve frostings, brownie mixes, and cookie mixes. In addition to our traditional cake mix offerings, our cake mix portfolio also includes premium offerings under the Duncan Hines Decadent and Duncan Hines Perfect Size brands. Duncan Hines is the #2 brand with a 28.9% market share in the $1.1 billion cake/brownie mix and frostings We compete in the shelf-stable salad dressings category with our Wish-Bone and Western brands, including our Wish-Bone E.V.O.O., Wish-Bone Ristorante Italiano and Wish-Bone Avocado Oil lines. We hold the #4 position in the $2.0 billion salad dressings category, with a combined share of 11.0%, and Wish-Bone holds the #1 position in the branded Italian segment of the category. Our Grocery segment also includes Armour, Nalley and Brooks canned meat, Mrs. Butterworth's and Log Cabin table syrups, Smart Balance premium margarine/spread, Comstock and Wilderness pie and pastry fruit fillings and Open Pit barbecue sauce. The Grocery segment also includes a diversified portfolio of shelf-stable and refrigerated products including a complete line of shelf-stable pickle products, primarily under the nationally-distributed Vlasic brand, and the regional brands under the Milwaukee's and Wiejske Wyroby brands. Our Vlasic brand, represented by its trademark Vlasic stork, has the highest consumer awareness and quality ratings in the pickle category. Vlasic is the #1 brand in the $790 million shelf-stable pickle category and Pinnacle pickle brands collectively hold a 34.3% market share. We offer a portfolio of gluten-free products under the
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
2 | No | {'bill_summary': 'Violence Against Women Reauthorization Act of 2019\n\nThis bill modifies and reauthorizes through FY2024 programs and activities under the Violence Against Women Act that seek to prevent and respond to domestic violence, sexual assault, dating violence, and stalking.\n\nAmong other things, the bill also authorizes new programs, makes changes to federal firearms laws, and establishes new protections to promote housing stability and economic security for victims of domestic violence, sexual assault, dating violence, and stalking.', 'bill_title': 'To reauthorize the Violence Against Women Act of 1994, and for other purposes.', 'company_description': 'Our mission is to improve lives by eliminating the back row in higher education. We are a global leader in education technology. For more than a decade, we have been improving lives by powering world-class digital education. As a trusted partner and brand steward of great universities, we build, deliver, and support online graduate programs and certificates for working adults. Our industry-leading short courses, offered by GetSmarter, are designed to equip life-long learners with in-demand career skills. Over the past decade, we have developed new and innovative tools within our platform to enhance the effectiveness of instructional methods and improve student outcomes and the student experience. During that time, we have also improved our data-driven digital marketing capabilities across our ecosystem of offerings to generate increased student enrollments in a cost effective manner. As a result, demand for our comprehensive platform of integrated technology and services has increased significantly. When 2U was formed in 2008, we had one university client and one 2U-powered graduate program. Today, our university client base has grown to 35, our platform powers 49 graduate programs and over 90 short courses, and from inception to date we have enrolled over 44,000 students in 2U-powered graduate programs and over 86,000 students in our short courses. Our core strategy is to launch graduate programs and short courses with new and existing university clients, to increase student enrollments and graduations across our portfolio of offerings and to expand our non-degree offerings across the career curriculum continuum. We are also committed to continuously improving our platform to deliver high-quality university and student experiences and outcomes at scale. In our Short Course Segment, we target working professionals seeking career advancement through skills attainment. Our Graduate Program Segment derives revenue primarily from a contractually specified percentage of the amounts our university clients receive from their students in the 2U-enabled graduate program for tuition and fees, less credit card fees and other specified charges we have agreed to exclude in certain of our universicty client contracts. The Short Course Segment derives revenue directly from students for the tuition and fees paid to enroll in and progress through our short courses. We share a contractually specified percentage of the tuition and fees received from students in each course with the relevant university client. Our platform, which we refer to as the 2U Operating System, or 2UOS, consists of a seamlessly integrated ecosystem of technology, people and data. Through 2UOS, we provide our university clients with front-end and back-end cloud-based SaaS technology and technology-enabled services. These two components are tightly integrated and optimized with data analysis and machine learning techniques. 2UOS delivers technology with a human touch and is the keystone of our commitment to provide our university clients the tools they need to lead the digital transformation in education. 2UOS provides the following front-end technology and services to students enrolled in our offerings and to faculty members and university administrators supporting our offerings: Our online learning platform is a cohesive end-to-end learning and teaching platform, where our university clients can reliably deliver their high-quality educational content to students. For our Graduate Program Segment, our online learning platform replicates an intimate and live classroom environment and is accessible through proprietary web, mobile and TV applications as well as in an offline mode for convenient consumption of asynchronous coursework. With the recent integration of stem-based education tools and collaborative annotation technology and an improved data-driven user experience, we have significantly enhanced the learning experience for students in 2U-powered graduate programs and instruction capabilities for faculty. Our short course offerings are delivered through a separate proprietary learning platform that shares many of the core features of our Graduate Program Segment learning platform, with some exceptions, such as the enhanced features that facilitate the live classroom environment in our graduate program leaning platform. ', 'company_name': '2U, Inc.', 'index': '2'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: To reauthorize the Violence Against Women Act of 1994, and for other purposes.
Official summary of bill: Violence Against Women Reauthorization Act of 2019
Among other things, the bill also authorizes new programs, makes changes to federal firearms laws, and establishes new protections to promote housing stability and economic security for victims of domestic violence, sexual assault, dating violence, and stalking.
Company name: 2U, Inc.
Company business description: Our mission is to improve lives by eliminating the back row in higher education. We are a global leader in education technology. For more than a decade, we have been improving lives by powering world-class digital education. As a trusted partner and brand steward of great universities, we build, deliver, and support online graduate programs and certificates for working adults. Our industry-leading short courses, offered by GetSmarter, are designed to equip life-long learners with in-demand career skills. Over the past decade, we have developed new and innovative tools within our platform to enhance the effectiveness of instructional methods and improve student outcomes and the student experience. During that time, we have also improved our data-driven digital marketing capabilities across our ecosystem of offerings to generate increased student enrollments in a cost effective manner. As a result, demand for our comprehensive platform of integrated technology and services has increased significantly. When 2U was formed in 2008, we had one university client and one 2U-powered graduate program. Today, our university client base has grown to 35, our platform powers 49 graduate programs and over 90 short courses, and from inception to date we have enrolled over 44,000 students in 2U-powered graduate programs and over 86,000 students in our short courses. Our core strategy is to launch graduate programs and short courses with new and existing university clients, to increase student enrollments and graduations across our portfolio of offerings and to expand our non-degree offerings across the career curriculum continuum. We are also committed to continuously improving our platform to deliver high-quality university and student experiences and outcomes at scale. In our Short Course Segment, we target working professionals seeking career advancement through skills attainment. Our Graduate Program Segment derives revenue primarily from a contractually specified percentage of the amounts our university clients receive from their students in the 2U-enabled graduate program for tuition and fees, less credit card fees and other specified charges we have agreed to exclude in certain of our universicty client contracts. The Short Course Segment derives revenue directly from students for the tuition and fees paid to enroll in and progress through our short courses. We share a contractually specified percentage of the tuition and fees received from students in each course with the relevant university client. Our platform, which we refer to as the 2U Operating System, or 2UOS, consists of a seamlessly integrated ecosystem of technology, people and data. Through 2UOS, we provide our university clients with front-end and back-end cloud-based SaaS technology and technology-enabled services. These two components are tightly integrated and optimized with data analysis and machine learning techniques. 2UOS delivers technology with a human touch and is the keystone of our commitment to provide our university clients the tools they need to lead the digital transformation in education. 2UOS provides the following front-end technology and services to students enrolled in our offerings and to faculty members and university administrators supporting our offerings: Our online learning platform is a cohesive end-to-end learning and teaching platform, where our university clients can reliably deliver their high-quality educational content to students. For our Graduate Program Segment, our online learning platform replicates an intimate and live classroom environment and is accessible through proprietary web, mobile and TV applications as well as in an offline mode for convenient consumption of asynchronous coursework. With the recent integration of stem-based education tools and collaborative annotation technology and an improved data-driven user experience, we have significantly enhanced the learning experience for students in 2U-powered graduate programs and instruction capabilities for faculty. Our short course offerings are delivered through a separate proprietary learning platform that shares many of the core features of our Graduate Program Segment learning platform, with some exceptions, such as the enhanced features that facilitate the live classroom environment in our graduate program leaning platform.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
5 | Yes | {'bill_summary': 'Patients First Act of 2019\n\nThis bill requires the National Institutes of Health (NIH) to support stem cell research. Specifically, the NIH must conduct and support basic and applied research to develop techniques for the isolation, derivation, production, testing, and human clinical use of stem cells that may result in improved understanding of, or treatments for, diseases and other adverse health conditions. However, such techniques must not involve (1) the creation of a human embryo for research purposes; (2) the destruction or discarding of, or risk of injury to, a human embryo; or (3) the use of any stem cell the derivation or provision of which would be inconsistent with this bill.\n\nThe NIH must also report on peer-reviewed stem cell research proposals that were not funded.', 'bill_title': 'To intensify stem cell research showing evidence of substantial clinical benefit to patients, and for other purposes.', 'company_description': 'We are a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases. Our research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta, or TGF-beta, protein superfamily. By combining our discovery and development expertise, including our proprietary knowledge of the TGF-beta superfamily, and our internal protein engineering and manufacturing capabilities, we have generated several innovative therapeutic candidates, all of which encompass novel potential first-in-class mechanisms of action. We have focused and prioritized our research and development activities within three key therapeutic areas: hematologic, neuromuscular and pulmonary. If successful, these candidates could have the potential to significantly improve clinical outcomes for patients across these areas of high, unmet need. Luspatercept, our lead program, and sotatercept, are partnered with Celgene Corporation, or Celgene. Luspatercept is an erythroid maturation agent designed to promote red blood cell production through a novel mechanism, and is being developed to treat chronic anemia and associated complications in myelodysplastic syndromes, or MDS, beta-thalassemia, and myelofibrosis. Celgene is currently conducting two Phase 3 clinical trials with luspatercept; one for the treatment of patients with lower-risk MDS, known as the "MEDALIST" trial, and another for the treatment of patients with beta-thalassemia, also known as the "BELIEVE" trial. Celgene has recently initiated a Phase 2 trial in non-transfusion-dependent beta-thalassemia patients, referred to as the "BEYOND" trial. We further expect Celgene to initiate a Phase 3 clinical trial, the "COMMANDS" trial, in first-line, lower-risk MDS patients in the first half of 2018. Enrollment is also currently ongoing in a Phase 2 clinical trial for the treatment of patients with myelofibrosis, a rare bone marrow disorder. If luspatercept were to receive regulatory approval for each of these indications in the United States and Europe, we believe that there is an aggregate sales opportunity for this product in excess of $2 billion. For sotatercept, we announced in September 2017 that Celgene granted us the rights to fund, develop, and lead the global commercialization of sotatercept in pulmonary hypertension, including pulmonary arterial hypertension, or PAH. PAH is a rare and chronic, rapidly progressing disorder characterized by the constriction of small pulmonary arteries, resulting in abnormally high blood pressure in the pulmonary arteries. If sotatercept is commercialized to treat PAH and we recognize such revenue, then Celgene will be eligible to receive a royalty in the low 20% range on global net sales. We expect to initiate a Phase 2 clinical trial for the treatment of patients with PAH in the first half of 2018. For luspatercept and, outside of pulmonary hypertension, sotatercept, Celgene is responsible for paying 100% of the development costs for all clinical trials. ACE-083 is designed for the treatment of focal muscle disorders, and we are currently conducting Phase 2 clinical trials with ACE-083 in patients with facioscapulohumeral dystrophy, or FSHD, as well as in patients with Charcot-Marie-Tooth disease, or CMT. In January 2018, we announced preliminary results for the first two cohorts in part 1 of the Phase 2 clinical trial with ACE-083 in patients with FSHD showing marked increases in the mean total muscle volume of the muscles treated with ACE-083 measured using magnetic resonance imaging, or MRI. We expect to initiate part 2 of the ACE-083 FSHD Phase 2 trial during the second quarter of this year, and we expect to report preliminary results from all dose-escalation cohorts of part 1 in our FSHD and CMT Phase 2 clinical trials with ACE-083 in the second half of this year. In addition to our mid- to late-stage clinical programs, we initiated a Phase 1 healthy volunteer study in early 2018 with ACE-2494, our wholly-owned systemic muscle agent from our proprietary platform technology, IntelliTrap™, and we expect to report initial results from this healthy volunteer study in the first half of 2019. We are also conducting research within our three focused disease areas—hematologic, neuromuscular and pulmonary—in order to identify new therapeutic candidates to advance into clinical trials. As of December 31, 2017 our operations have been funded primarily by $105.1 million in equity investments from venture investors, $539.7 million from public investors, $123.7 million in equity investments from our collaboration partners and $273.7 million in upfront payments, milestones, and net research and development payments from our collaboration partners. Announce MEDALIST Phase 3 clinical trial top-line results in mid-2018. Initiate the COMMANDS Phase 3 clinical trial in the first half of 2018. ', 'company_name': 'Acceleron Pharma, Inc.', 'index': '5'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: To intensify stem cell research showing evidence of substantial clinical benefit to patients, and for other purposes.
Official summary of bill: Patients First Act of 2019
The NIH must also report on peer-reviewed stem cell research proposals that were not funded.
Company name: Acceleron Pharma, Inc.
Company business description: We are a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases. Our research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta, or TGF-beta, protein superfamily. By combining our discovery and development expertise, including our proprietary knowledge of the TGF-beta superfamily, and our internal protein engineering and manufacturing capabilities, we have generated several innovative therapeutic candidates, all of which encompass novel potential first-in-class mechanisms of action. We have focused and prioritized our research and development activities within three key therapeutic areas: hematologic, neuromuscular and pulmonary. If successful, these candidates could have the potential to significantly improve clinical outcomes for patients across these areas of high, unmet need. Luspatercept, our lead program, and sotatercept, are partnered with Celgene Corporation, or Celgene. Luspatercept is an erythroid maturation agent designed to promote red blood cell production through a novel mechanism, and is being developed to treat chronic anemia and associated complications in myelodysplastic syndromes, or MDS, beta-thalassemia, and myelofibrosis. Celgene is currently conducting two Phase 3 clinical trials with luspatercept; one for the treatment of patients with lower-risk MDS, known as the "MEDALIST" trial, and another for the treatment of patients with beta-thalassemia, also known as the "BELIEVE" trial. Celgene has recently initiated a Phase 2 trial in non-transfusion-dependent beta-thalassemia patients, referred to as the "BEYOND" trial. We further expect Celgene to initiate a Phase 3 clinical trial, the "COMMANDS" trial, in first-line, lower-risk MDS patients in the first half of 2018. Enrollment is also currently ongoing in a Phase 2 clinical trial for the treatment of patients with myelofibrosis, a rare bone marrow disorder. If luspatercept were to receive regulatory approval for each of these indications in the United States and Europe, we believe that there is an aggregate sales opportunity for this product in excess of $2 billion. For sotatercept, we announced in September 2017 that Celgene granted us the rights to fund, develop, and lead the global commercialization of sotatercept in pulmonary hypertension, including pulmonary arterial hypertension, or PAH. PAH is a rare and chronic, rapidly progressing disorder characterized by the constriction of small pulmonary arteries, resulting in abnormally high blood pressure in the pulmonary arteries. If sotatercept is commercialized to treat PAH and we recognize such revenue, then Celgene will be eligible to receive a royalty in the low 20% range on global net sales. We expect to initiate a Phase 2 clinical trial for the treatment of patients with PAH in the first half of 2018. For luspatercept and, outside of pulmonary hypertension, sotatercept, Celgene is responsible for paying 100% of the development costs for all clinical trials. ACE-083 is designed for the treatment of focal muscle disorders, and we are currently conducting Phase 2 clinical trials with ACE-083 in patients with facioscapulohumeral dystrophy, or FSHD, as well as in patients with Charcot-Marie-Tooth disease, or CMT. In January 2018, we announced preliminary results for the first two cohorts in part 1 of the Phase 2 clinical trial with ACE-083 in patients with FSHD showing marked increases in the mean total muscle volume of the muscles treated with ACE-083 measured using magnetic resonance imaging, or MRI. We expect to initiate part 2 of the ACE-083 FSHD Phase 2 trial during the second quarter of this year, and we expect to report preliminary results from all dose-escalation cohorts of part 1 in our FSHD and CMT Phase 2 clinical trials with ACE-083 in the second half of this year. In addition to our mid- to late-stage clinical programs, we initiated a Phase 1 healthy volunteer study in early 2018 with ACE-2494, our wholly-owned systemic muscle agent from our proprietary platform technology, IntelliTrap™, and we expect to report initial results from this healthy volunteer study in the first half of 2019. We are also conducting research within our three focused disease areas—hematologic, neuromuscular and pulmonary—in order to identify new therapeutic candidates to advance into clinical trials. As of December 31, 2017 our operations have been funded primarily by $105.1 million in equity investments from venture investors, $539.7 million from public investors, $123.7 million in equity investments from our collaboration partners and $273.7 million in upfront payments, milestones, and net research and development payments from our collaboration partners. Announce MEDALIST Phase 3 clinical trial top-line results in mid-2018. Initiate the COMMANDS Phase 3 clinical trial in the first half of 2018.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
4 | No | {'bill_summary': 'Federal Register Modernization Act\n\nThis bill revises provisions regarding the Federal Register or the Code of Federal Regulations, including to replace requirements that the documents be printed with requirements that the documents be published.\n\nThe bill provides that in a continuity of operations event in which the Government Publishing Office (GPO) does not fulfill its publication requirements, the Office of the Federal Register may establish a website to publish the Federal Register until such time that GPO resumes publication.', 'bill_title': 'A bill to amend title 44, United States Code, to modernize the Federal Register, and for other purposes.', 'company_description': '"us" or the "Parent Company") is a leading provider of financial products to middle-income households in the United States and Canada with 130,736 licensed sales representatives as of December 31, 2018. This network of independent contractor sales representatives ("sales representatives" or "sales force") assists our clients in meeting their needs for term life insurance, which we underwrite, and mutual funds, annuities, managed investments and other financial products, which we distribute primarily on behalf of third parties. Licensed sales representatives primarily use our proprietary financial needs analysis tool ("FNA") and an educational approach to demonstrate how our product offerings can assist clients to provide financial protection for their families, save for their retirement and other needs, and manage their debt. Typically, our clients are the friends, family members and personal acquaintances of sales representatives. We provide an entrepreneurial business opportunity for individuals to distribute financial products. Low entry fees as well as the ability to select their own schedules and time commitments allow sales representatives to supplement their income by starting their own independent businesses without leaving their current jobs. Our unique compensation structure, technology, sales support and back-office processing are designed to enable sales representatives to successfully grow their independent businesses. We believe there is significant opportunity to meet the increasing array of financial services needs of our clients. We intend to leverage the sales force to meet such client needs, which will drive long-term value for all of our stakeholders. • Broadening and strengthening our protection product portfolio; • Providing offerings that enhance our Investment and Savings Products ("ISP") business; and • Developing digital capabilities to deepen our client relationships. Primerica Life Insurance Company ("Primerica Life"), our principal life insurance underwriting company; and • ("PFS Investments"), our investment and savings products company, broker-dealer and registered investment advisor. Primerica Life is domiciled in Tennessee, and its wholly owned subsidiary, National Benefit Life Insurance Company ("NBLIC"), is a New York-domiciled life insurance underwriting company. Primerica Life Insurance Company of Canada ("Primerica Life Canada"), our Canadian life insurance underwriting company; • ("PFSL Investments Canada"), our Canadian licensed mutual fund dealer; and • ("PFSL Fund Management"), our Canadian investment funds manager. Our clients are generally middle-income consumers, which we define as households with $30,000 to $100,000 of annual income. According to the 2017 U.S. Census Bureau Current Population Survey, the latest period for which data is available, almost 50% of U.S. households fall in this range. Many have inadequate or no life insurance coverage. Individual life insurance sales in the United States declined from 12.5 million policy sales in 1975 to 9.8 million policy sales in 2017, the latest period for which data is available, according to the Life Insurance Marketing and Research Association International, Inc. ("LIMRA"), a worldwide association of insurance and financial services companies. We believe that term life insurance, which we have provided to middle-income clients for many years, is generally the best option for them to meet their life insurance needs. Many need help saving for retirement and other personal goals.', 'company_name': 'Primerica, Inc.', 'index': '4'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: A bill to amend title 44, United States Code, to modernize the Federal Register, and for other purposes.
Official summary of bill: Federal Register Modernization Act
The bill provides that in a continuity of operations event in which the Government Publishing Office (GPO) does not fulfill its publication requirements, the Office of the Federal Register may establish a website to publish the Federal Register until such time that GPO resumes publication.
Company name: Primerica, Inc.
Company business description: "us" or the "Parent Company") is a leading provider of financial products to middle-income households in the United States and Canada with 130,736 licensed sales representatives as of December 31, 2018. This network of independent contractor sales representatives ("sales representatives" or "sales force") assists our clients in meeting their needs for term life insurance, which we underwrite, and mutual funds, annuities, managed investments and other financial products, which we distribute primarily on behalf of third parties. Licensed sales representatives primarily use our proprietary financial needs analysis tool ("FNA") and an educational approach to demonstrate how our product offerings can assist clients to provide financial protection for their families, save for their retirement and other needs, and manage their debt. Typically, our clients are the friends, family members and personal acquaintances of sales representatives. We provide an entrepreneurial business opportunity for individuals to distribute financial products. Low entry fees as well as the ability to select their own schedules and time commitments allow sales representatives to supplement their income by starting their own independent businesses without leaving their current jobs. Our unique compensation structure, technology, sales support and back-office processing are designed to enable sales representatives to successfully grow their independent businesses. We believe there is significant opportunity to meet the increasing array of financial services needs of our clients. We intend to leverage the sales force to meet such client needs, which will drive long-term value for all of our stakeholders. • Broadening and strengthening our protection product portfolio; • Providing offerings that enhance our Investment and Savings Products ("ISP") business; and • Developing digital capabilities to deepen our client relationships. Primerica Life Insurance Company ("Primerica Life"), our principal life insurance underwriting company; and • ("PFS Investments"), our investment and savings products company, broker-dealer and registered investment advisor. Primerica Life is domiciled in Tennessee, and its wholly owned subsidiary, National Benefit Life Insurance Company ("NBLIC"), is a New York-domiciled life insurance underwriting company. Primerica Life Insurance Company of Canada ("Primerica Life Canada"), our Canadian life insurance underwriting company; • ("PFSL Investments Canada"), our Canadian licensed mutual fund dealer; and • ("PFSL Fund Management"), our Canadian investment funds manager. Our clients are generally middle-income consumers, which we define as households with $30,000 to $100,000 of annual income. According to the 2017 U.S. Census Bureau Current Population Survey, the latest period for which data is available, almost 50% of U.S. households fall in this range. Many have inadequate or no life insurance coverage. Individual life insurance sales in the United States declined from 12.5 million policy sales in 1975 to 9.8 million policy sales in 2017, the latest period for which data is available, according to the Life Insurance Marketing and Research Association International, Inc. ("LIMRA"), a worldwide association of insurance and financial services companies. We believe that term life insurance, which we have provided to middle-income clients for many years, is generally the best option for them to meet their life insurance needs. Many need help saving for retirement and other personal goals.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
1 | No | {'bill_summary': 'Rehabilitation for Multiemployer Pensions Act of 2019\n\nThis bill establishes the Pension Rehabilitation Administration within the Department of the Treasury and a related trust fund to make loans to certain multiemployer defined benefit pension plans.\n\nTo receive a loan, a plan must be (1) in critical and declining status, including any plan with respect to which a suspension of benefits has been approved; (2) in critical status, have a modified funded percentage of less than 40%, and have a ratio of active to inactive participants which is less than two to five; or (3) insolvent, if the plan became insolvent after December 16, 2014, and has not been terminated.\n\nTreasury must transfer amounts, which may include proceeds from bonds and other obligations, from the general fund to the trust fund established by this bill as necessary to fund the program. The Pension Rehabilitation Administration may use the funds, without a further appropriation, to make loans, pay principal and interest on obligations, or for administrative and operating expenses.\n\nThe bill allows the sponsor of a multiemployer pension plan that is applying for a loan under this bill to also apply to the Pension Benefit Guaranty Corporation (PBGC) for financial assistance if, after receiving the loan, the plan will still become (or remain) insolvent within the 30-year period beginning on the date of the loan.\n\nThe bill also appropriates to the PBGC the funds that are necessary to provide the financial assistance required by this bill.\n\nThe bill modifies the requirements for the distribution of remaining pension benefits from certain defined contribution plans to a designated beneficiary upon death of an employee. The bill increases penalties for failure to file a tax return, and certain retirement plan returns.', 'bill_title': 'To amend the Internal Revenue Code of 1986 to create a Pension Rehabilitation Trust Fund, to establish a Pension Rehabilitation Administration within the Department of the Treasury to make loans to multiemployer defined benefit plans, and for other purposes.', 'company_description': 'We acquire, develop, own and operate self-storage facilities , which offer storage spaces for lease on a month-to-month basis, for personal and business use. We are the largest owner and operator of self-storage facilities in the U.S. We have direct and indirect equity interests in 2,429 self-storage facilities that we consolidate (an aggregate of 162 million net rentable square feet of space) located in 38 states within the U.S. operating under the "Public Storage" brand name. Ancillary Operations : We reinsure policies against losses to goods stored by customers in our self-storage facilities and sell merchandise, primarily locks and cardboard boxes, at our self-storage facilities. Inc. ("PSB"), a publicly held REIT that owns, operates, acquires and develops commercial properties, primarily multi-tenant flex, office, and industrial parks. At December 31, 201 8 , PSB owns and operates 28. 2 million rentable square feet of commercial space. : We have a 35 % equity inter est in Shurgard Self Storage SA ("Shurgard Europe"), a publicly held company trading under Euronext Brussels under the "SHUR" symbol , which owns 232 self-storage facilities (13 million net rentable square feet) located in seven countries in Western Europe operated under the "Shurgard" brand name. We believe Shurgard Europe is the largest owner and operator of self-storage facilities in Western Europe. We also manage 33 self-storage facilities for third parties . We are seeking to expand our third-party management operations to further increase our economies of scale and leverage our brand; however, there is no 5 assurance that we will be able to do so. We also own 0.8 million net rentable square feet of commercial space which is managed primarily by PSB . For all periods presented herein, we have elected to be treated as a REIT, as defined in the Internal Revenue Code of 1986, as amended (the "Code") . and we expect to continue to elect and qualify as a REIT. We believe that our customers genera lly store their goods within a three to f ive mile radius of their home or business . Our facilities compete with nearby self-storage facilities owned by other operators using marketing channels similar to ours , including Internet advertising, signage, and banners and offer services similar to ours . A s a result, competition is significant and affects the occupancy levels, rental rates, rental income and operating expenses of our facilities. In the last three years, there has been a marked increase in development of new self-storage facilities in many of the markets we operate in, due to the favorable economics of development which we have also taken advantage of. These newly developed facilities compete with many of the facilities we own, negatively impacting our occupancies, rental rates, and rental growth. This increase in supply has been most notable in Atlanta, Austin, Charlotte, Chicago, Dallas, Denver, Houston, New York, and Portland. Ownership and operation of self-storage facilities is highly fragmented. As the largest owner of self-storage facilities, we believe that we own approximately 7 % of the self-storage square footage in the U.S. and that collectively the five largest self-storage owners in the U.S. own approximately 15 %, with the remaining 8 5 % owned by numerous regional and local operators. We believe that we have significant market share and concentration in major metropolitan centers, with approximately 71 % of our 201 8 same-store revenues generated in the 20 Metropolitan Statistical Areas (each, an "MSA", as defined by the U.S. Census Bureau) with the highest population levels. Industry fragmentation also provides opportunities for us to acquire additional facilities; however, we compete with a wide variety of institutions and other investors who also view self-storage facilities as attractive investments. The amount of capital available for real estate investments greatly influences the competition for ownership interests in facilities and, by extension, the yields that we can achieve on newly acquired investments. a s well as analyze customer data and quickly change each of our individual properties', 'company_name': 'Public Storage', 'index': '1'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: To amend the Internal Revenue Code of 1986 to create a Pension Rehabilitation Trust Fund, to establish a Pension Rehabilitation Administration within the Department of the Treasury to make loans to multiemployer defined benefit plans, and for other purposes.
Official summary of bill: Rehabilitation for Multiemployer Pensions Act of 2019
The bill modifies the requirements for the distribution of remaining pension benefits from certain defined contribution plans to a designated beneficiary upon death of an employee. The bill increases penalties for failure to file a tax return, and certain retirement plan returns.
Company name: Public Storage
Company business description: We acquire, develop, own and operate self-storage facilities , which offer storage spaces for lease on a month-to-month basis, for personal and business use. We are the largest owner and operator of self-storage facilities in the U.S. We have direct and indirect equity interests in 2,429 self-storage facilities that we consolidate (an aggregate of 162 million net rentable square feet of space) located in 38 states within the U.S. operating under the "Public Storage" brand name. Ancillary Operations : We reinsure policies against losses to goods stored by customers in our self-storage facilities and sell merchandise, primarily locks and cardboard boxes, at our self-storage facilities. Inc. ("PSB"), a publicly held REIT that owns, operates, acquires and develops commercial properties, primarily multi-tenant flex, office, and industrial parks. At December 31, 201 8 , PSB owns and operates 28. 2 million rentable square feet of commercial space. : We have a 35 % equity inter est in Shurgard Self Storage SA ("Shurgard Europe"), a publicly held company trading under Euronext Brussels under the "SHUR" symbol , which owns 232 self-storage facilities (13 million net rentable square feet) located in seven countries in Western Europe operated under the "Shurgard" brand name. We believe Shurgard Europe is the largest owner and operator of self-storage facilities in Western Europe. We also manage 33 self-storage facilities for third parties . We are seeking to expand our third-party management operations to further increase our economies of scale and leverage our brand; however, there is no 5 assurance that we will be able to do so. We also own 0.8 million net rentable square feet of commercial space which is managed primarily by PSB . For all periods presented herein, we have elected to be treated as a REIT, as defined in the Internal Revenue Code of 1986, as amended (the "Code") . and we expect to continue to elect and qualify as a REIT. We believe that our customers genera lly store their goods within a three to f ive mile radius of their home or business . Our facilities compete with nearby self-storage facilities owned by other operators using marketing channels similar to ours , including Internet advertising, signage, and banners and offer services similar to ours . A s a result, competition is significant and affects the occupancy levels, rental rates, rental income and operating expenses of our facilities. In the last three years, there has been a marked increase in development of new self-storage facilities in many of the markets we operate in, due to the favorable economics of development which we have also taken advantage of. These newly developed facilities compete with many of the facilities we own, negatively impacting our occupancies, rental rates, and rental growth. This increase in supply has been most notable in Atlanta, Austin, Charlotte, Chicago, Dallas, Denver, Houston, New York, and Portland. Ownership and operation of self-storage facilities is highly fragmented. As the largest owner of self-storage facilities, we believe that we own approximately 7 % of the self-storage square footage in the U.S. and that collectively the five largest self-storage owners in the U.S. own approximately 15 %, with the remaining 8 5 % owned by numerous regional and local operators. We believe that we have significant market share and concentration in major metropolitan centers, with approximately 71 % of our 201 8 same-store revenues generated in the 20 Metropolitan Statistical Areas (each, an "MSA", as defined by the U.S. Census Bureau) with the highest population levels. Industry fragmentation also provides opportunities for us to acquire additional facilities; however, we compete with a wide variety of institutions and other investors who also view self-storage facilities as attractive investments. The amount of capital available for real estate investments greatly influences the competition for ownership interests in facilities and, by extension, the yields that we can achieve on newly acquired investments. a s well as analyze customer data and quickly change each of our individual properties
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
7 | No | {'bill_summary': 'Disability Integration Act of 2019\n\nThis bill prohibits government entities and insurance providers from denying community-based services to individuals with disabilities that require long-term service or support that would enable such individuals to live in the community and lead an independent life.\n\nSpecifically, these entities may not discriminate against such individuals in the provision of community-based services by such actions as imposing prohibited eligibility criteria, cost caps, or waiting lists or failing to provide a specific community-based service. Additionally, community-based services must be offered to individuals with such disabilities prior to institutionalization. Institutionalized individuals must be notified regularly of community-based alternatives.\n\nThe bill requires the Department of Justice and the Department of Health and Human Services (HHS) to issue regulations requiring government entities and insurance providers to offer community-based long-term services to individuals with such disabilities who would otherwise qualify for institutional placement. Government entities must ensure sufficient availability of affordable, accessible, and integrated housing that is not a disability-specific residential setting or a setting where services are tied to tenancy.\n\nRegulations shall also (1) require government entities and insurance providers to perform self-evaluation on current services, policies, and practices and concerning compliance with requirements of this bill; and (2) require government entities to submit a transition plan. HHS must determine annually whether each government entity is complying with the transition plan and must increase funding for those in compliance.\n\nThe bill allows civil actions by individuals subjected to, or about to be subjected to, a violation of its requirements.', 'bill_title': 'To prohibit discrimination against individuals with disabilities who need long-term services and supports, and for other purposes.', 'company_description': 'We are a leading manufacturer, marketer and distributor of high-quality, branded food products in North America, with annual net sales of approximately $3.1 billion in fiscal 2017. Our brand portfolio enjoys strong household penetration in the United States ("U.S."), where our products can be found in over 85% of U.S. households. Our products are sold through supermarkets, grocery wholesalers and distributors, mass merchandisers, super centers, convenience stores, dollar stores, natural and organic food stores, drug stores, e-commerce websites and warehouse clubs in the United States and Canada, as well as in military channels and foodservice locations. Pinnacle Foods Inc. is a holding company whose sole asset is 100% ownership of Peak Finance Holdings LLC ("PFH"). PFH is a holding company whose sole asset is 100% ownership of Pinnacle Foods Finance LLC. The Company\'s business is organized into the following four reportable segments: The Frozen segment, The Grocery segment, The Boulder segment and The Specialty segment Frozen Segment Birds Eye is the largest brand in the $3.3 billion frozen vegetables category, with a 31.9% market share. Government programs, such as the USDA\'s My Plate program, and nutrition and health professionals continue to identify increased vegetable consumption as a key to better health. We believe that enhancing the taste of vegetables and making them exceptionally convenient are keys to driving more vegetable consumption. Birds Eye has taken a leadership role in increasing vegetable consumption, including encouraging children to eat more vegetables. We are supporters of the USDA\'s My Plate program and have engaged in breakthrough marketing efforts with major multi-media family entertainment partners to encourage children to eat more vegetables. We also compete in the frozen complete bagged meals category with our Birds Eye Voila! frozen bagged meals provide consumers with a high quality complete meal, including protein, starch, and vegetables, that can be prepared in a skillet in just minutes. Our Frozen segment also includes Hungry-Man frozen entrées, Van de Kamp\'s and frozen prepared seafood, Lender\'s frozen and refrigerated bagels and Celeste frozen pizza. Grocery Segment Included in the Grocery segment is our Duncan Hines portfolio, which includes cake mixes, ready-to-serve frostings, brownie mixes, and cookie mixes. In addition to our traditional cake mix offerings, our cake mix portfolio also includes premium offerings under the Duncan Hines Decadent and Duncan Hines Perfect Size brands. Duncan Hines is the #2 brand with a 28.9% market share in the $1.1 billion cake/brownie mix and frostings We compete in the shelf-stable salad dressings category with our Wish-Bone and Western brands, including our Wish-Bone E.V.O.O., Wish-Bone Ristorante Italiano and Wish-Bone Avocado Oil lines. We hold the #4 position in the $2.0 billion salad dressings category, with a combined share of 11.0%, and Wish-Bone holds the #1 position in the branded Italian segment of the category. Our Grocery segment also includes Armour, Nalley and Brooks canned meat, Mrs. Butterworth\'s and Log Cabin table syrups, Smart Balance premium margarine/spread, Comstock and Wilderness pie and pastry fruit fillings and Open Pit barbecue sauce. The Grocery segment also includes a diversified portfolio of shelf-stable and refrigerated products including a complete line of shelf-stable pickle products, primarily under the nationally-distributed Vlasic brand, and the regional brands under the Milwaukee\'s and Wiejske Wyroby brands. Our Vlasic brand, represented by its trademark Vlasic stork, has the highest consumer awareness and quality ratings in the pickle category. Vlasic is the #1 brand in the $790 million shelf-stable pickle category and Pinnacle pickle brands collectively hold a 34.3% market share. We offer a portfolio of gluten-free products under the ', 'company_name': 'Pinnacle Foods, Inc.', 'index': '7'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: To prohibit discrimination against individuals with disabilities who need long-term services and supports, and for other purposes.
Official summary of bill: Disability Integration Act of 2019
The bill allows civil actions by individuals subjected to, or about to be subjected to, a violation of its requirements.
Company name: Pinnacle Foods, Inc.
Company business description: We are a leading manufacturer, marketer and distributor of high-quality, branded food products in North America, with annual net sales of approximately $3.1 billion in fiscal 2017. Our brand portfolio enjoys strong household penetration in the United States ("U.S."), where our products can be found in over 85% of U.S. households. Our products are sold through supermarkets, grocery wholesalers and distributors, mass merchandisers, super centers, convenience stores, dollar stores, natural and organic food stores, drug stores, e-commerce websites and warehouse clubs in the United States and Canada, as well as in military channels and foodservice locations. Pinnacle Foods Inc. is a holding company whose sole asset is 100% ownership of Peak Finance Holdings LLC ("PFH"). PFH is a holding company whose sole asset is 100% ownership of Pinnacle Foods Finance LLC. The Company's business is organized into the following four reportable segments: The Frozen segment, The Grocery segment, The Boulder segment and The Specialty segment Frozen Segment Birds Eye is the largest brand in the $3.3 billion frozen vegetables category, with a 31.9% market share. Government programs, such as the USDA's My Plate program, and nutrition and health professionals continue to identify increased vegetable consumption as a key to better health. We believe that enhancing the taste of vegetables and making them exceptionally convenient are keys to driving more vegetable consumption. Birds Eye has taken a leadership role in increasing vegetable consumption, including encouraging children to eat more vegetables. We are supporters of the USDA's My Plate program and have engaged in breakthrough marketing efforts with major multi-media family entertainment partners to encourage children to eat more vegetables. We also compete in the frozen complete bagged meals category with our Birds Eye Voila! frozen bagged meals provide consumers with a high quality complete meal, including protein, starch, and vegetables, that can be prepared in a skillet in just minutes. Our Frozen segment also includes Hungry-Man frozen entrées, Van de Kamp's and frozen prepared seafood, Lender's frozen and refrigerated bagels and Celeste frozen pizza. Grocery Segment Included in the Grocery segment is our Duncan Hines portfolio, which includes cake mixes, ready-to-serve frostings, brownie mixes, and cookie mixes. In addition to our traditional cake mix offerings, our cake mix portfolio also includes premium offerings under the Duncan Hines Decadent and Duncan Hines Perfect Size brands. Duncan Hines is the #2 brand with a 28.9% market share in the $1.1 billion cake/brownie mix and frostings We compete in the shelf-stable salad dressings category with our Wish-Bone and Western brands, including our Wish-Bone E.V.O.O., Wish-Bone Ristorante Italiano and Wish-Bone Avocado Oil lines. We hold the #4 position in the $2.0 billion salad dressings category, with a combined share of 11.0%, and Wish-Bone holds the #1 position in the branded Italian segment of the category. Our Grocery segment also includes Armour, Nalley and Brooks canned meat, Mrs. Butterworth's and Log Cabin table syrups, Smart Balance premium margarine/spread, Comstock and Wilderness pie and pastry fruit fillings and Open Pit barbecue sauce. The Grocery segment also includes a diversified portfolio of shelf-stable and refrigerated products including a complete line of shelf-stable pickle products, primarily under the nationally-distributed Vlasic brand, and the regional brands under the Milwaukee's and Wiejske Wyroby brands. Our Vlasic brand, represented by its trademark Vlasic stork, has the highest consumer awareness and quality ratings in the pickle category. Vlasic is the #1 brand in the $790 million shelf-stable pickle category and Pinnacle pickle brands collectively hold a 34.3% market share. We offer a portfolio of gluten-free products under the
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
11 | No | {'bill_summary': ' \n\n This resolution sets forth the rule for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for FY2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for FY2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for FY2024.', 'bill_title': '\nProviding for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for the fiscal year ending September 30, 2024, and for other purposes.\n\n', 'company_description': ' California Language Academy was founded in July 2010 by a family with the mission of providing personalized, intimate, and engaging language learning services. Together, we have established a high-quality, family-owned and operated language school that offers small class sizes to meet the individual needs of each student’s learning goals and objectives. We employ highly qualified and dedicated instructors and our comprehensive curricula are designed to build students’ skills and self-confidence when communicating in English or a foreign language in either an academic or professional setting. California Language Academy is unique because it is a family-owned and operated business where our team is friendly, professional, attentive and highly responsive. Our schedule is flexible, and the quick assessment of student skills and challenges creates a more “catered” client service.', 'company_name': ' California Language Academy', 'index': 11} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill:
Providing for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for the fiscal year ending September 30, 2024, and for other purposes.
This resolution sets forth the rule for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for FY2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for FY2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for FY2024.
Company name: California Language Academy
Company business description: California Language Academy was founded in July 2010 by a family with the mission of providing personalized, intimate, and engaging language learning services. Together, we have established a high-quality, family-owned and operated language school that offers small class sizes to meet the individual needs of each student’s learning goals and objectives. We employ highly qualified and dedicated instructors and our comprehensive curricula are designed to build students’ skills and self-confidence when communicating in English or a foreign language in either an academic or professional setting. California Language Academy is unique because it is a family-owned and operated business where our team is friendly, professional, attentive and highly responsive. Our schedule is flexible, and the quick assessment of student skills and challenges creates a more “catered” client service.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
13 | Yes | {'bill_summary': " his bill makes changes to the federal framework governing the reporting of crimes involving the online sexual exploitation of children.\n\nSpecifically, the bill makes changes to the requirements for electronic communication service providers and remote computing service providers (providers) to submit reports to the National Center for Missing and Exploited Children (NCMEC) when they become aware of violations involving the online sexual exploitation of children.\n\nAmong the changes, the bill\nincreases the amount of time—from 90 days to 1 year—that a provider must preserve the contents of a report,\nrequires (currently, authorizes) providers to report on a violation that may be planned or imminent, and\nextends the requirement for providers to report apparent violations involving the sexual exploitation of children to instances involving child sex trafficking or coercion or enticement of a minor to engage in prostitution or any other illegal sexual activity.\nAdditionally, the bill increases the maximum fines for providers who knowingly and willfully fail to submit reports.\n\nFinally, the bill limits the liability of vendors that contract with NCMEC for claims arising from storing and transferring visual depictions of child sexual abuse material (i.e., child pornography). It also limits the liability of minors, or persons acting on behalf of minors, for reporting to NCMEC's CyberTipline apparent violations involving child sexual abuse material in which the child is depicted, including a copy of the visual depiction of the minor.", 'bill_title': ' A bill to amend title 18, United States Code, to strengthen reporting to the CyberTipline related to online sexual exploitation of children, to modernize liabilities for such reports, to preserve the contents of such reports for 1 year, and for other purposes.', 'company_description': ' The Gatti Law Firm is an established, full-service personal injury law firm providing thoughtful, thorough, and zealous representation to people who have been injured and suffered loss. For over 50 years, we have been your advocates against the individuals, insurance companies, and corporations that have caused you harm. Our mission is to aid and protect victims of all types of personal injury including, automobile accidents, work injuries, nursing home abuse, sexual abuse, childbirth injuries, brain injuries, wrongful death, and other areas. We are dedicated to providing you with personalized, tenacious, and ethical representation.\n\nSOMEONE TO FIGHT FOR YOU\nOver the last five decades, our Oregon personal injury lawyers have fought and advocated for full and fair compensation for the harms and losses suffered by our thousands of clients. If you or someone you know has been injured in a car accident, while on the job or in some other way, don’t try to go it alone. Give us a call and get the protection and help you need to get the compensation you deserve.', 'company_name': ' Gatti Law Firm', 'index': 14} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: A bill to amend title 18, United States Code, to strengthen reporting to the CyberTipline related to online sexual exploitation of children, to modernize liabilities for such reports, to preserve the contents of such reports for 1 year, and for other purposes.
Official summary of bill: his bill makes changes to the federal framework governing the reporting of crimes involving the online sexual exploitation of children.
SOMEONE TO FIGHT FOR YOU
Over the last five decades, our Oregon personal injury lawyers have fought and advocated for full and fair compensation for the harms and losses suffered by our thousands of clients. If you or someone you know has been injured in a car accident, while on the job or in some other way, don’t try to go it alone. Give us a call and get the protection and help you need to get the compensation you deserve.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
5 | Yes | {'bill_summary': 'Patients First Act of 2019\n\nThis bill requires the National Institutes of Health (NIH) to support stem cell research. Specifically, the NIH must conduct and support basic and applied research to develop techniques for the isolation, derivation, production, testing, and human clinical use of stem cells that may result in improved understanding of, or treatments for, diseases and other adverse health conditions. However, such techniques must not involve (1) the creation of a human embryo for research purposes; (2) the destruction or discarding of, or risk of injury to, a human embryo; or (3) the use of any stem cell the derivation or provision of which would be inconsistent with this bill.\n\nThe NIH must also report on peer-reviewed stem cell research proposals that were not funded.', 'bill_title': 'To intensify stem cell research showing evidence of substantial clinical benefit to patients, and for other purposes.', 'company_description': 'We are a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases. Our research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta, or TGF-beta, protein superfamily. By combining our discovery and development expertise, including our proprietary knowledge of the TGF-beta superfamily, and our internal protein engineering and manufacturing capabilities, we have generated several innovative therapeutic candidates, all of which encompass novel potential first-in-class mechanisms of action. We have focused and prioritized our research and development activities within three key therapeutic areas: hematologic, neuromuscular and pulmonary. If successful, these candidates could have the potential to significantly improve clinical outcomes for patients across these areas of high, unmet need. Luspatercept, our lead program, and sotatercept, are partnered with Celgene Corporation, or Celgene. Luspatercept is an erythroid maturation agent designed to promote red blood cell production through a novel mechanism, and is being developed to treat chronic anemia and associated complications in myelodysplastic syndromes, or MDS, beta-thalassemia, and myelofibrosis. Celgene is currently conducting two Phase 3 clinical trials with luspatercept; one for the treatment of patients with lower-risk MDS, known as the "MEDALIST" trial, and another for the treatment of patients with beta-thalassemia, also known as the "BELIEVE" trial. Celgene has recently initiated a Phase 2 trial in non-transfusion-dependent beta-thalassemia patients, referred to as the "BEYOND" trial. We further expect Celgene to initiate a Phase 3 clinical trial, the "COMMANDS" trial, in first-line, lower-risk MDS patients in the first half of 2018. Enrollment is also currently ongoing in a Phase 2 clinical trial for the treatment of patients with myelofibrosis, a rare bone marrow disorder. If luspatercept were to receive regulatory approval for each of these indications in the United States and Europe, we believe that there is an aggregate sales opportunity for this product in excess of $2 billion. For sotatercept, we announced in September 2017 that Celgene granted us the rights to fund, develop, and lead the global commercialization of sotatercept in pulmonary hypertension, including pulmonary arterial hypertension, or PAH. PAH is a rare and chronic, rapidly progressing disorder characterized by the constriction of small pulmonary arteries, resulting in abnormally high blood pressure in the pulmonary arteries. If sotatercept is commercialized to treat PAH and we recognize such revenue, then Celgene will be eligible to receive a royalty in the low 20% range on global net sales. We expect to initiate a Phase 2 clinical trial for the treatment of patients with PAH in the first half of 2018. For luspatercept and, outside of pulmonary hypertension, sotatercept, Celgene is responsible for paying 100% of the development costs for all clinical trials. ACE-083 is designed for the treatment of focal muscle disorders, and we are currently conducting Phase 2 clinical trials with ACE-083 in patients with facioscapulohumeral dystrophy, or FSHD, as well as in patients with Charcot-Marie-Tooth disease, or CMT. In January 2018, we announced preliminary results for the first two cohorts in part 1 of the Phase 2 clinical trial with ACE-083 in patients with FSHD showing marked increases in the mean total muscle volume of the muscles treated with ACE-083 measured using magnetic resonance imaging, or MRI. We expect to initiate part 2 of the ACE-083 FSHD Phase 2 trial during the second quarter of this year, and we expect to report preliminary results from all dose-escalation cohorts of part 1 in our FSHD and CMT Phase 2 clinical trials with ACE-083 in the second half of this year. In addition to our mid- to late-stage clinical programs, we initiated a Phase 1 healthy volunteer study in early 2018 with ACE-2494, our wholly-owned systemic muscle agent from our proprietary platform technology, IntelliTrap™, and we expect to report initial results from this healthy volunteer study in the first half of 2019. We are also conducting research within our three focused disease areas—hematologic, neuromuscular and pulmonary—in order to identify new therapeutic candidates to advance into clinical trials. As of December 31, 2017 our operations have been funded primarily by $105.1 million in equity investments from venture investors, $539.7 million from public investors, $123.7 million in equity investments from our collaboration partners and $273.7 million in upfront payments, milestones, and net research and development payments from our collaboration partners. Announce MEDALIST Phase 3 clinical trial top-line results in mid-2018. Initiate the COMMANDS Phase 3 clinical trial in the first half of 2018. ', 'company_name': 'Acceleron Pharma, Inc.', 'index': '5'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: To intensify stem cell research showing evidence of substantial clinical benefit to patients, and for other purposes.
Official summary of bill: Patients First Act of 2019
The NIH must also report on peer-reviewed stem cell research proposals that were not funded.
Company name: Acceleron Pharma, Inc.
Company business description: We are a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases. Our research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta, or TGF-beta, protein superfamily. By combining our discovery and development expertise, including our proprietary knowledge of the TGF-beta superfamily, and our internal protein engineering and manufacturing capabilities, we have generated several innovative therapeutic candidates, all of which encompass novel potential first-in-class mechanisms of action. We have focused and prioritized our research and development activities within three key therapeutic areas: hematologic, neuromuscular and pulmonary. If successful, these candidates could have the potential to significantly improve clinical outcomes for patients across these areas of high, unmet need. Luspatercept, our lead program, and sotatercept, are partnered with Celgene Corporation, or Celgene. Luspatercept is an erythroid maturation agent designed to promote red blood cell production through a novel mechanism, and is being developed to treat chronic anemia and associated complications in myelodysplastic syndromes, or MDS, beta-thalassemia, and myelofibrosis. Celgene is currently conducting two Phase 3 clinical trials with luspatercept; one for the treatment of patients with lower-risk MDS, known as the "MEDALIST" trial, and another for the treatment of patients with beta-thalassemia, also known as the "BELIEVE" trial. Celgene has recently initiated a Phase 2 trial in non-transfusion-dependent beta-thalassemia patients, referred to as the "BEYOND" trial. We further expect Celgene to initiate a Phase 3 clinical trial, the "COMMANDS" trial, in first-line, lower-risk MDS patients in the first half of 2018. Enrollment is also currently ongoing in a Phase 2 clinical trial for the treatment of patients with myelofibrosis, a rare bone marrow disorder. If luspatercept were to receive regulatory approval for each of these indications in the United States and Europe, we believe that there is an aggregate sales opportunity for this product in excess of $2 billion. For sotatercept, we announced in September 2017 that Celgene granted us the rights to fund, develop, and lead the global commercialization of sotatercept in pulmonary hypertension, including pulmonary arterial hypertension, or PAH. PAH is a rare and chronic, rapidly progressing disorder characterized by the constriction of small pulmonary arteries, resulting in abnormally high blood pressure in the pulmonary arteries. If sotatercept is commercialized to treat PAH and we recognize such revenue, then Celgene will be eligible to receive a royalty in the low 20% range on global net sales. We expect to initiate a Phase 2 clinical trial for the treatment of patients with PAH in the first half of 2018. For luspatercept and, outside of pulmonary hypertension, sotatercept, Celgene is responsible for paying 100% of the development costs for all clinical trials. ACE-083 is designed for the treatment of focal muscle disorders, and we are currently conducting Phase 2 clinical trials with ACE-083 in patients with facioscapulohumeral dystrophy, or FSHD, as well as in patients with Charcot-Marie-Tooth disease, or CMT. In January 2018, we announced preliminary results for the first two cohorts in part 1 of the Phase 2 clinical trial with ACE-083 in patients with FSHD showing marked increases in the mean total muscle volume of the muscles treated with ACE-083 measured using magnetic resonance imaging, or MRI. We expect to initiate part 2 of the ACE-083 FSHD Phase 2 trial during the second quarter of this year, and we expect to report preliminary results from all dose-escalation cohorts of part 1 in our FSHD and CMT Phase 2 clinical trials with ACE-083 in the second half of this year. In addition to our mid- to late-stage clinical programs, we initiated a Phase 1 healthy volunteer study in early 2018 with ACE-2494, our wholly-owned systemic muscle agent from our proprietary platform technology, IntelliTrap™, and we expect to report initial results from this healthy volunteer study in the first half of 2019. We are also conducting research within our three focused disease areas—hematologic, neuromuscular and pulmonary—in order to identify new therapeutic candidates to advance into clinical trials. As of December 31, 2017 our operations have been funded primarily by $105.1 million in equity investments from venture investors, $539.7 million from public investors, $123.7 million in equity investments from our collaboration partners and $273.7 million in upfront payments, milestones, and net research and development payments from our collaboration partners. Announce MEDALIST Phase 3 clinical trial top-line results in mid-2018. Initiate the COMMANDS Phase 3 clinical trial in the first half of 2018.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
1 | No | {'bill_summary': 'Rehabilitation for Multiemployer Pensions Act of 2019\n\nThis bill establishes the Pension Rehabilitation Administration within the Department of the Treasury and a related trust fund to make loans to certain multiemployer defined benefit pension plans.\n\nTo receive a loan, a plan must be (1) in critical and declining status, including any plan with respect to which a suspension of benefits has been approved; (2) in critical status, have a modified funded percentage of less than 40%, and have a ratio of active to inactive participants which is less than two to five; or (3) insolvent, if the plan became insolvent after December 16, 2014, and has not been terminated.\n\nTreasury must transfer amounts, which may include proceeds from bonds and other obligations, from the general fund to the trust fund established by this bill as necessary to fund the program. The Pension Rehabilitation Administration may use the funds, without a further appropriation, to make loans, pay principal and interest on obligations, or for administrative and operating expenses.\n\nThe bill allows the sponsor of a multiemployer pension plan that is applying for a loan under this bill to also apply to the Pension Benefit Guaranty Corporation (PBGC) for financial assistance if, after receiving the loan, the plan will still become (or remain) insolvent within the 30-year period beginning on the date of the loan.\n\nThe bill also appropriates to the PBGC the funds that are necessary to provide the financial assistance required by this bill.\n\nThe bill modifies the requirements for the distribution of remaining pension benefits from certain defined contribution plans to a designated beneficiary upon death of an employee. The bill increases penalties for failure to file a tax return, and certain retirement plan returns.', 'bill_title': 'To amend the Internal Revenue Code of 1986 to create a Pension Rehabilitation Trust Fund, to establish a Pension Rehabilitation Administration within the Department of the Treasury to make loans to multiemployer defined benefit plans, and for other purposes.', 'company_description': 'We acquire, develop, own and operate self-storage facilities , which offer storage spaces for lease on a month-to-month basis, for personal and business use. We are the largest owner and operator of self-storage facilities in the U.S. We have direct and indirect equity interests in 2,429 self-storage facilities that we consolidate (an aggregate of 162 million net rentable square feet of space) located in 38 states within the U.S. operating under the "Public Storage" brand name. Ancillary Operations : We reinsure policies against losses to goods stored by customers in our self-storage facilities and sell merchandise, primarily locks and cardboard boxes, at our self-storage facilities. Inc. ("PSB"), a publicly held REIT that owns, operates, acquires and develops commercial properties, primarily multi-tenant flex, office, and industrial parks. At December 31, 201 8 , PSB owns and operates 28. 2 million rentable square feet of commercial space. : We have a 35 % equity inter est in Shurgard Self Storage SA ("Shurgard Europe"), a publicly held company trading under Euronext Brussels under the "SHUR" symbol , which owns 232 self-storage facilities (13 million net rentable square feet) located in seven countries in Western Europe operated under the "Shurgard" brand name. We believe Shurgard Europe is the largest owner and operator of self-storage facilities in Western Europe. We also manage 33 self-storage facilities for third parties . We are seeking to expand our third-party management operations to further increase our economies of scale and leverage our brand; however, there is no 5 assurance that we will be able to do so. We also own 0.8 million net rentable square feet of commercial space which is managed primarily by PSB . For all periods presented herein, we have elected to be treated as a REIT, as defined in the Internal Revenue Code of 1986, as amended (the "Code") . and we expect to continue to elect and qualify as a REIT. We believe that our customers genera lly store their goods within a three to f ive mile radius of their home or business . Our facilities compete with nearby self-storage facilities owned by other operators using marketing channels similar to ours , including Internet advertising, signage, and banners and offer services similar to ours . A s a result, competition is significant and affects the occupancy levels, rental rates, rental income and operating expenses of our facilities. In the last three years, there has been a marked increase in development of new self-storage facilities in many of the markets we operate in, due to the favorable economics of development which we have also taken advantage of. These newly developed facilities compete with many of the facilities we own, negatively impacting our occupancies, rental rates, and rental growth. This increase in supply has been most notable in Atlanta, Austin, Charlotte, Chicago, Dallas, Denver, Houston, New York, and Portland. Ownership and operation of self-storage facilities is highly fragmented. As the largest owner of self-storage facilities, we believe that we own approximately 7 % of the self-storage square footage in the U.S. and that collectively the five largest self-storage owners in the U.S. own approximately 15 %, with the remaining 8 5 % owned by numerous regional and local operators. We believe that we have significant market share and concentration in major metropolitan centers, with approximately 71 % of our 201 8 same-store revenues generated in the 20 Metropolitan Statistical Areas (each, an "MSA", as defined by the U.S. Census Bureau) with the highest population levels. Industry fragmentation also provides opportunities for us to acquire additional facilities; however, we compete with a wide variety of institutions and other investors who also view self-storage facilities as attractive investments. The amount of capital available for real estate investments greatly influences the competition for ownership interests in facilities and, by extension, the yields that we can achieve on newly acquired investments. a s well as analyze customer data and quickly change each of our individual properties', 'company_name': 'Public Storage', 'index': '1'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: To amend the Internal Revenue Code of 1986 to create a Pension Rehabilitation Trust Fund, to establish a Pension Rehabilitation Administration within the Department of the Treasury to make loans to multiemployer defined benefit plans, and for other purposes.
Official summary of bill: Rehabilitation for Multiemployer Pensions Act of 2019
The bill modifies the requirements for the distribution of remaining pension benefits from certain defined contribution plans to a designated beneficiary upon death of an employee. The bill increases penalties for failure to file a tax return, and certain retirement plan returns.
Company name: Public Storage
Company business description: We acquire, develop, own and operate self-storage facilities , which offer storage spaces for lease on a month-to-month basis, for personal and business use. We are the largest owner and operator of self-storage facilities in the U.S. We have direct and indirect equity interests in 2,429 self-storage facilities that we consolidate (an aggregate of 162 million net rentable square feet of space) located in 38 states within the U.S. operating under the "Public Storage" brand name. Ancillary Operations : We reinsure policies against losses to goods stored by customers in our self-storage facilities and sell merchandise, primarily locks and cardboard boxes, at our self-storage facilities. Inc. ("PSB"), a publicly held REIT that owns, operates, acquires and develops commercial properties, primarily multi-tenant flex, office, and industrial parks. At December 31, 201 8 , PSB owns and operates 28. 2 million rentable square feet of commercial space. : We have a 35 % equity inter est in Shurgard Self Storage SA ("Shurgard Europe"), a publicly held company trading under Euronext Brussels under the "SHUR" symbol , which owns 232 self-storage facilities (13 million net rentable square feet) located in seven countries in Western Europe operated under the "Shurgard" brand name. We believe Shurgard Europe is the largest owner and operator of self-storage facilities in Western Europe. We also manage 33 self-storage facilities for third parties . We are seeking to expand our third-party management operations to further increase our economies of scale and leverage our brand; however, there is no 5 assurance that we will be able to do so. We also own 0.8 million net rentable square feet of commercial space which is managed primarily by PSB . For all periods presented herein, we have elected to be treated as a REIT, as defined in the Internal Revenue Code of 1986, as amended (the "Code") . and we expect to continue to elect and qualify as a REIT. We believe that our customers genera lly store their goods within a three to f ive mile radius of their home or business . Our facilities compete with nearby self-storage facilities owned by other operators using marketing channels similar to ours , including Internet advertising, signage, and banners and offer services similar to ours . A s a result, competition is significant and affects the occupancy levels, rental rates, rental income and operating expenses of our facilities. In the last three years, there has been a marked increase in development of new self-storage facilities in many of the markets we operate in, due to the favorable economics of development which we have also taken advantage of. These newly developed facilities compete with many of the facilities we own, negatively impacting our occupancies, rental rates, and rental growth. This increase in supply has been most notable in Atlanta, Austin, Charlotte, Chicago, Dallas, Denver, Houston, New York, and Portland. Ownership and operation of self-storage facilities is highly fragmented. As the largest owner of self-storage facilities, we believe that we own approximately 7 % of the self-storage square footage in the U.S. and that collectively the five largest self-storage owners in the U.S. own approximately 15 %, with the remaining 8 5 % owned by numerous regional and local operators. We believe that we have significant market share and concentration in major metropolitan centers, with approximately 71 % of our 201 8 same-store revenues generated in the 20 Metropolitan Statistical Areas (each, an "MSA", as defined by the U.S. Census Bureau) with the highest population levels. Industry fragmentation also provides opportunities for us to acquire additional facilities; however, we compete with a wide variety of institutions and other investors who also view self-storage facilities as attractive investments. The amount of capital available for real estate investments greatly influences the competition for ownership interests in facilities and, by extension, the yields that we can achieve on newly acquired investments. a s well as analyze customer data and quickly change each of our individual properties
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
11 | No | {'bill_summary': ' \n\n This resolution sets forth the rule for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for FY2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for FY2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for FY2024.', 'bill_title': '\nProviding for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for the fiscal year ending September 30, 2024, and for other purposes.\n\n', 'company_description': ' California Language Academy was founded in July 2010 by a family with the mission of providing personalized, intimate, and engaging language learning services. Together, we have established a high-quality, family-owned and operated language school that offers small class sizes to meet the individual needs of each student’s learning goals and objectives. We employ highly qualified and dedicated instructors and our comprehensive curricula are designed to build students’ skills and self-confidence when communicating in English or a foreign language in either an academic or professional setting. California Language Academy is unique because it is a family-owned and operated business where our team is friendly, professional, attentive and highly responsive. Our schedule is flexible, and the quick assessment of student skills and challenges creates a more “catered” client service.', 'company_name': ' California Language Academy', 'index': 11} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill:
Providing for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for the fiscal year ending September 30, 2024, and for other purposes.
This resolution sets forth the rule for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for FY2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for FY2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for FY2024.
Company name: California Language Academy
Company business description: California Language Academy was founded in July 2010 by a family with the mission of providing personalized, intimate, and engaging language learning services. Together, we have established a high-quality, family-owned and operated language school that offers small class sizes to meet the individual needs of each student’s learning goals and objectives. We employ highly qualified and dedicated instructors and our comprehensive curricula are designed to build students’ skills and self-confidence when communicating in English or a foreign language in either an academic or professional setting. California Language Academy is unique because it is a family-owned and operated business where our team is friendly, professional, attentive and highly responsive. Our schedule is flexible, and the quick assessment of student skills and challenges creates a more “catered” client service.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
4 | No | {'bill_summary': 'Federal Register Modernization Act\n\nThis bill revises provisions regarding the Federal Register or the Code of Federal Regulations, including to replace requirements that the documents be printed with requirements that the documents be published.\n\nThe bill provides that in a continuity of operations event in which the Government Publishing Office (GPO) does not fulfill its publication requirements, the Office of the Federal Register may establish a website to publish the Federal Register until such time that GPO resumes publication.', 'bill_title': 'A bill to amend title 44, United States Code, to modernize the Federal Register, and for other purposes.', 'company_description': '"us" or the "Parent Company") is a leading provider of financial products to middle-income households in the United States and Canada with 130,736 licensed sales representatives as of December 31, 2018. This network of independent contractor sales representatives ("sales representatives" or "sales force") assists our clients in meeting their needs for term life insurance, which we underwrite, and mutual funds, annuities, managed investments and other financial products, which we distribute primarily on behalf of third parties. Licensed sales representatives primarily use our proprietary financial needs analysis tool ("FNA") and an educational approach to demonstrate how our product offerings can assist clients to provide financial protection for their families, save for their retirement and other needs, and manage their debt. Typically, our clients are the friends, family members and personal acquaintances of sales representatives. We provide an entrepreneurial business opportunity for individuals to distribute financial products. Low entry fees as well as the ability to select their own schedules and time commitments allow sales representatives to supplement their income by starting their own independent businesses without leaving their current jobs. Our unique compensation structure, technology, sales support and back-office processing are designed to enable sales representatives to successfully grow their independent businesses. We believe there is significant opportunity to meet the increasing array of financial services needs of our clients. We intend to leverage the sales force to meet such client needs, which will drive long-term value for all of our stakeholders. • Broadening and strengthening our protection product portfolio; • Providing offerings that enhance our Investment and Savings Products ("ISP") business; and • Developing digital capabilities to deepen our client relationships. Primerica Life Insurance Company ("Primerica Life"), our principal life insurance underwriting company; and • ("PFS Investments"), our investment and savings products company, broker-dealer and registered investment advisor. Primerica Life is domiciled in Tennessee, and its wholly owned subsidiary, National Benefit Life Insurance Company ("NBLIC"), is a New York-domiciled life insurance underwriting company. Primerica Life Insurance Company of Canada ("Primerica Life Canada"), our Canadian life insurance underwriting company; • ("PFSL Investments Canada"), our Canadian licensed mutual fund dealer; and • ("PFSL Fund Management"), our Canadian investment funds manager. Our clients are generally middle-income consumers, which we define as households with $30,000 to $100,000 of annual income. According to the 2017 U.S. Census Bureau Current Population Survey, the latest period for which data is available, almost 50% of U.S. households fall in this range. Many have inadequate or no life insurance coverage. Individual life insurance sales in the United States declined from 12.5 million policy sales in 1975 to 9.8 million policy sales in 2017, the latest period for which data is available, according to the Life Insurance Marketing and Research Association International, Inc. ("LIMRA"), a worldwide association of insurance and financial services companies. We believe that term life insurance, which we have provided to middle-income clients for many years, is generally the best option for them to meet their life insurance needs. Many need help saving for retirement and other personal goals.', 'company_name': 'Primerica, Inc.', 'index': '4'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: A bill to amend title 44, United States Code, to modernize the Federal Register, and for other purposes.
Official summary of bill: Federal Register Modernization Act
The bill provides that in a continuity of operations event in which the Government Publishing Office (GPO) does not fulfill its publication requirements, the Office of the Federal Register may establish a website to publish the Federal Register until such time that GPO resumes publication.
Company name: Primerica, Inc.
Company business description: "us" or the "Parent Company") is a leading provider of financial products to middle-income households in the United States and Canada with 130,736 licensed sales representatives as of December 31, 2018. This network of independent contractor sales representatives ("sales representatives" or "sales force") assists our clients in meeting their needs for term life insurance, which we underwrite, and mutual funds, annuities, managed investments and other financial products, which we distribute primarily on behalf of third parties. Licensed sales representatives primarily use our proprietary financial needs analysis tool ("FNA") and an educational approach to demonstrate how our product offerings can assist clients to provide financial protection for their families, save for their retirement and other needs, and manage their debt. Typically, our clients are the friends, family members and personal acquaintances of sales representatives. We provide an entrepreneurial business opportunity for individuals to distribute financial products. Low entry fees as well as the ability to select their own schedules and time commitments allow sales representatives to supplement their income by starting their own independent businesses without leaving their current jobs. Our unique compensation structure, technology, sales support and back-office processing are designed to enable sales representatives to successfully grow their independent businesses. We believe there is significant opportunity to meet the increasing array of financial services needs of our clients. We intend to leverage the sales force to meet such client needs, which will drive long-term value for all of our stakeholders. • Broadening and strengthening our protection product portfolio; • Providing offerings that enhance our Investment and Savings Products ("ISP") business; and • Developing digital capabilities to deepen our client relationships. Primerica Life Insurance Company ("Primerica Life"), our principal life insurance underwriting company; and • ("PFS Investments"), our investment and savings products company, broker-dealer and registered investment advisor. Primerica Life is domiciled in Tennessee, and its wholly owned subsidiary, National Benefit Life Insurance Company ("NBLIC"), is a New York-domiciled life insurance underwriting company. Primerica Life Insurance Company of Canada ("Primerica Life Canada"), our Canadian life insurance underwriting company; • ("PFSL Investments Canada"), our Canadian licensed mutual fund dealer; and • ("PFSL Fund Management"), our Canadian investment funds manager. Our clients are generally middle-income consumers, which we define as households with $30,000 to $100,000 of annual income. According to the 2017 U.S. Census Bureau Current Population Survey, the latest period for which data is available, almost 50% of U.S. households fall in this range. Many have inadequate or no life insurance coverage. Individual life insurance sales in the United States declined from 12.5 million policy sales in 1975 to 9.8 million policy sales in 2017, the latest period for which data is available, according to the Life Insurance Marketing and Research Association International, Inc. ("LIMRA"), a worldwide association of insurance and financial services companies. We believe that term life insurance, which we have provided to middle-income clients for many years, is generally the best option for them to meet their life insurance needs. Many need help saving for retirement and other personal goals.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
0 | No | {'bill_summary': "Hualapai Tribe Water Rights Settlement Act of 2019\n\nThis bill modifies and ratifies the Hualapai Tribe water rights settlement agreement negotiated between the tribe, the United States, Arizona, and others, thus satisfying the tribe's claims for groundwater and surface water rights to water in Arizona, including the Verde River, the Bill Williams River, and the Colorado River.\n\nThe bill outlines the tribe's water rights, including the right to divert, use, and store 4,000 acre-feet of agricultural priority water of the Central Arizona Project that was previously allocated to nontribal agricultural entities, but retained by the Department of the Interior for reallocation to tribes in Arizona pursuant to the Central Arizona Project Settlement Act of 2004.\n\nThe Bureau of Reclamation must construct the Hualapai Water Project. The project must be designed to divert, treat, and convey at least 3,414 acre-feet of water per year from the Colorado River for municipal, commercial, and industrial uses on the Hualapai Reservation.\n\nThe bill provides for land to be added to the reservation and taken into trust for the benefit of the tribe. In the future, land located outside the reservation may only be taken into trust through an act of Congress.\n\nThe bill outlines (1) waivers, releases, and retentions of claims by the tribe and the United States under the settlement agreement; and (2) a limited waiver of sovereign immunity by the United States and the tribe with respect to certain claims.", 'bill_title': 'To approve the settlement of water rights claims of the Hualapai Tribe and certain allottees in the State of Arizona, to authorize construction of a water project relating to those water rights claims, and for other purposes.', 'company_description': 'the total domestic capacity for our restaurants; expectations for consumer spending on casual dining restaurant occasions; • the availability and cost of key commodities and labor used in our restaurants and brewing operations; menu price increases and their effect, if any, on revenue and results of operations; projected revenues, operating costs, including commodities, labor and other expenses; Any inability to open new restaurants on schedule in accordance with our targeted capacity growth or problems associated with securing suitable restaurant locations, leases and licenses, recruiting and training qualified 1 managers and hourly employees and other factors, some of which are beyond our control and difficult to forecast accurately may adversely affect our operations. Our corporate office is located in California and a significant number of our restaurants are located in California, Texas and Florida which makes us particularly sensitive to economic, regulatory, weather and other risk factors and conditions that are more prevalent in those states. Any negative publicity about us, our restaurants, other restaurants, or others across the food supply chain, due to food borne illness or other reasons, whether or not accurate may adversely affect the reputation and popularity of our restaurants and our results of operations. Any adverse changes in the supply of food, labor, brewing, energy and other expenses, including those resulting from climate change, may adversely affect our operating results. Periodic reviews and audits of our internal brewing, independent third party brewing and beer distribution arrangements by various federal, state and local governmental and regulatory agencies may adversely affect our operations and our operating results. Government laws and regulations affecting the operation of our restaurants, including but not limited to those that apply to the acquisition and maintenance of our brewing and retail liquor licenses, minimum wages, federal or state exemption rules, health insurance coverage, or other employment benefits such as paid time off, consumer health and safety, nutritional disclosures, and employment eligibility-related documentation requirements may cause disruptions to our operations, adversely affect our operating costs and restrict our growth. The first BJ\'s restaurant, which opened in 1978 in Orange County, California, was a small sit down pizzeria that featured Chicago style deep-dish pizza with a unique California twist. Our goal then and still today, is to be the best casual dining concept ever by focusing on high quality menu options, at a compelling value, a dining experience that exceeds customers\' expectations for service, hospitality and enjoyment, and an atmosphere that is always welcoming and approachable. In 1996, we introduced our initial proprietary craft beers and expanded the BJ\'s concept from its beginnings as a small pizzeria to a full-service, high energy casual dining restaurant when we opened our first large format restaurant featuring a brewing operations in Brea, California. Today our restaurants feature over 140 menu offerings including: slow roasted entrees, such as, prime rib; EnLIGHTened Entrees® such as our Cherry Chipotle Glazed Salmon; our original signature deep-dish pizza; the often imitated, but never replicated world-famous Pizookie® dessert; and our award-winning BJ\'s proprietary craft beers. As of February 25, 2019, we own and operate 202 restaurants located in 27 states, and our proprietary craft beer is produced at several of our locations, our Temple, Texas brewpub locations and by independent third party brewers using our proprietary recipes. We compete in the casual dining segment of the restaurant industry, which is a large, highly fragmented segment with estimated annual sales in the $100+ billion range. We believe that the BJ\'s restaurant concept offers consumers a higher quality, more contemporary and approachable "casual plus," "premium casual," or "polished casual" dining experience than the more mature, mass market casual dining concepts. Our Gold Standard of Operational Excellence is our genuine commitment to take pride in passionately connecting with every customer on every visit, through flawless and relentless execution of every detail, during every shift – to create and keep fanatical fans of BJ\' Our Gold Standard of Operational Excellence is focused on the following key areas that help to differentiate BJ\'s from other casual dining restaurants: Over the years we have expanded the BJ\'s concept to include menu options that meet our customers \' preferences for any dining occasion.', 'company_name': "BJ's Restaurants, Inc.", 'index': '0'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: To approve the settlement of water rights claims of the Hualapai Tribe and certain allottees in the State of Arizona, to authorize construction of a water project relating to those water rights claims, and for other purposes.
Official summary of bill: Hualapai Tribe Water Rights Settlement Act of 2019
The bill outlines (1) waivers, releases, and retentions of claims by the tribe and the United States under the settlement agreement; and (2) a limited waiver of sovereign immunity by the United States and the tribe with respect to certain claims.
Company name: BJ's Restaurants, Inc.
Company business description: the total domestic capacity for our restaurants; expectations for consumer spending on casual dining restaurant occasions; • the availability and cost of key commodities and labor used in our restaurants and brewing operations; menu price increases and their effect, if any, on revenue and results of operations; projected revenues, operating costs, including commodities, labor and other expenses; Any inability to open new restaurants on schedule in accordance with our targeted capacity growth or problems associated with securing suitable restaurant locations, leases and licenses, recruiting and training qualified 1 managers and hourly employees and other factors, some of which are beyond our control and difficult to forecast accurately may adversely affect our operations. Our corporate office is located in California and a significant number of our restaurants are located in California, Texas and Florida which makes us particularly sensitive to economic, regulatory, weather and other risk factors and conditions that are more prevalent in those states. Any negative publicity about us, our restaurants, other restaurants, or others across the food supply chain, due to food borne illness or other reasons, whether or not accurate may adversely affect the reputation and popularity of our restaurants and our results of operations. Any adverse changes in the supply of food, labor, brewing, energy and other expenses, including those resulting from climate change, may adversely affect our operating results. Periodic reviews and audits of our internal brewing, independent third party brewing and beer distribution arrangements by various federal, state and local governmental and regulatory agencies may adversely affect our operations and our operating results. Government laws and regulations affecting the operation of our restaurants, including but not limited to those that apply to the acquisition and maintenance of our brewing and retail liquor licenses, minimum wages, federal or state exemption rules, health insurance coverage, or other employment benefits such as paid time off, consumer health and safety, nutritional disclosures, and employment eligibility-related documentation requirements may cause disruptions to our operations, adversely affect our operating costs and restrict our growth. The first BJ's restaurant, which opened in 1978 in Orange County, California, was a small sit down pizzeria that featured Chicago style deep-dish pizza with a unique California twist. Our goal then and still today, is to be the best casual dining concept ever by focusing on high quality menu options, at a compelling value, a dining experience that exceeds customers' expectations for service, hospitality and enjoyment, and an atmosphere that is always welcoming and approachable. In 1996, we introduced our initial proprietary craft beers and expanded the BJ's concept from its beginnings as a small pizzeria to a full-service, high energy casual dining restaurant when we opened our first large format restaurant featuring a brewing operations in Brea, California. Today our restaurants feature over 140 menu offerings including: slow roasted entrees, such as, prime rib; EnLIGHTened Entrees® such as our Cherry Chipotle Glazed Salmon; our original signature deep-dish pizza; the often imitated, but never replicated world-famous Pizookie® dessert; and our award-winning BJ's proprietary craft beers. As of February 25, 2019, we own and operate 202 restaurants located in 27 states, and our proprietary craft beer is produced at several of our locations, our Temple, Texas brewpub locations and by independent third party brewers using our proprietary recipes. We compete in the casual dining segment of the restaurant industry, which is a large, highly fragmented segment with estimated annual sales in the $100+ billion range. We believe that the BJ's restaurant concept offers consumers a higher quality, more contemporary and approachable "casual plus," "premium casual," or "polished casual" dining experience than the more mature, mass market casual dining concepts. Our Gold Standard of Operational Excellence is our genuine commitment to take pride in passionately connecting with every customer on every visit, through flawless and relentless execution of every detail, during every shift – to create and keep fanatical fans of BJ' Our Gold Standard of Operational Excellence is focused on the following key areas that help to differentiate BJ's from other casual dining restaurants: Over the years we have expanded the BJ's concept to include menu options that meet our customers ' preferences for any dining occasion.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
11 | No | {'bill_summary': ' \n\n This resolution sets forth the rule for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for FY2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for FY2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for FY2024.', 'bill_title': '\nProviding for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for the fiscal year ending September 30, 2024, and for other purposes.\n\n', 'company_description': ' California Language Academy was founded in July 2010 by a family with the mission of providing personalized, intimate, and engaging language learning services. Together, we have established a high-quality, family-owned and operated language school that offers small class sizes to meet the individual needs of each student’s learning goals and objectives. We employ highly qualified and dedicated instructors and our comprehensive curricula are designed to build students’ skills and self-confidence when communicating in English or a foreign language in either an academic or professional setting. California Language Academy is unique because it is a family-owned and operated business where our team is friendly, professional, attentive and highly responsive. Our schedule is flexible, and the quick assessment of student skills and challenges creates a more “catered” client service.', 'company_name': ' California Language Academy', 'index': 11} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill:
Providing for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for the fiscal year ending September 30, 2024, and for other purposes.
This resolution sets forth the rule for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for FY2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for FY2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for FY2024.
Company name: California Language Academy
Company business description: California Language Academy was founded in July 2010 by a family with the mission of providing personalized, intimate, and engaging language learning services. Together, we have established a high-quality, family-owned and operated language school that offers small class sizes to meet the individual needs of each student’s learning goals and objectives. We employ highly qualified and dedicated instructors and our comprehensive curricula are designed to build students’ skills and self-confidence when communicating in English or a foreign language in either an academic or professional setting. California Language Academy is unique because it is a family-owned and operated business where our team is friendly, professional, attentive and highly responsive. Our schedule is flexible, and the quick assessment of student skills and challenges creates a more “catered” client service.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
9 | Yes | {'bill_summary': "Move America Act of 2019\n\nThis bill allows tax-exempt Move America bonds and Move America tax credits to be used for certain infrastructure projects.\n\nA Move America bond is treated as a tax-exempt private facility bond with certain exceptions. At least 95% of the net proceeds from the issuance of the bond must be used for infrastructure projects, including\n\n airports; docks and wharves; mass commuting facilities; facilities for the furnishing of water; sewage facilities; railroads; certain surface transportation projects eligible for federal assistance, projects for an international bridge or tunnel, or facilities for transferring freight from truck to rail or rail to truck; flood diversions; inland waterways; or rural broadband service infrastructure. The bill specifies exceptions and modifications to existing rules for bonds regarding land acquisition, government ownership, rehabilitation expenditures, and the alternative minimum tax.\n\nThe bonds are subject to a volume cap equal to 50% of a state's current private activity bond volume cap. States may exchange all or a portion of the volume cap for Move America tax credits to be allocated to taxpayers. The credits include (1) an equity credit for a portion of the basis of each qualified facility; and (2) an infrastructure fund credit for investments in qualified infrastructure funds, including a state infrastructure bank, a water pollution control revolving fund, or a drinking water treatment revolving loan fund.", 'bill_title': 'A bill to amend the Internal Revenue Code of 1986 to provide for Move America bonds and Move America credits.', 'company_description': 'We acquire, develop, own and operate self-storage facilities , which offer storage spaces for lease on a month-to-month basis, for personal and business use. We are the largest owner and operator of self-storage facilities in the U.S. We have direct and indirect equity interests in 2,3 8 6 self-storage facilities that we consolidate (an aggregate of 15 9 million net rentable square feet of space) located in 38 states within the U.S. operating under the "Public Storage" brand name. We also own one self -storage facility in London, England which is managed by Shurgard Europe (defined below). Ancillary Operations : We reinsure policies against losses to goods stored by customers in our self-storage facilities and sell merchandise, primarily locks and cardboard boxes, at our self-storage facilities. Inc. ("PSB"), a publicly held REIT that owns, operates, acquires and develops commercial properties, primarily multi-tenant flex, office, and industrial parks. 0 million rentable square feet of commercial space. Shurgard Self Storage Europe Limited ("Shurgard Europe") which owns 221 self-storage facilities (twelve million net rentable square feet) located in seven countries in Western Europe operated under the "Shurgard" brand name. We believe Shurgard Europe is the largest owner and operator of self-storage facilities in Western Europe. We also manage approximately 27 self-storage facilities for third parties . We are seeking to expand our third-party management operations to further increase our economies of scale and leverage our brand; however, there is no assurance that we will be able to do so. We also own 0.9 million net rentable square feet of commercial space which is managed primarily by PSB . For all periods presented herein, we have elected to be treated as a REIT, as defined in the Internal Revenue Code of 1986, as amended (the "Code") . and we expect to continue to elect and qualify as a REIT. We believe that our customers generally store their goods within a five mile radius of their home or business . Our facilities compete with nearby self-storage facilities owned by other operators using marketing channels similar to ours , including Internet advertising, signage, and banners and offer services similar to ours . A s a result, competition is significant and affects the occupancy levels, rental rates, rental income and operating expenses of our facilities. There has been an increase in supply of newly constructed self-storage facilities in several of our markets, most notably Atlanta, Austin, Charlotte, Chicago, Dallas, Denver, Houston, and New York. Ownership and operation of self- storage facilities is highly fragmented. As the largest owner of self-storage facilities, we believe that we own approximately 7 % of the self-storage square footage in the U.S. and that collectively the five largest self-storage owners in the U.S. own approximately 15 %, with the remaining 8 5 % owned by numerous regional and local operators. We believe that we have significant market share and concentration in major metropolitan centers, with approximately 71 % of our 201 7 same-store revenues generated in the 20 Metropolitan Statistical Areas (each, an "MSA", as defined by the U.S. Census Bureau) with the highest population levels. Industry fragmentation also provides opportunities for us to acquire additional facilities; however, we compete with a wide variety of institutions and other investors who also view self-storage facilities as attractive investments. The amount of capital available for real estate investments greatly influences the competition for ownership interests in facilities and, by extension, the yields that we can achieve on newly acquired investments. a s well as analyze customer data and quickly change each of our individual properties \' pricing and promotion s on an automated basis. ', 'company_name': 'Public Storage', 'index': '9'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: A bill to amend the Internal Revenue Code of 1986 to provide for Move America bonds and Move America credits.
Official summary of bill: Move America Act of 2019
The bonds are subject to a volume cap equal to 50% of a state's current private activity bond volume cap. States may exchange all or a portion of the volume cap for Move America tax credits to be allocated to taxpayers. The credits include (1) an equity credit for a portion of the basis of each qualified facility; and (2) an infrastructure fund credit for investments in qualified infrastructure funds, including a state infrastructure bank, a water pollution control revolving fund, or a drinking water treatment revolving loan fund.
Company name: Public Storage
Company business description: We acquire, develop, own and operate self-storage facilities , which offer storage spaces for lease on a month-to-month basis, for personal and business use. We are the largest owner and operator of self-storage facilities in the U.S. We have direct and indirect equity interests in 2,3 8 6 self-storage facilities that we consolidate (an aggregate of 15 9 million net rentable square feet of space) located in 38 states within the U.S. operating under the "Public Storage" brand name. We also own one self -storage facility in London, England which is managed by Shurgard Europe (defined below). Ancillary Operations : We reinsure policies against losses to goods stored by customers in our self-storage facilities and sell merchandise, primarily locks and cardboard boxes, at our self-storage facilities. Inc. ("PSB"), a publicly held REIT that owns, operates, acquires and develops commercial properties, primarily multi-tenant flex, office, and industrial parks. 0 million rentable square feet of commercial space. Shurgard Self Storage Europe Limited ("Shurgard Europe") which owns 221 self-storage facilities (twelve million net rentable square feet) located in seven countries in Western Europe operated under the "Shurgard" brand name. We believe Shurgard Europe is the largest owner and operator of self-storage facilities in Western Europe. We also manage approximately 27 self-storage facilities for third parties . We are seeking to expand our third-party management operations to further increase our economies of scale and leverage our brand; however, there is no assurance that we will be able to do so. We also own 0.9 million net rentable square feet of commercial space which is managed primarily by PSB . For all periods presented herein, we have elected to be treated as a REIT, as defined in the Internal Revenue Code of 1986, as amended (the "Code") . and we expect to continue to elect and qualify as a REIT. We believe that our customers generally store their goods within a five mile radius of their home or business . Our facilities compete with nearby self-storage facilities owned by other operators using marketing channels similar to ours , including Internet advertising, signage, and banners and offer services similar to ours . A s a result, competition is significant and affects the occupancy levels, rental rates, rental income and operating expenses of our facilities. There has been an increase in supply of newly constructed self-storage facilities in several of our markets, most notably Atlanta, Austin, Charlotte, Chicago, Dallas, Denver, Houston, and New York. Ownership and operation of self- storage facilities is highly fragmented. As the largest owner of self-storage facilities, we believe that we own approximately 7 % of the self-storage square footage in the U.S. and that collectively the five largest self-storage owners in the U.S. own approximately 15 %, with the remaining 8 5 % owned by numerous regional and local operators. We believe that we have significant market share and concentration in major metropolitan centers, with approximately 71 % of our 201 7 same-store revenues generated in the 20 Metropolitan Statistical Areas (each, an "MSA", as defined by the U.S. Census Bureau) with the highest population levels. Industry fragmentation also provides opportunities for us to acquire additional facilities; however, we compete with a wide variety of institutions and other investors who also view self-storage facilities as attractive investments. The amount of capital available for real estate investments greatly influences the competition for ownership interests in facilities and, by extension, the yields that we can achieve on newly acquired investments. a s well as analyze customer data and quickly change each of our individual properties ' pricing and promotion s on an automated basis.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
5 | Yes | {'bill_summary': 'Patients First Act of 2019\n\nThis bill requires the National Institutes of Health (NIH) to support stem cell research. Specifically, the NIH must conduct and support basic and applied research to develop techniques for the isolation, derivation, production, testing, and human clinical use of stem cells that may result in improved understanding of, or treatments for, diseases and other adverse health conditions. However, such techniques must not involve (1) the creation of a human embryo for research purposes; (2) the destruction or discarding of, or risk of injury to, a human embryo; or (3) the use of any stem cell the derivation or provision of which would be inconsistent with this bill.\n\nThe NIH must also report on peer-reviewed stem cell research proposals that were not funded.', 'bill_title': 'To intensify stem cell research showing evidence of substantial clinical benefit to patients, and for other purposes.', 'company_description': 'We are a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases. Our research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta, or TGF-beta, protein superfamily. By combining our discovery and development expertise, including our proprietary knowledge of the TGF-beta superfamily, and our internal protein engineering and manufacturing capabilities, we have generated several innovative therapeutic candidates, all of which encompass novel potential first-in-class mechanisms of action. We have focused and prioritized our research and development activities within three key therapeutic areas: hematologic, neuromuscular and pulmonary. If successful, these candidates could have the potential to significantly improve clinical outcomes for patients across these areas of high, unmet need. Luspatercept, our lead program, and sotatercept, are partnered with Celgene Corporation, or Celgene. Luspatercept is an erythroid maturation agent designed to promote red blood cell production through a novel mechanism, and is being developed to treat chronic anemia and associated complications in myelodysplastic syndromes, or MDS, beta-thalassemia, and myelofibrosis. Celgene is currently conducting two Phase 3 clinical trials with luspatercept; one for the treatment of patients with lower-risk MDS, known as the "MEDALIST" trial, and another for the treatment of patients with beta-thalassemia, also known as the "BELIEVE" trial. Celgene has recently initiated a Phase 2 trial in non-transfusion-dependent beta-thalassemia patients, referred to as the "BEYOND" trial. We further expect Celgene to initiate a Phase 3 clinical trial, the "COMMANDS" trial, in first-line, lower-risk MDS patients in the first half of 2018. Enrollment is also currently ongoing in a Phase 2 clinical trial for the treatment of patients with myelofibrosis, a rare bone marrow disorder. If luspatercept were to receive regulatory approval for each of these indications in the United States and Europe, we believe that there is an aggregate sales opportunity for this product in excess of $2 billion. For sotatercept, we announced in September 2017 that Celgene granted us the rights to fund, develop, and lead the global commercialization of sotatercept in pulmonary hypertension, including pulmonary arterial hypertension, or PAH. PAH is a rare and chronic, rapidly progressing disorder characterized by the constriction of small pulmonary arteries, resulting in abnormally high blood pressure in the pulmonary arteries. If sotatercept is commercialized to treat PAH and we recognize such revenue, then Celgene will be eligible to receive a royalty in the low 20% range on global net sales. We expect to initiate a Phase 2 clinical trial for the treatment of patients with PAH in the first half of 2018. For luspatercept and, outside of pulmonary hypertension, sotatercept, Celgene is responsible for paying 100% of the development costs for all clinical trials. ACE-083 is designed for the treatment of focal muscle disorders, and we are currently conducting Phase 2 clinical trials with ACE-083 in patients with facioscapulohumeral dystrophy, or FSHD, as well as in patients with Charcot-Marie-Tooth disease, or CMT. In January 2018, we announced preliminary results for the first two cohorts in part 1 of the Phase 2 clinical trial with ACE-083 in patients with FSHD showing marked increases in the mean total muscle volume of the muscles treated with ACE-083 measured using magnetic resonance imaging, or MRI. We expect to initiate part 2 of the ACE-083 FSHD Phase 2 trial during the second quarter of this year, and we expect to report preliminary results from all dose-escalation cohorts of part 1 in our FSHD and CMT Phase 2 clinical trials with ACE-083 in the second half of this year. In addition to our mid- to late-stage clinical programs, we initiated a Phase 1 healthy volunteer study in early 2018 with ACE-2494, our wholly-owned systemic muscle agent from our proprietary platform technology, IntelliTrap™, and we expect to report initial results from this healthy volunteer study in the first half of 2019. We are also conducting research within our three focused disease areas—hematologic, neuromuscular and pulmonary—in order to identify new therapeutic candidates to advance into clinical trials. As of December 31, 2017 our operations have been funded primarily by $105.1 million in equity investments from venture investors, $539.7 million from public investors, $123.7 million in equity investments from our collaboration partners and $273.7 million in upfront payments, milestones, and net research and development payments from our collaboration partners. Announce MEDALIST Phase 3 clinical trial top-line results in mid-2018. Initiate the COMMANDS Phase 3 clinical trial in the first half of 2018. ', 'company_name': 'Acceleron Pharma, Inc.', 'index': '5'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: To intensify stem cell research showing evidence of substantial clinical benefit to patients, and for other purposes.
Official summary of bill: Patients First Act of 2019
The NIH must also report on peer-reviewed stem cell research proposals that were not funded.
Company name: Acceleron Pharma, Inc.
Company business description: We are a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases. Our research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta, or TGF-beta, protein superfamily. By combining our discovery and development expertise, including our proprietary knowledge of the TGF-beta superfamily, and our internal protein engineering and manufacturing capabilities, we have generated several innovative therapeutic candidates, all of which encompass novel potential first-in-class mechanisms of action. We have focused and prioritized our research and development activities within three key therapeutic areas: hematologic, neuromuscular and pulmonary. If successful, these candidates could have the potential to significantly improve clinical outcomes for patients across these areas of high, unmet need. Luspatercept, our lead program, and sotatercept, are partnered with Celgene Corporation, or Celgene. Luspatercept is an erythroid maturation agent designed to promote red blood cell production through a novel mechanism, and is being developed to treat chronic anemia and associated complications in myelodysplastic syndromes, or MDS, beta-thalassemia, and myelofibrosis. Celgene is currently conducting two Phase 3 clinical trials with luspatercept; one for the treatment of patients with lower-risk MDS, known as the "MEDALIST" trial, and another for the treatment of patients with beta-thalassemia, also known as the "BELIEVE" trial. Celgene has recently initiated a Phase 2 trial in non-transfusion-dependent beta-thalassemia patients, referred to as the "BEYOND" trial. We further expect Celgene to initiate a Phase 3 clinical trial, the "COMMANDS" trial, in first-line, lower-risk MDS patients in the first half of 2018. Enrollment is also currently ongoing in a Phase 2 clinical trial for the treatment of patients with myelofibrosis, a rare bone marrow disorder. If luspatercept were to receive regulatory approval for each of these indications in the United States and Europe, we believe that there is an aggregate sales opportunity for this product in excess of $2 billion. For sotatercept, we announced in September 2017 that Celgene granted us the rights to fund, develop, and lead the global commercialization of sotatercept in pulmonary hypertension, including pulmonary arterial hypertension, or PAH. PAH is a rare and chronic, rapidly progressing disorder characterized by the constriction of small pulmonary arteries, resulting in abnormally high blood pressure in the pulmonary arteries. If sotatercept is commercialized to treat PAH and we recognize such revenue, then Celgene will be eligible to receive a royalty in the low 20% range on global net sales. We expect to initiate a Phase 2 clinical trial for the treatment of patients with PAH in the first half of 2018. For luspatercept and, outside of pulmonary hypertension, sotatercept, Celgene is responsible for paying 100% of the development costs for all clinical trials. ACE-083 is designed for the treatment of focal muscle disorders, and we are currently conducting Phase 2 clinical trials with ACE-083 in patients with facioscapulohumeral dystrophy, or FSHD, as well as in patients with Charcot-Marie-Tooth disease, or CMT. In January 2018, we announced preliminary results for the first two cohorts in part 1 of the Phase 2 clinical trial with ACE-083 in patients with FSHD showing marked increases in the mean total muscle volume of the muscles treated with ACE-083 measured using magnetic resonance imaging, or MRI. We expect to initiate part 2 of the ACE-083 FSHD Phase 2 trial during the second quarter of this year, and we expect to report preliminary results from all dose-escalation cohorts of part 1 in our FSHD and CMT Phase 2 clinical trials with ACE-083 in the second half of this year. In addition to our mid- to late-stage clinical programs, we initiated a Phase 1 healthy volunteer study in early 2018 with ACE-2494, our wholly-owned systemic muscle agent from our proprietary platform technology, IntelliTrap™, and we expect to report initial results from this healthy volunteer study in the first half of 2019. We are also conducting research within our three focused disease areas—hematologic, neuromuscular and pulmonary—in order to identify new therapeutic candidates to advance into clinical trials. As of December 31, 2017 our operations have been funded primarily by $105.1 million in equity investments from venture investors, $539.7 million from public investors, $123.7 million in equity investments from our collaboration partners and $273.7 million in upfront payments, milestones, and net research and development payments from our collaboration partners. Announce MEDALIST Phase 3 clinical trial top-line results in mid-2018. Initiate the COMMANDS Phase 3 clinical trial in the first half of 2018.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
12 | No | {'bill_summary': " This bill requires federal courts to make remote access to certain criminal court proceedings available for victims of the bombing of Pan American Flight 103 over Lockerbie, Scotland, on December 21, 1988.\n\nSpecifically, federal courts must make remote access available to the proceedings in the criminal case against Abu Agila Mohammed Mas'ud Kheir Al-Marimi and against any co-conspirator subsequently charged and prosecuted in federal court for crimes related to the bombing of Pan American Flight 103.", 'bill_title': ' S.3250 - A bill to provide remote access to court proceedings for victims of the 1988 Bombing of Pan Am Flight 103 over Lockerbie, Scotland.', 'company_description': ' \nFeeding America’s story began in the late 1960s when a mother visiting a local meal program suggested there should be a place where food could be stored for people to pick up rather than being thrown away. With that, food banking was born.\n\nSince then, Feeding America has become the leading voice on ending hunger in America.\n\n \nToday, we’re part of a nationwide network that includes food banks, food pantries, and local meal programs. \n\nWe’re committed to listening to the tens of millions of people who experience food insecurity and working together to help the communities most impacted by hunger get the food and resources they need to thrive. We advocate for policies that address the root causes of hunger and continue to innovate solutions that increase equitable access to nutritious food.', 'company_name': ' Feeding America', 'index': 13} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: S.3250 - A bill to provide remote access to court proceedings for victims of the 1988 Bombing of Pan Am Flight 103 over Lockerbie, Scotland.
Official summary of bill: This bill requires federal courts to make remote access to certain criminal court proceedings available for victims of the bombing of Pan American Flight 103 over Lockerbie, Scotland, on December 21, 1988.
We’re committed to listening to the tens of millions of people who experience food insecurity and working together to help the communities most impacted by hunger get the food and resources they need to thrive. We advocate for policies that address the root causes of hunger and continue to innovate solutions that increase equitable access to nutritious food.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
11 | No | {'bill_summary': ' \n\n This resolution sets forth the rule for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for FY2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for FY2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for FY2024.', 'bill_title': '\nProviding for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for the fiscal year ending September 30, 2024, and for other purposes.\n\n', 'company_description': ' California Language Academy was founded in July 2010 by a family with the mission of providing personalized, intimate, and engaging language learning services. Together, we have established a high-quality, family-owned and operated language school that offers small class sizes to meet the individual needs of each student’s learning goals and objectives. We employ highly qualified and dedicated instructors and our comprehensive curricula are designed to build students’ skills and self-confidence when communicating in English or a foreign language in either an academic or professional setting. California Language Academy is unique because it is a family-owned and operated business where our team is friendly, professional, attentive and highly responsive. Our schedule is flexible, and the quick assessment of student skills and challenges creates a more “catered” client service.', 'company_name': ' California Language Academy', 'index': 11} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill:
Providing for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for the fiscal year ending September 30, 2024, and for other purposes.
This resolution sets forth the rule for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for FY2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for FY2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for FY2024.
Company name: California Language Academy
Company business description: California Language Academy was founded in July 2010 by a family with the mission of providing personalized, intimate, and engaging language learning services. Together, we have established a high-quality, family-owned and operated language school that offers small class sizes to meet the individual needs of each student’s learning goals and objectives. We employ highly qualified and dedicated instructors and our comprehensive curricula are designed to build students’ skills and self-confidence when communicating in English or a foreign language in either an academic or professional setting. California Language Academy is unique because it is a family-owned and operated business where our team is friendly, professional, attentive and highly responsive. Our schedule is flexible, and the quick assessment of student skills and challenges creates a more “catered” client service.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
8 | No | {'bill_summary': 'Genetically Engineered Salmon Labeling Act\n\nThis bill requires the market name of genetically engineered (commonly called genetically modified or GMO) salmon to include Genetically Engineered or GE in front of the existing market name.\n\nThe Department of Health and Human Services must ensure that an independent scientific organization conducts a review of the environmental assessment carried out by the Food and Drug Administration in support of a new drug related to AquAdvantage Salmon.', 'bill_title': 'To amend the market name of genetically altered salmon in the United States, and for other purposes.', 'company_description': "We develop, manufacture and market bedding products, which we sell globally. Our brand portfolio includes many highly recognized brands in the industry, including TEMPUR®, Tempur-Pedic®, Sealy® featuring Posturepedic® Technology, and Stearns & Foster®. Our comprehensive suite of bedding products offers a variety of products to consumers across a broad range of channels. We operate in two segments: North America and International. Our North America segment consists of Tempur and Sealy manufacturing and distribution subsidiaries, joint ventures and licensees located in the U.S. and Canada. Our International segment consists of Tempur and Sealy manufacturing and distribution subsidiaries, joint ventures and licensees located in Europe, Asia-Pacific and Latin America. In the first quarter of 2017, we updated our primary selling channels to Wholesale and Direct. Wholesale includes all third party retailers, including third party distribution, hospitality and healthcare. Direct includes company-owned stores, e-commerce, and call centers. Retail included furniture and bedding retailers, department stores, specialty retailers and warehouse clubs. Other included direct-to-consumer, third party distributors, hospitality and healthcare customers. Our goal is to improve the sleep of more people, every night, all around the world. Our Products and Brands We have a comprehensive offering of products that appeal to a broad range of consumers, some of which are covered by one or more patents and/or patent applications. In order to achieve our goal to improve the sleep of more people, every night, all around the world, one of our strategic initiatives is to leverage and strengthen our comprehensive portfolio of iconic brands and products. Our brand portfolio includes many highly recognized brands, including TEMPUR®, Tempur-Pedic®, Sealy® featuring Posturepedic® Technology and Stearns & Foster®, which are described below: ® - Founded in 1991, the Tempur brand is our specialty innovation category leader designed to provide life changing sleep for our wellness-seeking consumers. Our proprietary Tempur material precisely adapts to the shape, weight and temperature of the consumer and creates fewer pressure points, reduces motion transfer and provides personalized comfort and support. The Stearns & Foster brand offers our consumers high quality mattresses built by certified craftsmen who have been specially trained. Founded in 1846, the brand is designed and built with precise engineering and relentless attention to detail and fuses new innovative technologies with time-honored techniques, creating supremely comfortable beds. The Sealy brand originated in 1881 in Sealy, Texas, and for over a century has focused on offering trusted comfort, durability and excellent value while maintaining contemporary styles and great support. The Sealy Posturepedic brand, introduced in 1950, was engineered to provide all-over support and body alignment to allow full relaxation and deliver a comfortable night's sleep. In 2017, Sealy Posturepedic no longer represented its own separate brand as we united all of our Sealy products under one masterbrand, which features the Posturepedic Technology™ in the Sealy Performance The Cocoon by Sealy brand, introduced in 2016, is our offering in the below $1,000 e-commerce space, made with the high quality materials that consumers expect from Sealy, sold online at www.cocoonbysealy.com and delivered in a box directly to consumers' doorsteps. In North America, we united all of our Sealy products under one masterbrand. Product introductions included new Sealy products in two distinct lines: Response and Conform.", 'company_name': 'Tempur Sealy International, Inc.', 'index': '8'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: To amend the market name of genetically altered salmon in the United States, and for other purposes.
Official summary of bill: Genetically Engineered Salmon Labeling Act
The Department of Health and Human Services must ensure that an independent scientific organization conducts a review of the environmental assessment carried out by the Food and Drug Administration in support of a new drug related to AquAdvantage Salmon.
Company name: Tempur Sealy International, Inc.
Company business description: We develop, manufacture and market bedding products, which we sell globally. Our brand portfolio includes many highly recognized brands in the industry, including TEMPUR®, Tempur-Pedic®, Sealy® featuring Posturepedic® Technology, and Stearns & Foster®. Our comprehensive suite of bedding products offers a variety of products to consumers across a broad range of channels. We operate in two segments: North America and International. Our North America segment consists of Tempur and Sealy manufacturing and distribution subsidiaries, joint ventures and licensees located in the U.S. and Canada. Our International segment consists of Tempur and Sealy manufacturing and distribution subsidiaries, joint ventures and licensees located in Europe, Asia-Pacific and Latin America. In the first quarter of 2017, we updated our primary selling channels to Wholesale and Direct. Wholesale includes all third party retailers, including third party distribution, hospitality and healthcare. Direct includes company-owned stores, e-commerce, and call centers. Retail included furniture and bedding retailers, department stores, specialty retailers and warehouse clubs. Other included direct-to-consumer, third party distributors, hospitality and healthcare customers. Our goal is to improve the sleep of more people, every night, all around the world. Our Products and Brands We have a comprehensive offering of products that appeal to a broad range of consumers, some of which are covered by one or more patents and/or patent applications. In order to achieve our goal to improve the sleep of more people, every night, all around the world, one of our strategic initiatives is to leverage and strengthen our comprehensive portfolio of iconic brands and products. Our brand portfolio includes many highly recognized brands, including TEMPUR®, Tempur-Pedic®, Sealy® featuring Posturepedic® Technology and Stearns & Foster®, which are described below: ® - Founded in 1991, the Tempur brand is our specialty innovation category leader designed to provide life changing sleep for our wellness-seeking consumers. Our proprietary Tempur material precisely adapts to the shape, weight and temperature of the consumer and creates fewer pressure points, reduces motion transfer and provides personalized comfort and support. The Stearns & Foster brand offers our consumers high quality mattresses built by certified craftsmen who have been specially trained. Founded in 1846, the brand is designed and built with precise engineering and relentless attention to detail and fuses new innovative technologies with time-honored techniques, creating supremely comfortable beds. The Sealy brand originated in 1881 in Sealy, Texas, and for over a century has focused on offering trusted comfort, durability and excellent value while maintaining contemporary styles and great support. The Sealy Posturepedic brand, introduced in 1950, was engineered to provide all-over support and body alignment to allow full relaxation and deliver a comfortable night's sleep. In 2017, Sealy Posturepedic no longer represented its own separate brand as we united all of our Sealy products under one masterbrand, which features the Posturepedic Technology™ in the Sealy Performance The Cocoon by Sealy brand, introduced in 2016, is our offering in the below $1,000 e-commerce space, made with the high quality materials that consumers expect from Sealy, sold online at www.cocoonbysealy.com and delivered in a box directly to consumers' doorsteps. In North America, we united all of our Sealy products under one masterbrand. Product introductions included new Sealy products in two distinct lines: Response and Conform.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
0 | No | {'bill_summary': "Hualapai Tribe Water Rights Settlement Act of 2019\n\nThis bill modifies and ratifies the Hualapai Tribe water rights settlement agreement negotiated between the tribe, the United States, Arizona, and others, thus satisfying the tribe's claims for groundwater and surface water rights to water in Arizona, including the Verde River, the Bill Williams River, and the Colorado River.\n\nThe bill outlines the tribe's water rights, including the right to divert, use, and store 4,000 acre-feet of agricultural priority water of the Central Arizona Project that was previously allocated to nontribal agricultural entities, but retained by the Department of the Interior for reallocation to tribes in Arizona pursuant to the Central Arizona Project Settlement Act of 2004.\n\nThe Bureau of Reclamation must construct the Hualapai Water Project. The project must be designed to divert, treat, and convey at least 3,414 acre-feet of water per year from the Colorado River for municipal, commercial, and industrial uses on the Hualapai Reservation.\n\nThe bill provides for land to be added to the reservation and taken into trust for the benefit of the tribe. In the future, land located outside the reservation may only be taken into trust through an act of Congress.\n\nThe bill outlines (1) waivers, releases, and retentions of claims by the tribe and the United States under the settlement agreement; and (2) a limited waiver of sovereign immunity by the United States and the tribe with respect to certain claims.", 'bill_title': 'To approve the settlement of water rights claims of the Hualapai Tribe and certain allottees in the State of Arizona, to authorize construction of a water project relating to those water rights claims, and for other purposes.', 'company_description': 'the total domestic capacity for our restaurants; expectations for consumer spending on casual dining restaurant occasions; • the availability and cost of key commodities and labor used in our restaurants and brewing operations; menu price increases and their effect, if any, on revenue and results of operations; projected revenues, operating costs, including commodities, labor and other expenses; Any inability to open new restaurants on schedule in accordance with our targeted capacity growth or problems associated with securing suitable restaurant locations, leases and licenses, recruiting and training qualified 1 managers and hourly employees and other factors, some of which are beyond our control and difficult to forecast accurately may adversely affect our operations. Our corporate office is located in California and a significant number of our restaurants are located in California, Texas and Florida which makes us particularly sensitive to economic, regulatory, weather and other risk factors and conditions that are more prevalent in those states. Any negative publicity about us, our restaurants, other restaurants, or others across the food supply chain, due to food borne illness or other reasons, whether or not accurate may adversely affect the reputation and popularity of our restaurants and our results of operations. Any adverse changes in the supply of food, labor, brewing, energy and other expenses, including those resulting from climate change, may adversely affect our operating results. Periodic reviews and audits of our internal brewing, independent third party brewing and beer distribution arrangements by various federal, state and local governmental and regulatory agencies may adversely affect our operations and our operating results. Government laws and regulations affecting the operation of our restaurants, including but not limited to those that apply to the acquisition and maintenance of our brewing and retail liquor licenses, minimum wages, federal or state exemption rules, health insurance coverage, or other employment benefits such as paid time off, consumer health and safety, nutritional disclosures, and employment eligibility-related documentation requirements may cause disruptions to our operations, adversely affect our operating costs and restrict our growth. The first BJ\'s restaurant, which opened in 1978 in Orange County, California, was a small sit down pizzeria that featured Chicago style deep-dish pizza with a unique California twist. Our goal then and still today, is to be the best casual dining concept ever by focusing on high quality menu options, at a compelling value, a dining experience that exceeds customers\' expectations for service, hospitality and enjoyment, and an atmosphere that is always welcoming and approachable. In 1996, we introduced our initial proprietary craft beers and expanded the BJ\'s concept from its beginnings as a small pizzeria to a full-service, high energy casual dining restaurant when we opened our first large format restaurant featuring a brewing operations in Brea, California. Today our restaurants feature over 140 menu offerings including: slow roasted entrees, such as, prime rib; EnLIGHTened Entrees® such as our Cherry Chipotle Glazed Salmon; our original signature deep-dish pizza; the often imitated, but never replicated world-famous Pizookie® dessert; and our award-winning BJ\'s proprietary craft beers. As of February 25, 2019, we own and operate 202 restaurants located in 27 states, and our proprietary craft beer is produced at several of our locations, our Temple, Texas brewpub locations and by independent third party brewers using our proprietary recipes. We compete in the casual dining segment of the restaurant industry, which is a large, highly fragmented segment with estimated annual sales in the $100+ billion range. We believe that the BJ\'s restaurant concept offers consumers a higher quality, more contemporary and approachable "casual plus," "premium casual," or "polished casual" dining experience than the more mature, mass market casual dining concepts. Our Gold Standard of Operational Excellence is our genuine commitment to take pride in passionately connecting with every customer on every visit, through flawless and relentless execution of every detail, during every shift – to create and keep fanatical fans of BJ\' Our Gold Standard of Operational Excellence is focused on the following key areas that help to differentiate BJ\'s from other casual dining restaurants: Over the years we have expanded the BJ\'s concept to include menu options that meet our customers \' preferences for any dining occasion.', 'company_name': "BJ's Restaurants, Inc.", 'index': '0'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: To approve the settlement of water rights claims of the Hualapai Tribe and certain allottees in the State of Arizona, to authorize construction of a water project relating to those water rights claims, and for other purposes.
Official summary of bill: Hualapai Tribe Water Rights Settlement Act of 2019
The bill outlines (1) waivers, releases, and retentions of claims by the tribe and the United States under the settlement agreement; and (2) a limited waiver of sovereign immunity by the United States and the tribe with respect to certain claims.
Company name: BJ's Restaurants, Inc.
Company business description: the total domestic capacity for our restaurants; expectations for consumer spending on casual dining restaurant occasions; • the availability and cost of key commodities and labor used in our restaurants and brewing operations; menu price increases and their effect, if any, on revenue and results of operations; projected revenues, operating costs, including commodities, labor and other expenses; Any inability to open new restaurants on schedule in accordance with our targeted capacity growth or problems associated with securing suitable restaurant locations, leases and licenses, recruiting and training qualified 1 managers and hourly employees and other factors, some of which are beyond our control and difficult to forecast accurately may adversely affect our operations. Our corporate office is located in California and a significant number of our restaurants are located in California, Texas and Florida which makes us particularly sensitive to economic, regulatory, weather and other risk factors and conditions that are more prevalent in those states. Any negative publicity about us, our restaurants, other restaurants, or others across the food supply chain, due to food borne illness or other reasons, whether or not accurate may adversely affect the reputation and popularity of our restaurants and our results of operations. Any adverse changes in the supply of food, labor, brewing, energy and other expenses, including those resulting from climate change, may adversely affect our operating results. Periodic reviews and audits of our internal brewing, independent third party brewing and beer distribution arrangements by various federal, state and local governmental and regulatory agencies may adversely affect our operations and our operating results. Government laws and regulations affecting the operation of our restaurants, including but not limited to those that apply to the acquisition and maintenance of our brewing and retail liquor licenses, minimum wages, federal or state exemption rules, health insurance coverage, or other employment benefits such as paid time off, consumer health and safety, nutritional disclosures, and employment eligibility-related documentation requirements may cause disruptions to our operations, adversely affect our operating costs and restrict our growth. The first BJ's restaurant, which opened in 1978 in Orange County, California, was a small sit down pizzeria that featured Chicago style deep-dish pizza with a unique California twist. Our goal then and still today, is to be the best casual dining concept ever by focusing on high quality menu options, at a compelling value, a dining experience that exceeds customers' expectations for service, hospitality and enjoyment, and an atmosphere that is always welcoming and approachable. In 1996, we introduced our initial proprietary craft beers and expanded the BJ's concept from its beginnings as a small pizzeria to a full-service, high energy casual dining restaurant when we opened our first large format restaurant featuring a brewing operations in Brea, California. Today our restaurants feature over 140 menu offerings including: slow roasted entrees, such as, prime rib; EnLIGHTened Entrees® such as our Cherry Chipotle Glazed Salmon; our original signature deep-dish pizza; the often imitated, but never replicated world-famous Pizookie® dessert; and our award-winning BJ's proprietary craft beers. As of February 25, 2019, we own and operate 202 restaurants located in 27 states, and our proprietary craft beer is produced at several of our locations, our Temple, Texas brewpub locations and by independent third party brewers using our proprietary recipes. We compete in the casual dining segment of the restaurant industry, which is a large, highly fragmented segment with estimated annual sales in the $100+ billion range. We believe that the BJ's restaurant concept offers consumers a higher quality, more contemporary and approachable "casual plus," "premium casual," or "polished casual" dining experience than the more mature, mass market casual dining concepts. Our Gold Standard of Operational Excellence is our genuine commitment to take pride in passionately connecting with every customer on every visit, through flawless and relentless execution of every detail, during every shift – to create and keep fanatical fans of BJ' Our Gold Standard of Operational Excellence is focused on the following key areas that help to differentiate BJ's from other casual dining restaurants: Over the years we have expanded the BJ's concept to include menu options that meet our customers ' preferences for any dining occasion.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
10 | Yes | {'bill_summary': '\nThis bill provides FY2024 supplemental appropriations for federal departments and agencies to respond to the conflict in Ukraine. The bill designates the funding as emergency spending, which is exempt from discretionary spending limits.\n\nSpecifically, the bill provides appropriations to the\n\nDepartment of Defense (DOD),\nDepartment of Energy science programs,\nthe National Nuclear Security Administration,\nthe Administration for Children and Families,\nthe Department of State, and\nthe U.S. Agency for International Development.\nThe funding is provided for purposes such as\n\nsupporting current U.S. military operations in the region,\nthe Ukraine Security Assistance Initiative,\nreplacing defense articles that were provided to Ukraine,\nreimbursing DOD for defense services and training provided to Ukraine,\nthe Foreign Military Financing Program,\neconomic support for Ukraine,\nrefugee and entrant assistance,\ninternational narcotics control and law enforcement, and\nthe development and production of isotopes.\nThe bill also includes provisions that\n\nexpand the authorities of the President to transfer defense articles and services from DOD to foreign countries or international organizations,\nrequire the President to transfer long-range Army Tactical Missile Systems to Ukraine,\nrequire the President to enter into an agreement with Ukraine regarding repaying the United States for the economic assistance it has provided to Ukraine,\nrequire certain funds that are provided for Ukraine to be matched by other donors, and\nestablish various oversight and reporting requirements for assistance provided to Ukraine.\n', 'bill_title': 'H.R.8035 - Ukraine Security Supplemental Appropriations Act, 2024. A bill for making emergency supplemental appropriations to respond to the situation in Ukraine and for related expenses for the fiscal year ending September 30, 2024, and for other purposes.', 'company_description': 'U.S. Bancorp, with more than 70,000 employees and $663 billion in assets as of December 31, 2023, is the\nparent company of U.S. Bank National Association. Headquartered in Minneapolis, the company serves millions\nof customers locally, nationally and globally through a diversified mix of businesses including consumer banking,\nbusiness banking, commercial banking, institutional banking, payments and wealth management. U.S. Bancorp\nhas been recognized for its approach to digital innovation, community partnerships and customer service,\nincluding being named one of the 2023 World’s Most Ethical Companies and Fortune’s most admired superregional\nbank. ', 'company_name': 'U.S. Bancorp ', 'index': 10} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: H.R.8035 - Ukraine Security Supplemental Appropriations Act, 2024. A bill for making emergency supplemental appropriations to respond to the situation in Ukraine and for related expenses for the fiscal year ending September 30, 2024, and for other purposes.
Official summary of bill:
This bill provides FY2024 supplemental appropriations for federal departments and agencies to respond to the conflict in Ukraine. The bill designates the funding as emergency spending, which is exempt from discretionary spending limits.
Company name: U.S. Bancorp
Company business description: U.S. Bancorp, with more than 70,000 employees and $663 billion in assets as of December 31, 2023, is the
parent company of U.S. Bank National Association. Headquartered in Minneapolis, the company serves millions
of customers locally, nationally and globally through a diversified mix of businesses including consumer banking,
business banking, commercial banking, institutional banking, payments and wealth management. U.S. Bancorp
has been recognized for its approach to digital innovation, community partnerships and customer service,
including being named one of the 2023 World’s Most Ethical Companies and Fortune’s most admired superregional
bank.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
10 | Yes | {'bill_summary': '\nThis bill provides FY2024 supplemental appropriations for federal departments and agencies to respond to the conflict in Ukraine. The bill designates the funding as emergency spending, which is exempt from discretionary spending limits.\n\nSpecifically, the bill provides appropriations to the\n\nDepartment of Defense (DOD),\nDepartment of Energy science programs,\nthe National Nuclear Security Administration,\nthe Administration for Children and Families,\nthe Department of State, and\nthe U.S. Agency for International Development.\nThe funding is provided for purposes such as\n\nsupporting current U.S. military operations in the region,\nthe Ukraine Security Assistance Initiative,\nreplacing defense articles that were provided to Ukraine,\nreimbursing DOD for defense services and training provided to Ukraine,\nthe Foreign Military Financing Program,\neconomic support for Ukraine,\nrefugee and entrant assistance,\ninternational narcotics control and law enforcement, and\nthe development and production of isotopes.\nThe bill also includes provisions that\n\nexpand the authorities of the President to transfer defense articles and services from DOD to foreign countries or international organizations,\nrequire the President to transfer long-range Army Tactical Missile Systems to Ukraine,\nrequire the President to enter into an agreement with Ukraine regarding repaying the United States for the economic assistance it has provided to Ukraine,\nrequire certain funds that are provided for Ukraine to be matched by other donors, and\nestablish various oversight and reporting requirements for assistance provided to Ukraine.\n', 'bill_title': 'H.R.8035 - Ukraine Security Supplemental Appropriations Act, 2024. A bill for making emergency supplemental appropriations to respond to the situation in Ukraine and for related expenses for the fiscal year ending September 30, 2024, and for other purposes.', 'company_description': 'U.S. Bancorp, with more than 70,000 employees and $663 billion in assets as of December 31, 2023, is the\nparent company of U.S. Bank National Association. Headquartered in Minneapolis, the company serves millions\nof customers locally, nationally and globally through a diversified mix of businesses including consumer banking,\nbusiness banking, commercial banking, institutional banking, payments and wealth management. U.S. Bancorp\nhas been recognized for its approach to digital innovation, community partnerships and customer service,\nincluding being named one of the 2023 World’s Most Ethical Companies and Fortune’s most admired superregional\nbank. ', 'company_name': 'U.S. Bancorp ', 'index': 10} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: H.R.8035 - Ukraine Security Supplemental Appropriations Act, 2024. A bill for making emergency supplemental appropriations to respond to the situation in Ukraine and for related expenses for the fiscal year ending September 30, 2024, and for other purposes.
Official summary of bill:
This bill provides FY2024 supplemental appropriations for federal departments and agencies to respond to the conflict in Ukraine. The bill designates the funding as emergency spending, which is exempt from discretionary spending limits.
Company name: U.S. Bancorp
Company business description: U.S. Bancorp, with more than 70,000 employees and $663 billion in assets as of December 31, 2023, is the
parent company of U.S. Bank National Association. Headquartered in Minneapolis, the company serves millions
of customers locally, nationally and globally through a diversified mix of businesses including consumer banking,
business banking, commercial banking, institutional banking, payments and wealth management. U.S. Bancorp
has been recognized for its approach to digital innovation, community partnerships and customer service,
including being named one of the 2023 World’s Most Ethical Companies and Fortune’s most admired superregional
bank.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
9 | Yes | {'bill_summary': "Move America Act of 2019\n\nThis bill allows tax-exempt Move America bonds and Move America tax credits to be used for certain infrastructure projects.\n\nA Move America bond is treated as a tax-exempt private facility bond with certain exceptions. At least 95% of the net proceeds from the issuance of the bond must be used for infrastructure projects, including\n\n airports; docks and wharves; mass commuting facilities; facilities for the furnishing of water; sewage facilities; railroads; certain surface transportation projects eligible for federal assistance, projects for an international bridge or tunnel, or facilities for transferring freight from truck to rail or rail to truck; flood diversions; inland waterways; or rural broadband service infrastructure. The bill specifies exceptions and modifications to existing rules for bonds regarding land acquisition, government ownership, rehabilitation expenditures, and the alternative minimum tax.\n\nThe bonds are subject to a volume cap equal to 50% of a state's current private activity bond volume cap. States may exchange all or a portion of the volume cap for Move America tax credits to be allocated to taxpayers. The credits include (1) an equity credit for a portion of the basis of each qualified facility; and (2) an infrastructure fund credit for investments in qualified infrastructure funds, including a state infrastructure bank, a water pollution control revolving fund, or a drinking water treatment revolving loan fund.", 'bill_title': 'A bill to amend the Internal Revenue Code of 1986 to provide for Move America bonds and Move America credits.', 'company_description': 'We acquire, develop, own and operate self-storage facilities , which offer storage spaces for lease on a month-to-month basis, for personal and business use. We are the largest owner and operator of self-storage facilities in the U.S. We have direct and indirect equity interests in 2,3 8 6 self-storage facilities that we consolidate (an aggregate of 15 9 million net rentable square feet of space) located in 38 states within the U.S. operating under the "Public Storage" brand name. We also own one self -storage facility in London, England which is managed by Shurgard Europe (defined below). Ancillary Operations : We reinsure policies against losses to goods stored by customers in our self-storage facilities and sell merchandise, primarily locks and cardboard boxes, at our self-storage facilities. Inc. ("PSB"), a publicly held REIT that owns, operates, acquires and develops commercial properties, primarily multi-tenant flex, office, and industrial parks. 0 million rentable square feet of commercial space. Shurgard Self Storage Europe Limited ("Shurgard Europe") which owns 221 self-storage facilities (twelve million net rentable square feet) located in seven countries in Western Europe operated under the "Shurgard" brand name. We believe Shurgard Europe is the largest owner and operator of self-storage facilities in Western Europe. We also manage approximately 27 self-storage facilities for third parties . We are seeking to expand our third-party management operations to further increase our economies of scale and leverage our brand; however, there is no assurance that we will be able to do so. We also own 0.9 million net rentable square feet of commercial space which is managed primarily by PSB . For all periods presented herein, we have elected to be treated as a REIT, as defined in the Internal Revenue Code of 1986, as amended (the "Code") . and we expect to continue to elect and qualify as a REIT. We believe that our customers generally store their goods within a five mile radius of their home or business . Our facilities compete with nearby self-storage facilities owned by other operators using marketing channels similar to ours , including Internet advertising, signage, and banners and offer services similar to ours . A s a result, competition is significant and affects the occupancy levels, rental rates, rental income and operating expenses of our facilities. There has been an increase in supply of newly constructed self-storage facilities in several of our markets, most notably Atlanta, Austin, Charlotte, Chicago, Dallas, Denver, Houston, and New York. Ownership and operation of self- storage facilities is highly fragmented. As the largest owner of self-storage facilities, we believe that we own approximately 7 % of the self-storage square footage in the U.S. and that collectively the five largest self-storage owners in the U.S. own approximately 15 %, with the remaining 8 5 % owned by numerous regional and local operators. We believe that we have significant market share and concentration in major metropolitan centers, with approximately 71 % of our 201 7 same-store revenues generated in the 20 Metropolitan Statistical Areas (each, an "MSA", as defined by the U.S. Census Bureau) with the highest population levels. Industry fragmentation also provides opportunities for us to acquire additional facilities; however, we compete with a wide variety of institutions and other investors who also view self-storage facilities as attractive investments. The amount of capital available for real estate investments greatly influences the competition for ownership interests in facilities and, by extension, the yields that we can achieve on newly acquired investments. a s well as analyze customer data and quickly change each of our individual properties \' pricing and promotion s on an automated basis. ', 'company_name': 'Public Storage', 'index': '9'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: A bill to amend the Internal Revenue Code of 1986 to provide for Move America bonds and Move America credits.
Official summary of bill: Move America Act of 2019
The bonds are subject to a volume cap equal to 50% of a state's current private activity bond volume cap. States may exchange all or a portion of the volume cap for Move America tax credits to be allocated to taxpayers. The credits include (1) an equity credit for a portion of the basis of each qualified facility; and (2) an infrastructure fund credit for investments in qualified infrastructure funds, including a state infrastructure bank, a water pollution control revolving fund, or a drinking water treatment revolving loan fund.
Company name: Public Storage
Company business description: We acquire, develop, own and operate self-storage facilities , which offer storage spaces for lease on a month-to-month basis, for personal and business use. We are the largest owner and operator of self-storage facilities in the U.S. We have direct and indirect equity interests in 2,3 8 6 self-storage facilities that we consolidate (an aggregate of 15 9 million net rentable square feet of space) located in 38 states within the U.S. operating under the "Public Storage" brand name. We also own one self -storage facility in London, England which is managed by Shurgard Europe (defined below). Ancillary Operations : We reinsure policies against losses to goods stored by customers in our self-storage facilities and sell merchandise, primarily locks and cardboard boxes, at our self-storage facilities. Inc. ("PSB"), a publicly held REIT that owns, operates, acquires and develops commercial properties, primarily multi-tenant flex, office, and industrial parks. 0 million rentable square feet of commercial space. Shurgard Self Storage Europe Limited ("Shurgard Europe") which owns 221 self-storage facilities (twelve million net rentable square feet) located in seven countries in Western Europe operated under the "Shurgard" brand name. We believe Shurgard Europe is the largest owner and operator of self-storage facilities in Western Europe. We also manage approximately 27 self-storage facilities for third parties . We are seeking to expand our third-party management operations to further increase our economies of scale and leverage our brand; however, there is no assurance that we will be able to do so. We also own 0.9 million net rentable square feet of commercial space which is managed primarily by PSB . For all periods presented herein, we have elected to be treated as a REIT, as defined in the Internal Revenue Code of 1986, as amended (the "Code") . and we expect to continue to elect and qualify as a REIT. We believe that our customers generally store their goods within a five mile radius of their home or business . Our facilities compete with nearby self-storage facilities owned by other operators using marketing channels similar to ours , including Internet advertising, signage, and banners and offer services similar to ours . A s a result, competition is significant and affects the occupancy levels, rental rates, rental income and operating expenses of our facilities. There has been an increase in supply of newly constructed self-storage facilities in several of our markets, most notably Atlanta, Austin, Charlotte, Chicago, Dallas, Denver, Houston, and New York. Ownership and operation of self- storage facilities is highly fragmented. As the largest owner of self-storage facilities, we believe that we own approximately 7 % of the self-storage square footage in the U.S. and that collectively the five largest self-storage owners in the U.S. own approximately 15 %, with the remaining 8 5 % owned by numerous regional and local operators. We believe that we have significant market share and concentration in major metropolitan centers, with approximately 71 % of our 201 7 same-store revenues generated in the 20 Metropolitan Statistical Areas (each, an "MSA", as defined by the U.S. Census Bureau) with the highest population levels. Industry fragmentation also provides opportunities for us to acquire additional facilities; however, we compete with a wide variety of institutions and other investors who also view self-storage facilities as attractive investments. The amount of capital available for real estate investments greatly influences the competition for ownership interests in facilities and, by extension, the yields that we can achieve on newly acquired investments. a s well as analyze customer data and quickly change each of our individual properties ' pricing and promotion s on an automated basis.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
11 | No | {'bill_summary': ' \n\n This resolution sets forth the rule for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for FY2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for FY2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for FY2024.', 'bill_title': '\nProviding for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for the fiscal year ending September 30, 2024, and for other purposes.\n\n', 'company_description': ' California Language Academy was founded in July 2010 by a family with the mission of providing personalized, intimate, and engaging language learning services. Together, we have established a high-quality, family-owned and operated language school that offers small class sizes to meet the individual needs of each student’s learning goals and objectives. We employ highly qualified and dedicated instructors and our comprehensive curricula are designed to build students’ skills and self-confidence when communicating in English or a foreign language in either an academic or professional setting. California Language Academy is unique because it is a family-owned and operated business where our team is friendly, professional, attentive and highly responsive. Our schedule is flexible, and the quick assessment of student skills and challenges creates a more “catered” client service.', 'company_name': ' California Language Academy', 'index': 11} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill:
Providing for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for the fiscal year ending September 30, 2024, and for other purposes.
This resolution sets forth the rule for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for FY2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for FY2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for FY2024.
Company name: California Language Academy
Company business description: California Language Academy was founded in July 2010 by a family with the mission of providing personalized, intimate, and engaging language learning services. Together, we have established a high-quality, family-owned and operated language school that offers small class sizes to meet the individual needs of each student’s learning goals and objectives. We employ highly qualified and dedicated instructors and our comprehensive curricula are designed to build students’ skills and self-confidence when communicating in English or a foreign language in either an academic or professional setting. California Language Academy is unique because it is a family-owned and operated business where our team is friendly, professional, attentive and highly responsive. Our schedule is flexible, and the quick assessment of student skills and challenges creates a more “catered” client service.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
11 | No | {'bill_summary': ' \n\n This resolution sets forth the rule for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for FY2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for FY2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for FY2024.', 'bill_title': '\nProviding for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for the fiscal year ending September 30, 2024, and for other purposes.\n\n', 'company_description': ' California Language Academy was founded in July 2010 by a family with the mission of providing personalized, intimate, and engaging language learning services. Together, we have established a high-quality, family-owned and operated language school that offers small class sizes to meet the individual needs of each student’s learning goals and objectives. We employ highly qualified and dedicated instructors and our comprehensive curricula are designed to build students’ skills and self-confidence when communicating in English or a foreign language in either an academic or professional setting. California Language Academy is unique because it is a family-owned and operated business where our team is friendly, professional, attentive and highly responsive. Our schedule is flexible, and the quick assessment of student skills and challenges creates a more “catered” client service.', 'company_name': ' California Language Academy', 'index': 11} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill:
Providing for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for the fiscal year ending September 30, 2024, and for other purposes.
This resolution sets forth the rule for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for FY2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for FY2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for FY2024.
Company name: California Language Academy
Company business description: California Language Academy was founded in July 2010 by a family with the mission of providing personalized, intimate, and engaging language learning services. Together, we have established a high-quality, family-owned and operated language school that offers small class sizes to meet the individual needs of each student’s learning goals and objectives. We employ highly qualified and dedicated instructors and our comprehensive curricula are designed to build students’ skills and self-confidence when communicating in English or a foreign language in either an academic or professional setting. California Language Academy is unique because it is a family-owned and operated business where our team is friendly, professional, attentive and highly responsive. Our schedule is flexible, and the quick assessment of student skills and challenges creates a more “catered” client service.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
13 | Yes | {'bill_summary': " his bill makes changes to the federal framework governing the reporting of crimes involving the online sexual exploitation of children.\n\nSpecifically, the bill makes changes to the requirements for electronic communication service providers and remote computing service providers (providers) to submit reports to the National Center for Missing and Exploited Children (NCMEC) when they become aware of violations involving the online sexual exploitation of children.\n\nAmong the changes, the bill\nincreases the amount of time—from 90 days to 1 year—that a provider must preserve the contents of a report,\nrequires (currently, authorizes) providers to report on a violation that may be planned or imminent, and\nextends the requirement for providers to report apparent violations involving the sexual exploitation of children to instances involving child sex trafficking or coercion or enticement of a minor to engage in prostitution or any other illegal sexual activity.\nAdditionally, the bill increases the maximum fines for providers who knowingly and willfully fail to submit reports.\n\nFinally, the bill limits the liability of vendors that contract with NCMEC for claims arising from storing and transferring visual depictions of child sexual abuse material (i.e., child pornography). It also limits the liability of minors, or persons acting on behalf of minors, for reporting to NCMEC's CyberTipline apparent violations involving child sexual abuse material in which the child is depicted, including a copy of the visual depiction of the minor.", 'bill_title': ' A bill to amend title 18, United States Code, to strengthen reporting to the CyberTipline related to online sexual exploitation of children, to modernize liabilities for such reports, to preserve the contents of such reports for 1 year, and for other purposes.', 'company_description': ' The Gatti Law Firm is an established, full-service personal injury law firm providing thoughtful, thorough, and zealous representation to people who have been injured and suffered loss. For over 50 years, we have been your advocates against the individuals, insurance companies, and corporations that have caused you harm. Our mission is to aid and protect victims of all types of personal injury including, automobile accidents, work injuries, nursing home abuse, sexual abuse, childbirth injuries, brain injuries, wrongful death, and other areas. We are dedicated to providing you with personalized, tenacious, and ethical representation.\n\nSOMEONE TO FIGHT FOR YOU\nOver the last five decades, our Oregon personal injury lawyers have fought and advocated for full and fair compensation for the harms and losses suffered by our thousands of clients. If you or someone you know has been injured in a car accident, while on the job or in some other way, don’t try to go it alone. Give us a call and get the protection and help you need to get the compensation you deserve.', 'company_name': ' Gatti Law Firm', 'index': 14} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: A bill to amend title 18, United States Code, to strengthen reporting to the CyberTipline related to online sexual exploitation of children, to modernize liabilities for such reports, to preserve the contents of such reports for 1 year, and for other purposes.
Official summary of bill: his bill makes changes to the federal framework governing the reporting of crimes involving the online sexual exploitation of children.
SOMEONE TO FIGHT FOR YOU
Over the last five decades, our Oregon personal injury lawyers have fought and advocated for full and fair compensation for the harms and losses suffered by our thousands of clients. If you or someone you know has been injured in a car accident, while on the job or in some other way, don’t try to go it alone. Give us a call and get the protection and help you need to get the compensation you deserve.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
13 | Yes | {'bill_summary': " his bill makes changes to the federal framework governing the reporting of crimes involving the online sexual exploitation of children.\n\nSpecifically, the bill makes changes to the requirements for electronic communication service providers and remote computing service providers (providers) to submit reports to the National Center for Missing and Exploited Children (NCMEC) when they become aware of violations involving the online sexual exploitation of children.\n\nAmong the changes, the bill\nincreases the amount of time—from 90 days to 1 year—that a provider must preserve the contents of a report,\nrequires (currently, authorizes) providers to report on a violation that may be planned or imminent, and\nextends the requirement for providers to report apparent violations involving the sexual exploitation of children to instances involving child sex trafficking or coercion or enticement of a minor to engage in prostitution or any other illegal sexual activity.\nAdditionally, the bill increases the maximum fines for providers who knowingly and willfully fail to submit reports.\n\nFinally, the bill limits the liability of vendors that contract with NCMEC for claims arising from storing and transferring visual depictions of child sexual abuse material (i.e., child pornography). It also limits the liability of minors, or persons acting on behalf of minors, for reporting to NCMEC's CyberTipline apparent violations involving child sexual abuse material in which the child is depicted, including a copy of the visual depiction of the minor.", 'bill_title': ' A bill to amend title 18, United States Code, to strengthen reporting to the CyberTipline related to online sexual exploitation of children, to modernize liabilities for such reports, to preserve the contents of such reports for 1 year, and for other purposes.', 'company_description': ' The Gatti Law Firm is an established, full-service personal injury law firm providing thoughtful, thorough, and zealous representation to people who have been injured and suffered loss. For over 50 years, we have been your advocates against the individuals, insurance companies, and corporations that have caused you harm. Our mission is to aid and protect victims of all types of personal injury including, automobile accidents, work injuries, nursing home abuse, sexual abuse, childbirth injuries, brain injuries, wrongful death, and other areas. We are dedicated to providing you with personalized, tenacious, and ethical representation.\n\nSOMEONE TO FIGHT FOR YOU\nOver the last five decades, our Oregon personal injury lawyers have fought and advocated for full and fair compensation for the harms and losses suffered by our thousands of clients. If you or someone you know has been injured in a car accident, while on the job or in some other way, don’t try to go it alone. Give us a call and get the protection and help you need to get the compensation you deserve.', 'company_name': ' Gatti Law Firm', 'index': 14} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: A bill to amend title 18, United States Code, to strengthen reporting to the CyberTipline related to online sexual exploitation of children, to modernize liabilities for such reports, to preserve the contents of such reports for 1 year, and for other purposes.
Official summary of bill: his bill makes changes to the federal framework governing the reporting of crimes involving the online sexual exploitation of children.
SOMEONE TO FIGHT FOR YOU
Over the last five decades, our Oregon personal injury lawyers have fought and advocated for full and fair compensation for the harms and losses suffered by our thousands of clients. If you or someone you know has been injured in a car accident, while on the job or in some other way, don’t try to go it alone. Give us a call and get the protection and help you need to get the compensation you deserve.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
13 | Yes | {'bill_summary': " his bill makes changes to the federal framework governing the reporting of crimes involving the online sexual exploitation of children.\n\nSpecifically, the bill makes changes to the requirements for electronic communication service providers and remote computing service providers (providers) to submit reports to the National Center for Missing and Exploited Children (NCMEC) when they become aware of violations involving the online sexual exploitation of children.\n\nAmong the changes, the bill\nincreases the amount of time—from 90 days to 1 year—that a provider must preserve the contents of a report,\nrequires (currently, authorizes) providers to report on a violation that may be planned or imminent, and\nextends the requirement for providers to report apparent violations involving the sexual exploitation of children to instances involving child sex trafficking or coercion or enticement of a minor to engage in prostitution or any other illegal sexual activity.\nAdditionally, the bill increases the maximum fines for providers who knowingly and willfully fail to submit reports.\n\nFinally, the bill limits the liability of vendors that contract with NCMEC for claims arising from storing and transferring visual depictions of child sexual abuse material (i.e., child pornography). It also limits the liability of minors, or persons acting on behalf of minors, for reporting to NCMEC's CyberTipline apparent violations involving child sexual abuse material in which the child is depicted, including a copy of the visual depiction of the minor.", 'bill_title': ' A bill to amend title 18, United States Code, to strengthen reporting to the CyberTipline related to online sexual exploitation of children, to modernize liabilities for such reports, to preserve the contents of such reports for 1 year, and for other purposes.', 'company_description': ' The Gatti Law Firm is an established, full-service personal injury law firm providing thoughtful, thorough, and zealous representation to people who have been injured and suffered loss. For over 50 years, we have been your advocates against the individuals, insurance companies, and corporations that have caused you harm. Our mission is to aid and protect victims of all types of personal injury including, automobile accidents, work injuries, nursing home abuse, sexual abuse, childbirth injuries, brain injuries, wrongful death, and other areas. We are dedicated to providing you with personalized, tenacious, and ethical representation.\n\nSOMEONE TO FIGHT FOR YOU\nOver the last five decades, our Oregon personal injury lawyers have fought and advocated for full and fair compensation for the harms and losses suffered by our thousands of clients. If you or someone you know has been injured in a car accident, while on the job or in some other way, don’t try to go it alone. Give us a call and get the protection and help you need to get the compensation you deserve.', 'company_name': ' Gatti Law Firm', 'index': 14} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: A bill to amend title 18, United States Code, to strengthen reporting to the CyberTipline related to online sexual exploitation of children, to modernize liabilities for such reports, to preserve the contents of such reports for 1 year, and for other purposes.
Official summary of bill: his bill makes changes to the federal framework governing the reporting of crimes involving the online sexual exploitation of children.
SOMEONE TO FIGHT FOR YOU
Over the last five decades, our Oregon personal injury lawyers have fought and advocated for full and fair compensation for the harms and losses suffered by our thousands of clients. If you or someone you know has been injured in a car accident, while on the job or in some other way, don’t try to go it alone. Give us a call and get the protection and help you need to get the compensation you deserve.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
2 | No | {'bill_summary': 'Violence Against Women Reauthorization Act of 2019\n\nThis bill modifies and reauthorizes through FY2024 programs and activities under the Violence Against Women Act that seek to prevent and respond to domestic violence, sexual assault, dating violence, and stalking.\n\nAmong other things, the bill also authorizes new programs, makes changes to federal firearms laws, and establishes new protections to promote housing stability and economic security for victims of domestic violence, sexual assault, dating violence, and stalking.', 'bill_title': 'To reauthorize the Violence Against Women Act of 1994, and for other purposes.', 'company_description': 'Our mission is to improve lives by eliminating the back row in higher education. We are a global leader in education technology. For more than a decade, we have been improving lives by powering world-class digital education. As a trusted partner and brand steward of great universities, we build, deliver, and support online graduate programs and certificates for working adults. Our industry-leading short courses, offered by GetSmarter, are designed to equip life-long learners with in-demand career skills. Over the past decade, we have developed new and innovative tools within our platform to enhance the effectiveness of instructional methods and improve student outcomes and the student experience. During that time, we have also improved our data-driven digital marketing capabilities across our ecosystem of offerings to generate increased student enrollments in a cost effective manner. As a result, demand for our comprehensive platform of integrated technology and services has increased significantly. When 2U was formed in 2008, we had one university client and one 2U-powered graduate program. Today, our university client base has grown to 35, our platform powers 49 graduate programs and over 90 short courses, and from inception to date we have enrolled over 44,000 students in 2U-powered graduate programs and over 86,000 students in our short courses. Our core strategy is to launch graduate programs and short courses with new and existing university clients, to increase student enrollments and graduations across our portfolio of offerings and to expand our non-degree offerings across the career curriculum continuum. We are also committed to continuously improving our platform to deliver high-quality university and student experiences and outcomes at scale. In our Short Course Segment, we target working professionals seeking career advancement through skills attainment. Our Graduate Program Segment derives revenue primarily from a contractually specified percentage of the amounts our university clients receive from their students in the 2U-enabled graduate program for tuition and fees, less credit card fees and other specified charges we have agreed to exclude in certain of our universicty client contracts. The Short Course Segment derives revenue directly from students for the tuition and fees paid to enroll in and progress through our short courses. We share a contractually specified percentage of the tuition and fees received from students in each course with the relevant university client. Our platform, which we refer to as the 2U Operating System, or 2UOS, consists of a seamlessly integrated ecosystem of technology, people and data. Through 2UOS, we provide our university clients with front-end and back-end cloud-based SaaS technology and technology-enabled services. These two components are tightly integrated and optimized with data analysis and machine learning techniques. 2UOS delivers technology with a human touch and is the keystone of our commitment to provide our university clients the tools they need to lead the digital transformation in education. 2UOS provides the following front-end technology and services to students enrolled in our offerings and to faculty members and university administrators supporting our offerings: Our online learning platform is a cohesive end-to-end learning and teaching platform, where our university clients can reliably deliver their high-quality educational content to students. For our Graduate Program Segment, our online learning platform replicates an intimate and live classroom environment and is accessible through proprietary web, mobile and TV applications as well as in an offline mode for convenient consumption of asynchronous coursework. With the recent integration of stem-based education tools and collaborative annotation technology and an improved data-driven user experience, we have significantly enhanced the learning experience for students in 2U-powered graduate programs and instruction capabilities for faculty. Our short course offerings are delivered through a separate proprietary learning platform that shares many of the core features of our Graduate Program Segment learning platform, with some exceptions, such as the enhanced features that facilitate the live classroom environment in our graduate program leaning platform. ', 'company_name': '2U, Inc.', 'index': '2'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: To reauthorize the Violence Against Women Act of 1994, and for other purposes.
Official summary of bill: Violence Against Women Reauthorization Act of 2019
Among other things, the bill also authorizes new programs, makes changes to federal firearms laws, and establishes new protections to promote housing stability and economic security for victims of domestic violence, sexual assault, dating violence, and stalking.
Company name: 2U, Inc.
Company business description: Our mission is to improve lives by eliminating the back row in higher education. We are a global leader in education technology. For more than a decade, we have been improving lives by powering world-class digital education. As a trusted partner and brand steward of great universities, we build, deliver, and support online graduate programs and certificates for working adults. Our industry-leading short courses, offered by GetSmarter, are designed to equip life-long learners with in-demand career skills. Over the past decade, we have developed new and innovative tools within our platform to enhance the effectiveness of instructional methods and improve student outcomes and the student experience. During that time, we have also improved our data-driven digital marketing capabilities across our ecosystem of offerings to generate increased student enrollments in a cost effective manner. As a result, demand for our comprehensive platform of integrated technology and services has increased significantly. When 2U was formed in 2008, we had one university client and one 2U-powered graduate program. Today, our university client base has grown to 35, our platform powers 49 graduate programs and over 90 short courses, and from inception to date we have enrolled over 44,000 students in 2U-powered graduate programs and over 86,000 students in our short courses. Our core strategy is to launch graduate programs and short courses with new and existing university clients, to increase student enrollments and graduations across our portfolio of offerings and to expand our non-degree offerings across the career curriculum continuum. We are also committed to continuously improving our platform to deliver high-quality university and student experiences and outcomes at scale. In our Short Course Segment, we target working professionals seeking career advancement through skills attainment. Our Graduate Program Segment derives revenue primarily from a contractually specified percentage of the amounts our university clients receive from their students in the 2U-enabled graduate program for tuition and fees, less credit card fees and other specified charges we have agreed to exclude in certain of our universicty client contracts. The Short Course Segment derives revenue directly from students for the tuition and fees paid to enroll in and progress through our short courses. We share a contractually specified percentage of the tuition and fees received from students in each course with the relevant university client. Our platform, which we refer to as the 2U Operating System, or 2UOS, consists of a seamlessly integrated ecosystem of technology, people and data. Through 2UOS, we provide our university clients with front-end and back-end cloud-based SaaS technology and technology-enabled services. These two components are tightly integrated and optimized with data analysis and machine learning techniques. 2UOS delivers technology with a human touch and is the keystone of our commitment to provide our university clients the tools they need to lead the digital transformation in education. 2UOS provides the following front-end technology and services to students enrolled in our offerings and to faculty members and university administrators supporting our offerings: Our online learning platform is a cohesive end-to-end learning and teaching platform, where our university clients can reliably deliver their high-quality educational content to students. For our Graduate Program Segment, our online learning platform replicates an intimate and live classroom environment and is accessible through proprietary web, mobile and TV applications as well as in an offline mode for convenient consumption of asynchronous coursework. With the recent integration of stem-based education tools and collaborative annotation technology and an improved data-driven user experience, we have significantly enhanced the learning experience for students in 2U-powered graduate programs and instruction capabilities for faculty. Our short course offerings are delivered through a separate proprietary learning platform that shares many of the core features of our Graduate Program Segment learning platform, with some exceptions, such as the enhanced features that facilitate the live classroom environment in our graduate program leaning platform.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
11 | No | {'bill_summary': ' \n\n This resolution sets forth the rule for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for FY2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for FY2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for FY2024.', 'bill_title': '\nProviding for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for the fiscal year ending September 30, 2024, and for other purposes.\n\n', 'company_description': ' California Language Academy was founded in July 2010 by a family with the mission of providing personalized, intimate, and engaging language learning services. Together, we have established a high-quality, family-owned and operated language school that offers small class sizes to meet the individual needs of each student’s learning goals and objectives. We employ highly qualified and dedicated instructors and our comprehensive curricula are designed to build students’ skills and self-confidence when communicating in English or a foreign language in either an academic or professional setting. California Language Academy is unique because it is a family-owned and operated business where our team is friendly, professional, attentive and highly responsive. Our schedule is flexible, and the quick assessment of student skills and challenges creates a more “catered” client service.', 'company_name': ' California Language Academy', 'index': 11} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill:
Providing for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for the fiscal year ending September 30, 2024, and for other purposes.
This resolution sets forth the rule for consideration of the bill (H.R. 4821) making appropriations for the Department of the Interior, environment, and related agencies for FY2024, and for other purposes; providing for consideration of the bill (H.R. 4820) making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for FY2024, and for other purposes; and providing for consideration of the bill (H.R. 6126) making emergency supplemental appropriations to respond to the attacks in Israel for FY2024.
Company name: California Language Academy
Company business description: California Language Academy was founded in July 2010 by a family with the mission of providing personalized, intimate, and engaging language learning services. Together, we have established a high-quality, family-owned and operated language school that offers small class sizes to meet the individual needs of each student’s learning goals and objectives. We employ highly qualified and dedicated instructors and our comprehensive curricula are designed to build students’ skills and self-confidence when communicating in English or a foreign language in either an academic or professional setting. California Language Academy is unique because it is a family-owned and operated business where our team is friendly, professional, attentive and highly responsive. Our schedule is flexible, and the quick assessment of student skills and challenges creates a more “catered” client service.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
6 | Yes | {'bill_summary': 'Medicare Negotiation and Competitive Licensing Act of 2019\n\nThis bill requires the Centers for Medicare & Medicaid Services (CMS) to negotiate with pharmaceutical companies regarding prices for drugs covered under the Medicare prescription drug benefit. (Current law prohibits the CMS from doing so.)\n\nThe CMS must take certain factors into account during negotiations, including the clinical- and cost-effectiveness of the drug, the financial burden on patients, and unmet patient needs. If the CMS is unable to negotiate the price of a drug, such drug is subject to competitive licensing in order to further its sale under Medicare, notwithstanding existing government-granted exclusivities.\n\nAdditionally, for one year after a drug is provided under a competitive license, such drug is also subject to specified price limitations; if the drug is not offered at such prices, the drug is\xa0subject to additional licensing that furthers its sale under any federal program (e.g., Medicaid).', 'bill_title': 'To amend title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate prices of prescription drugs furnished under part D of the Medicare program.', 'company_description': 'Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to research, develop and commercialize, both with partners and on its own, pharmaceutical products that are designed to address unmet medical needs of patients in major therapeutic areas. Alkermes has a diversified portfolio of marketed drug products and a clinical pipeline of products that address central nervous system ("CNS") disorders such as schizophrenia, depression, addiction and multiple sclerosis ("MS"). Headquartered in Dublin, Ireland, Alkermes has a research and development ("R & D") center in Waltham, Massachusetts; an R & D and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. The key marketed products discussed below are expected to generate significant revenues for us. None Commercialized by Alkermes in the U.S. Alcohol dependence and Opioid dependence Russia and Commonwealth of Independent States ("CIS") 5 Summary information regarding products that use our proprietary technologies: Product Indication(s) Treatment to improve walking in patients with MS, as demonstrated by an increase in walking speed We develop and commercialize products designed to address the unmet needs of patients suffering from addiction and schizophrenia. ARISTADA ARISTADA (aripiprazole lauroxil) is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia. ARISTADA is the first of our products to utilize our proprietary LinkeRx technology. ARISTADA is a prodrug; once in the body, ARISTADA is likely converted by enzyme-mediated hydrolysis to N-hydroxymethyl aripiprazole, which is then hydrolyzed to aripiprazole. ARISTADA is the first atypical antipsychotic with once-monthly, once-every-six-weeks and once-every-two-months dosing options to deliver and maintain therapeutic levels of medication in the body. ARISTADA has four dosing options (441 mg, 662 mg, 882 mg and 1064 mg) and is packaged in a ready-to-use, pre-filled product format. ARISTADA 1064 mg, our two-month dosing option, was approved by the U.S. Food and Drug Administration (the "FDA") in June 2017. We developed ARISTADA and manufacture and commercialize it in the U.S. Schizophrenia is a chronic, severe and disabling brain disorder. The disease is marked by positive symptoms (hallucinations and delusions) and negative symptoms (depression, blunted emotions and social withdrawal), as well as by disorganized thinking. An estimated 2.4 million Americans over the age of 18 have schizophrenia in a given year, with men and women affected equally. Worldwide, it is estimated that one person in every 100 develops schizophrenia. Studies have demonstrated that as many as 75% of patients with schizophrenia have difficulty taking their oral medication on a regular basis, which can lead to worsening of symptoms. VIVITROL VIVITROL (naltrexone for extended-release injectable suspension) is a once-monthly, non-narcotic, injectable medication approved in the U.S., Russia and certain countries of the CIS for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. VIVITROL uses our polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through one intramuscular injection every four weeks. We developed and exclusively manufacture VIVITROL. What are opioid dependence and alcohol dependence? Opioid dependence is a serious and chronic brain disease characterized by compulsive, prolonged self-administration of opioid substances that are not used for a medical purpose.', 'company_name': 'Alkermes Plc', 'index': '6'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: To amend title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate prices of prescription drugs furnished under part D of the Medicare program.
Official summary of bill: Medicare Negotiation and Competitive Licensing Act of 2019
Additionally, for one year after a drug is provided under a competitive license, such drug is also subject to specified price limitations; if the drug is not offered at such prices, the drug is subject to additional licensing that furthers its sale under any federal program (e.g., Medicaid).
Company name: Alkermes Plc
Company business description: Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to research, develop and commercialize, both with partners and on its own, pharmaceutical products that are designed to address unmet medical needs of patients in major therapeutic areas. Alkermes has a diversified portfolio of marketed drug products and a clinical pipeline of products that address central nervous system ("CNS") disorders such as schizophrenia, depression, addiction and multiple sclerosis ("MS"). Headquartered in Dublin, Ireland, Alkermes has a research and development ("R & D") center in Waltham, Massachusetts; an R & D and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. The key marketed products discussed below are expected to generate significant revenues for us. None Commercialized by Alkermes in the U.S. Alcohol dependence and Opioid dependence Russia and Commonwealth of Independent States ("CIS") 5 Summary information regarding products that use our proprietary technologies: Product Indication(s) Treatment to improve walking in patients with MS, as demonstrated by an increase in walking speed We develop and commercialize products designed to address the unmet needs of patients suffering from addiction and schizophrenia. ARISTADA ARISTADA (aripiprazole lauroxil) is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia. ARISTADA is the first of our products to utilize our proprietary LinkeRx technology. ARISTADA is a prodrug; once in the body, ARISTADA is likely converted by enzyme-mediated hydrolysis to N-hydroxymethyl aripiprazole, which is then hydrolyzed to aripiprazole. ARISTADA is the first atypical antipsychotic with once-monthly, once-every-six-weeks and once-every-two-months dosing options to deliver and maintain therapeutic levels of medication in the body. ARISTADA has four dosing options (441 mg, 662 mg, 882 mg and 1064 mg) and is packaged in a ready-to-use, pre-filled product format. ARISTADA 1064 mg, our two-month dosing option, was approved by the U.S. Food and Drug Administration (the "FDA") in June 2017. We developed ARISTADA and manufacture and commercialize it in the U.S. Schizophrenia is a chronic, severe and disabling brain disorder. The disease is marked by positive symptoms (hallucinations and delusions) and negative symptoms (depression, blunted emotions and social withdrawal), as well as by disorganized thinking. An estimated 2.4 million Americans over the age of 18 have schizophrenia in a given year, with men and women affected equally. Worldwide, it is estimated that one person in every 100 develops schizophrenia. Studies have demonstrated that as many as 75% of patients with schizophrenia have difficulty taking their oral medication on a regular basis, which can lead to worsening of symptoms. VIVITROL VIVITROL (naltrexone for extended-release injectable suspension) is a once-monthly, non-narcotic, injectable medication approved in the U.S., Russia and certain countries of the CIS for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. VIVITROL uses our polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through one intramuscular injection every four weeks. We developed and exclusively manufacture VIVITROL. What are opioid dependence and alcohol dependence? Opioid dependence is a serious and chronic brain disease characterized by compulsive, prolonged self-administration of opioid substances that are not used for a medical purpose.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
3 | No | {'bill_summary': 'Advancing Human Spaceflight Act\n\nThis bill addresses the establishment of U.S. policy, programs, and activities pertaining to human presence in space.\n\nThe bill declares that it is U.S. policy to permanently establish a human presence in low-Earth orbit and that such capability shall\n\n maintain U.S. global leadership and relations with partners and allies, contribute to the general welfare of the United States, and be affordable so as to not preclude a robust portfolio of other human space exploration activities. The National Aeronautics and Space Administration (NASA) shall ensure that the International Space Station (ISS) remains a viable and productive facility capable of potential U.S. use through at least FY2030.\n\nNASA must submit a strategy that includes how it will transition to a successor platform to the ISS.\n\nThe bill expands the objectives of NASA to include the expansion of permanent human presence beyond Earth in a way that enables human space settlement and a thriving space economy.\n\nNASA shall establish a program of developing space suits and associated technologies.', 'bill_title': 'A bill to extend the commitment of the United States to the International Space Station, to develop advanced space suits, and to enable human space settlement, and for other purposes.', 'company_description': 'Our mission is to improve lives by eliminating the back row in higher education. We are a global leader in education technology. For more than a decade, we have been improving lives by powering world-class digital education. As a trusted partner and brand steward of great universities, we build, deliver, and support online graduate programs and certificates for working adults. Our industry-leading short courses, offered by GetSmarter, are designed to equip life-long learners with in-demand career skills. Over the past decade, we have developed new and innovative tools within our platform to enhance the effectiveness of instructional methods and improve student outcomes and the student experience. During that time, we have also improved our data-driven digital marketing capabilities across our ecosystem of offerings to generate increased student enrollments in a cost effective manner. As a result, demand for our comprehensive platform of integrated technology and services has increased significantly. When 2U was formed in 2008, we had one university client and one 2U-powered graduate program. Today, our university client base has grown to 35, our platform powers 49 graduate programs and over 90 short courses, and from inception to date we have enrolled over 44,000 students in 2U-powered graduate programs and over 86,000 students in our short courses. Our core strategy is to launch graduate programs and short courses with new and existing university clients, to increase student enrollments and graduations across our portfolio of offerings and to expand our non-degree offerings across the career curriculum continuum. We are also committed to continuously improving our platform to deliver high-quality university and student experiences and outcomes at scale. In our Short Course Segment, we target working professionals seeking career advancement through skills attainment. Our Graduate Program Segment derives revenue primarily from a contractually specified percentage of the amounts our university clients receive from their students in the 2U-enabled graduate program for tuition and fees, less credit card fees and other specified charges we have agreed to exclude in certain of our universicty client contracts. The Short Course Segment derives revenue directly from students for the tuition and fees paid to enroll in and progress through our short courses. We share a contractually specified percentage of the tuition and fees received from students in each course with the relevant university client. Our platform, which we refer to as the 2U Operating System, or 2UOS, consists of a seamlessly integrated ecosystem of technology, people and data. Through 2UOS, we provide our university clients with front-end and back-end cloud-based SaaS technology and technology-enabled services. These two components are tightly integrated and optimized with data analysis and machine learning techniques. 2UOS delivers technology with a human touch and is the keystone of our commitment to provide our university clients the tools they need to lead the digital transformation in education. 2UOS provides the following front-end technology and services to students enrolled in our offerings and to faculty members and university administrators supporting our offerings: Our online learning platform is a cohesive end-to-end learning and teaching platform, where our university clients can reliably deliver their high-quality educational content to students. For our Graduate Program Segment, our online learning platform replicates an intimate and live classroom environment and is accessible through proprietary web, mobile and TV applications as well as in an offline mode for convenient consumption of asynchronous coursework. With the recent integration of stem-based education tools and collaborative annotation technology and an improved data-driven user experience, we have significantly enhanced the learning experience for students in 2U-powered graduate programs and instruction capabilities for faculty. Our short course offerings are delivered through a separate proprietary learning platform that shares many of the core features of our Graduate Program Segment learning platform, with some exceptions, such as the enhanced features that facilitate the live classroom environment in our graduate program leaning platform. ', 'company_name': '2U, Inc.', 'index': '3'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: A bill to extend the commitment of the United States to the International Space Station, to develop advanced space suits, and to enable human space settlement, and for other purposes.
Official summary of bill: Advancing Human Spaceflight Act
NASA shall establish a program of developing space suits and associated technologies.
Company name: 2U, Inc.
Company business description: Our mission is to improve lives by eliminating the back row in higher education. We are a global leader in education technology. For more than a decade, we have been improving lives by powering world-class digital education. As a trusted partner and brand steward of great universities, we build, deliver, and support online graduate programs and certificates for working adults. Our industry-leading short courses, offered by GetSmarter, are designed to equip life-long learners with in-demand career skills. Over the past decade, we have developed new and innovative tools within our platform to enhance the effectiveness of instructional methods and improve student outcomes and the student experience. During that time, we have also improved our data-driven digital marketing capabilities across our ecosystem of offerings to generate increased student enrollments in a cost effective manner. As a result, demand for our comprehensive platform of integrated technology and services has increased significantly. When 2U was formed in 2008, we had one university client and one 2U-powered graduate program. Today, our university client base has grown to 35, our platform powers 49 graduate programs and over 90 short courses, and from inception to date we have enrolled over 44,000 students in 2U-powered graduate programs and over 86,000 students in our short courses. Our core strategy is to launch graduate programs and short courses with new and existing university clients, to increase student enrollments and graduations across our portfolio of offerings and to expand our non-degree offerings across the career curriculum continuum. We are also committed to continuously improving our platform to deliver high-quality university and student experiences and outcomes at scale. In our Short Course Segment, we target working professionals seeking career advancement through skills attainment. Our Graduate Program Segment derives revenue primarily from a contractually specified percentage of the amounts our university clients receive from their students in the 2U-enabled graduate program for tuition and fees, less credit card fees and other specified charges we have agreed to exclude in certain of our universicty client contracts. The Short Course Segment derives revenue directly from students for the tuition and fees paid to enroll in and progress through our short courses. We share a contractually specified percentage of the tuition and fees received from students in each course with the relevant university client. Our platform, which we refer to as the 2U Operating System, or 2UOS, consists of a seamlessly integrated ecosystem of technology, people and data. Through 2UOS, we provide our university clients with front-end and back-end cloud-based SaaS technology and technology-enabled services. These two components are tightly integrated and optimized with data analysis and machine learning techniques. 2UOS delivers technology with a human touch and is the keystone of our commitment to provide our university clients the tools they need to lead the digital transformation in education. 2UOS provides the following front-end technology and services to students enrolled in our offerings and to faculty members and university administrators supporting our offerings: Our online learning platform is a cohesive end-to-end learning and teaching platform, where our university clients can reliably deliver their high-quality educational content to students. For our Graduate Program Segment, our online learning platform replicates an intimate and live classroom environment and is accessible through proprietary web, mobile and TV applications as well as in an offline mode for convenient consumption of asynchronous coursework. With the recent integration of stem-based education tools and collaborative annotation technology and an improved data-driven user experience, we have significantly enhanced the learning experience for students in 2U-powered graduate programs and instruction capabilities for faculty. Our short course offerings are delivered through a separate proprietary learning platform that shares many of the core features of our Graduate Program Segment learning platform, with some exceptions, such as the enhanced features that facilitate the live classroom environment in our graduate program leaning platform.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
8 | No | {'bill_summary': 'Genetically Engineered Salmon Labeling Act\n\nThis bill requires the market name of genetically engineered (commonly called genetically modified or GMO) salmon to include Genetically Engineered or GE in front of the existing market name.\n\nThe Department of Health and Human Services must ensure that an independent scientific organization conducts a review of the environmental assessment carried out by the Food and Drug Administration in support of a new drug related to AquAdvantage Salmon.', 'bill_title': 'To amend the market name of genetically altered salmon in the United States, and for other purposes.', 'company_description': "We develop, manufacture and market bedding products, which we sell globally. Our brand portfolio includes many highly recognized brands in the industry, including TEMPUR®, Tempur-Pedic®, Sealy® featuring Posturepedic® Technology, and Stearns & Foster®. Our comprehensive suite of bedding products offers a variety of products to consumers across a broad range of channels. We operate in two segments: North America and International. Our North America segment consists of Tempur and Sealy manufacturing and distribution subsidiaries, joint ventures and licensees located in the U.S. and Canada. Our International segment consists of Tempur and Sealy manufacturing and distribution subsidiaries, joint ventures and licensees located in Europe, Asia-Pacific and Latin America. In the first quarter of 2017, we updated our primary selling channels to Wholesale and Direct. Wholesale includes all third party retailers, including third party distribution, hospitality and healthcare. Direct includes company-owned stores, e-commerce, and call centers. Retail included furniture and bedding retailers, department stores, specialty retailers and warehouse clubs. Other included direct-to-consumer, third party distributors, hospitality and healthcare customers. Our goal is to improve the sleep of more people, every night, all around the world. Our Products and Brands We have a comprehensive offering of products that appeal to a broad range of consumers, some of which are covered by one or more patents and/or patent applications. In order to achieve our goal to improve the sleep of more people, every night, all around the world, one of our strategic initiatives is to leverage and strengthen our comprehensive portfolio of iconic brands and products. Our brand portfolio includes many highly recognized brands, including TEMPUR®, Tempur-Pedic®, Sealy® featuring Posturepedic® Technology and Stearns & Foster®, which are described below: ® - Founded in 1991, the Tempur brand is our specialty innovation category leader designed to provide life changing sleep for our wellness-seeking consumers. Our proprietary Tempur material precisely adapts to the shape, weight and temperature of the consumer and creates fewer pressure points, reduces motion transfer and provides personalized comfort and support. The Stearns & Foster brand offers our consumers high quality mattresses built by certified craftsmen who have been specially trained. Founded in 1846, the brand is designed and built with precise engineering and relentless attention to detail and fuses new innovative technologies with time-honored techniques, creating supremely comfortable beds. The Sealy brand originated in 1881 in Sealy, Texas, and for over a century has focused on offering trusted comfort, durability and excellent value while maintaining contemporary styles and great support. The Sealy Posturepedic brand, introduced in 1950, was engineered to provide all-over support and body alignment to allow full relaxation and deliver a comfortable night's sleep. In 2017, Sealy Posturepedic no longer represented its own separate brand as we united all of our Sealy products under one masterbrand, which features the Posturepedic Technology™ in the Sealy Performance The Cocoon by Sealy brand, introduced in 2016, is our offering in the below $1,000 e-commerce space, made with the high quality materials that consumers expect from Sealy, sold online at www.cocoonbysealy.com and delivered in a box directly to consumers' doorsteps. In North America, we united all of our Sealy products under one masterbrand. Product introductions included new Sealy products in two distinct lines: Response and Conform.", 'company_name': 'Tempur Sealy International, Inc.', 'index': '8'} | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: {{bill_title}}
Official summary of bill: {{bill_summary}}
Company name: {{company_name}}
Company business description: {{company_description}}
Is this bill potentially relevant to the company? FINAL ANSWER: | You are a lobbyist analyzing Congressional bills for their impacts on companies.
Given the title and summary of the bill, plus information on the company from its 10K SEC filing, it is your job to determine if a bill is at least somewhat relevant to a company in terms of whether it could impact the company's bottom-line if it was enacted (by saying YES or NO; note the all-caps).
Official title of bill: To amend the market name of genetically altered salmon in the United States, and for other purposes.
Official summary of bill: Genetically Engineered Salmon Labeling Act
The Department of Health and Human Services must ensure that an independent scientific organization conducts a review of the environmental assessment carried out by the Food and Drug Administration in support of a new drug related to AquAdvantage Salmon.
Company name: Tempur Sealy International, Inc.
Company business description: We develop, manufacture and market bedding products, which we sell globally. Our brand portfolio includes many highly recognized brands in the industry, including TEMPUR®, Tempur-Pedic®, Sealy® featuring Posturepedic® Technology, and Stearns & Foster®. Our comprehensive suite of bedding products offers a variety of products to consumers across a broad range of channels. We operate in two segments: North America and International. Our North America segment consists of Tempur and Sealy manufacturing and distribution subsidiaries, joint ventures and licensees located in the U.S. and Canada. Our International segment consists of Tempur and Sealy manufacturing and distribution subsidiaries, joint ventures and licensees located in Europe, Asia-Pacific and Latin America. In the first quarter of 2017, we updated our primary selling channels to Wholesale and Direct. Wholesale includes all third party retailers, including third party distribution, hospitality and healthcare. Direct includes company-owned stores, e-commerce, and call centers. Retail included furniture and bedding retailers, department stores, specialty retailers and warehouse clubs. Other included direct-to-consumer, third party distributors, hospitality and healthcare customers. Our goal is to improve the sleep of more people, every night, all around the world. Our Products and Brands We have a comprehensive offering of products that appeal to a broad range of consumers, some of which are covered by one or more patents and/or patent applications. In order to achieve our goal to improve the sleep of more people, every night, all around the world, one of our strategic initiatives is to leverage and strengthen our comprehensive portfolio of iconic brands and products. Our brand portfolio includes many highly recognized brands, including TEMPUR®, Tempur-Pedic®, Sealy® featuring Posturepedic® Technology and Stearns & Foster®, which are described below: ® - Founded in 1991, the Tempur brand is our specialty innovation category leader designed to provide life changing sleep for our wellness-seeking consumers. Our proprietary Tempur material precisely adapts to the shape, weight and temperature of the consumer and creates fewer pressure points, reduces motion transfer and provides personalized comfort and support. The Stearns & Foster brand offers our consumers high quality mattresses built by certified craftsmen who have been specially trained. Founded in 1846, the brand is designed and built with precise engineering and relentless attention to detail and fuses new innovative technologies with time-honored techniques, creating supremely comfortable beds. The Sealy brand originated in 1881 in Sealy, Texas, and for over a century has focused on offering trusted comfort, durability and excellent value while maintaining contemporary styles and great support. The Sealy Posturepedic brand, introduced in 1950, was engineered to provide all-over support and body alignment to allow full relaxation and deliver a comfortable night's sleep. In 2017, Sealy Posturepedic no longer represented its own separate brand as we united all of our Sealy products under one masterbrand, which features the Posturepedic Technology™ in the Sealy Performance The Cocoon by Sealy brand, introduced in 2016, is our offering in the below $1,000 e-commerce space, made with the high quality materials that consumers expect from Sealy, sold online at www.cocoonbysealy.com and delivered in a box directly to consumers' doorsteps. In North America, we united all of our Sealy products under one masterbrand. Product introductions included new Sealy products in two distinct lines: Response and Conform.
Is this bill potentially relevant to the company? FINAL ANSWER: | corporate_lobbying |
6 | YES | {'index': 6, 'text': '2.1.2 CAR Field License Grant. Anthrogenesis hereby grants to Celgene and its Affiliates a non-exclusive, royalty-free, fully-paid up, worldwide, license, with the right to grant sublicenses, under the Anthrogenesis IP to Develop, Manufacture, Commercialize and otherwise fully exploit products and services in the CAR Field. The foregoing license grant shall be non-transferable and non-assignable, except as provided by Section 6.4 of this Agreement.', 'document_name': 'Anthrogenesis IP agreement'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: 2.1.2 CAR Field License Grant. Anthrogenesis hereby grants to Celgene and its Affiliates a non-exclusive, royalty-free, fully-paid up, worldwide, license, with the right to grant sublicenses, under the Anthrogenesis IP to Develop, Manufacture, Commercialize and otherwise fully exploit products and services in the CAR Field. The foregoing license grant shall be non-transferable and non-assignable, except as provided by Section 6.4 of this Agreement.
Label: | cuad_affiliate_license-licensee |
3 | No | {'index': '3', 'text': 'Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.', 'document_name': 'ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement.pdf'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: | cuad_affiliate_license-licensee |
10 | NO | {'index': 10, 'text': " License Grant. Subject to the terms and conditions of this Agreement and the due performance by Licensee of Licensee's obligations under this Agreement and in reliance on Licensee's representations and warranties set forth in this Agreement, Licensor hereby grants to Licensee an exclusive license under the Licensed Patent for the Term in the Territory to import, offer to sell, and sell Licensed Product.", 'document_name': 'Licensor Licensee agreement c'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: License Grant. Subject to the terms and conditions of this Agreement and the due performance by Licensee of Licensee's obligations under this Agreement and in reliance on Licensee's representations and warranties set forth in this Agreement, Licensor hereby grants to Licensee an exclusive license under the Licensed Patent for the Term in the Territory to import, offer to sell, and sell Licensed Product.
Label: | cuad_affiliate_license-licensee |
7 | YES | {'index': 7, 'text': ' 2.1 License Grant. Subject to the terms and conditions of this Agreement, as of the Execution Date provided that the Initial License Fee as defined in Section 4.1 of this Agreement is paid as of the Execution Date and, IMUN hereby grants, and shall procure that each of its relevant Affiliates shall grant, to Forte (i) an exclusive, royalty-bearing license (or sublicense, including the right to sublicense solely as set forth in Section 2.3 and elsewhere in this Agreement), under the IMUN Patent Rights and the IMUN Know-How to the extent specific to the Compound and the Product; and (ii) a non-exclusive, royalty-bearing (as set forth in Section 4.3) license (or sublicense including the right to sublicense solely as set forth in Section 2.3 and elsewhere in this Agreement), under the IMUN Know-How that is not specific but is related to one or both of the Compounds and/or the Products; in each case, to make, have made, use, sell, have sold, offer for sale, and import Compounds and Products in the Field in the Territory during the Term (collectively, the “License Grant”).', 'document_name': 'License grant clause'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: 2.1 License Grant. Subject to the terms and conditions of this Agreement, as of the Execution Date provided that the Initial License Fee as defined in Section 4.1 of this Agreement is paid as of the Execution Date and, IMUN hereby grants, and shall procure that each of its relevant Affiliates shall grant, to Forte (i) an exclusive, royalty-bearing license (or sublicense, including the right to sublicense solely as set forth in Section 2.3 and elsewhere in this Agreement), under the IMUN Patent Rights and the IMUN Know-How to the extent specific to the Compound and the Product; and (ii) a non-exclusive, royalty-bearing (as set forth in Section 4.3) license (or sublicense including the right to sublicense solely as set forth in Section 2.3 and elsewhere in this Agreement), under the IMUN Know-How that is not specific but is related to one or both of the Compounds and/or the Products; in each case, to make, have made, use, sell, have sold, offer for sale, and import Compounds and Products in the Field in the Territory during the Term (collectively, the “License Grant”).
Label: | cuad_affiliate_license-licensee |
4 | No | {'index': '4', 'text': 'Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.', 'document_name': 'Microgenics Corporation - Collaborative Development and Commercialization Agreement.PDF'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: | cuad_affiliate_license-licensee |
6 | YES | {'index': 6, 'text': '2.1.2 CAR Field License Grant. Anthrogenesis hereby grants to Celgene and its Affiliates a non-exclusive, royalty-free, fully-paid up, worldwide, license, with the right to grant sublicenses, under the Anthrogenesis IP to Develop, Manufacture, Commercialize and otherwise fully exploit products and services in the CAR Field. The foregoing license grant shall be non-transferable and non-assignable, except as provided by Section 6.4 of this Agreement.', 'document_name': 'Anthrogenesis IP agreement'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: 2.1.2 CAR Field License Grant. Anthrogenesis hereby grants to Celgene and its Affiliates a non-exclusive, royalty-free, fully-paid up, worldwide, license, with the right to grant sublicenses, under the Anthrogenesis IP to Develop, Manufacture, Commercialize and otherwise fully exploit products and services in the CAR Field. The foregoing license grant shall be non-transferable and non-assignable, except as provided by Section 6.4 of this Agreement.
Label: | cuad_affiliate_license-licensee |
9 | NO | {'index': 9, 'text': ' 1.\tSubject to the other terms and conditions of the License Agreement as herein modified, Licensor amends and restates §4 of its License Modification to grant a non-exclusive license to Licensee to use Licensed Trademarks in connection with medical instruments that are tissue emulsifiers and/or aspirators for use in liposuction. ', 'document_name': 'Licensor Licensee agreement b'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: 1. Subject to the other terms and conditions of the License Agreement as herein modified, Licensor amends and restates §4 of its License Modification to grant a non-exclusive license to Licensee to use Licensed Trademarks in connection with medical instruments that are tissue emulsifiers and/or aspirators for use in liposuction.
Label: | cuad_affiliate_license-licensee |
2 | Yes | {'index': '2', 'text': "For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.", 'document_name': 'ArconicRolledProductsCorp_20191217_10-12B_EX-2.7_11923804_EX-2.7_Trademark License Agreement.pdf'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: | cuad_affiliate_license-licensee |
6 | YES | {'index': 6, 'text': '2.1.2 CAR Field License Grant. Anthrogenesis hereby grants to Celgene and its Affiliates a non-exclusive, royalty-free, fully-paid up, worldwide, license, with the right to grant sublicenses, under the Anthrogenesis IP to Develop, Manufacture, Commercialize and otherwise fully exploit products and services in the CAR Field. The foregoing license grant shall be non-transferable and non-assignable, except as provided by Section 6.4 of this Agreement.', 'document_name': 'Anthrogenesis IP agreement'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: 2.1.2 CAR Field License Grant. Anthrogenesis hereby grants to Celgene and its Affiliates a non-exclusive, royalty-free, fully-paid up, worldwide, license, with the right to grant sublicenses, under the Anthrogenesis IP to Develop, Manufacture, Commercialize and otherwise fully exploit products and services in the CAR Field. The foregoing license grant shall be non-transferable and non-assignable, except as provided by Section 6.4 of this Agreement.
Label: | cuad_affiliate_license-licensee |
10 | NO | {'index': 10, 'text': " License Grant. Subject to the terms and conditions of this Agreement and the due performance by Licensee of Licensee's obligations under this Agreement and in reliance on Licensee's representations and warranties set forth in this Agreement, Licensor hereby grants to Licensee an exclusive license under the Licensed Patent for the Term in the Territory to import, offer to sell, and sell Licensed Product.", 'document_name': 'Licensor Licensee agreement c'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: License Grant. Subject to the terms and conditions of this Agreement and the due performance by Licensee of Licensee's obligations under this Agreement and in reliance on Licensee's representations and warranties set forth in this Agreement, Licensor hereby grants to Licensee an exclusive license under the Licensed Patent for the Term in the Territory to import, offer to sell, and sell Licensed Product.
Label: | cuad_affiliate_license-licensee |
10 | NO | {'index': 10, 'text': " License Grant. Subject to the terms and conditions of this Agreement and the due performance by Licensee of Licensee's obligations under this Agreement and in reliance on Licensee's representations and warranties set forth in this Agreement, Licensor hereby grants to Licensee an exclusive license under the Licensed Patent for the Term in the Territory to import, offer to sell, and sell Licensed Product.", 'document_name': 'Licensor Licensee agreement c'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: License Grant. Subject to the terms and conditions of this Agreement and the due performance by Licensee of Licensee's obligations under this Agreement and in reliance on Licensee's representations and warranties set forth in this Agreement, Licensor hereby grants to Licensee an exclusive license under the Licensed Patent for the Term in the Territory to import, offer to sell, and sell Licensed Product.
Label: | cuad_affiliate_license-licensee |
7 | YES | {'index': 7, 'text': ' 2.1 License Grant. Subject to the terms and conditions of this Agreement, as of the Execution Date provided that the Initial License Fee as defined in Section 4.1 of this Agreement is paid as of the Execution Date and, IMUN hereby grants, and shall procure that each of its relevant Affiliates shall grant, to Forte (i) an exclusive, royalty-bearing license (or sublicense, including the right to sublicense solely as set forth in Section 2.3 and elsewhere in this Agreement), under the IMUN Patent Rights and the IMUN Know-How to the extent specific to the Compound and the Product; and (ii) a non-exclusive, royalty-bearing (as set forth in Section 4.3) license (or sublicense including the right to sublicense solely as set forth in Section 2.3 and elsewhere in this Agreement), under the IMUN Know-How that is not specific but is related to one or both of the Compounds and/or the Products; in each case, to make, have made, use, sell, have sold, offer for sale, and import Compounds and Products in the Field in the Territory during the Term (collectively, the “License Grant”).', 'document_name': 'License grant clause'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: 2.1 License Grant. Subject to the terms and conditions of this Agreement, as of the Execution Date provided that the Initial License Fee as defined in Section 4.1 of this Agreement is paid as of the Execution Date and, IMUN hereby grants, and shall procure that each of its relevant Affiliates shall grant, to Forte (i) an exclusive, royalty-bearing license (or sublicense, including the right to sublicense solely as set forth in Section 2.3 and elsewhere in this Agreement), under the IMUN Patent Rights and the IMUN Know-How to the extent specific to the Compound and the Product; and (ii) a non-exclusive, royalty-bearing (as set forth in Section 4.3) license (or sublicense including the right to sublicense solely as set forth in Section 2.3 and elsewhere in this Agreement), under the IMUN Know-How that is not specific but is related to one or both of the Compounds and/or the Products; in each case, to make, have made, use, sell, have sold, offer for sale, and import Compounds and Products in the Field in the Territory during the Term (collectively, the “License Grant”).
Label: | cuad_affiliate_license-licensee |
4 | No | {'index': '4', 'text': 'Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.', 'document_name': 'Microgenics Corporation - Collaborative Development and Commercialization Agreement.PDF'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: | cuad_affiliate_license-licensee |
3 | No | {'index': '3', 'text': 'Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.', 'document_name': 'ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement.pdf'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: | cuad_affiliate_license-licensee |
7 | YES | {'index': 7, 'text': ' 2.1 License Grant. Subject to the terms and conditions of this Agreement, as of the Execution Date provided that the Initial License Fee as defined in Section 4.1 of this Agreement is paid as of the Execution Date and, IMUN hereby grants, and shall procure that each of its relevant Affiliates shall grant, to Forte (i) an exclusive, royalty-bearing license (or sublicense, including the right to sublicense solely as set forth in Section 2.3 and elsewhere in this Agreement), under the IMUN Patent Rights and the IMUN Know-How to the extent specific to the Compound and the Product; and (ii) a non-exclusive, royalty-bearing (as set forth in Section 4.3) license (or sublicense including the right to sublicense solely as set forth in Section 2.3 and elsewhere in this Agreement), under the IMUN Know-How that is not specific but is related to one or both of the Compounds and/or the Products; in each case, to make, have made, use, sell, have sold, offer for sale, and import Compounds and Products in the Field in the Territory during the Term (collectively, the “License Grant”).', 'document_name': 'License grant clause'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: 2.1 License Grant. Subject to the terms and conditions of this Agreement, as of the Execution Date provided that the Initial License Fee as defined in Section 4.1 of this Agreement is paid as of the Execution Date and, IMUN hereby grants, and shall procure that each of its relevant Affiliates shall grant, to Forte (i) an exclusive, royalty-bearing license (or sublicense, including the right to sublicense solely as set forth in Section 2.3 and elsewhere in this Agreement), under the IMUN Patent Rights and the IMUN Know-How to the extent specific to the Compound and the Product; and (ii) a non-exclusive, royalty-bearing (as set forth in Section 4.3) license (or sublicense including the right to sublicense solely as set forth in Section 2.3 and elsewhere in this Agreement), under the IMUN Know-How that is not specific but is related to one or both of the Compounds and/or the Products; in each case, to make, have made, use, sell, have sold, offer for sale, and import Compounds and Products in the Field in the Territory during the Term (collectively, the “License Grant”).
Label: | cuad_affiliate_license-licensee |
7 | YES | {'index': 7, 'text': ' 2.1 License Grant. Subject to the terms and conditions of this Agreement, as of the Execution Date provided that the Initial License Fee as defined in Section 4.1 of this Agreement is paid as of the Execution Date and, IMUN hereby grants, and shall procure that each of its relevant Affiliates shall grant, to Forte (i) an exclusive, royalty-bearing license (or sublicense, including the right to sublicense solely as set forth in Section 2.3 and elsewhere in this Agreement), under the IMUN Patent Rights and the IMUN Know-How to the extent specific to the Compound and the Product; and (ii) a non-exclusive, royalty-bearing (as set forth in Section 4.3) license (or sublicense including the right to sublicense solely as set forth in Section 2.3 and elsewhere in this Agreement), under the IMUN Know-How that is not specific but is related to one or both of the Compounds and/or the Products; in each case, to make, have made, use, sell, have sold, offer for sale, and import Compounds and Products in the Field in the Territory during the Term (collectively, the “License Grant”).', 'document_name': 'License grant clause'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: 2.1 License Grant. Subject to the terms and conditions of this Agreement, as of the Execution Date provided that the Initial License Fee as defined in Section 4.1 of this Agreement is paid as of the Execution Date and, IMUN hereby grants, and shall procure that each of its relevant Affiliates shall grant, to Forte (i) an exclusive, royalty-bearing license (or sublicense, including the right to sublicense solely as set forth in Section 2.3 and elsewhere in this Agreement), under the IMUN Patent Rights and the IMUN Know-How to the extent specific to the Compound and the Product; and (ii) a non-exclusive, royalty-bearing (as set forth in Section 4.3) license (or sublicense including the right to sublicense solely as set forth in Section 2.3 and elsewhere in this Agreement), under the IMUN Know-How that is not specific but is related to one or both of the Compounds and/or the Products; in each case, to make, have made, use, sell, have sold, offer for sale, and import Compounds and Products in the Field in the Territory during the Term (collectively, the “License Grant”).
Label: | cuad_affiliate_license-licensee |
2 | Yes | {'index': '2', 'text': "For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.", 'document_name': 'ArconicRolledProductsCorp_20191217_10-12B_EX-2.7_11923804_EX-2.7_Trademark License Agreement.pdf'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: | cuad_affiliate_license-licensee |
5 | No | {'index': '5', 'text': "Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.", 'document_name': 'PAXMEDICA,INC_07_02_2020-EX-10.12-Master Service Agreement.PDF'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: | cuad_affiliate_license-licensee |
4 | No | {'index': '4', 'text': 'Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.', 'document_name': 'Microgenics Corporation - Collaborative Development and Commercialization Agreement.PDF'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: | cuad_affiliate_license-licensee |
1 | Yes | {'index': '1', 'text': 'Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.', 'document_name': 'INGEVITYCORP_05_16_2016-EX-10.5-INTELLECTUAL PROPERTY AGREEMENT.PDF'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: | cuad_affiliate_license-licensee |
7 | YES | {'index': 7, 'text': ' 2.1 License Grant. Subject to the terms and conditions of this Agreement, as of the Execution Date provided that the Initial License Fee as defined in Section 4.1 of this Agreement is paid as of the Execution Date and, IMUN hereby grants, and shall procure that each of its relevant Affiliates shall grant, to Forte (i) an exclusive, royalty-bearing license (or sublicense, including the right to sublicense solely as set forth in Section 2.3 and elsewhere in this Agreement), under the IMUN Patent Rights and the IMUN Know-How to the extent specific to the Compound and the Product; and (ii) a non-exclusive, royalty-bearing (as set forth in Section 4.3) license (or sublicense including the right to sublicense solely as set forth in Section 2.3 and elsewhere in this Agreement), under the IMUN Know-How that is not specific but is related to one or both of the Compounds and/or the Products; in each case, to make, have made, use, sell, have sold, offer for sale, and import Compounds and Products in the Field in the Territory during the Term (collectively, the “License Grant”).', 'document_name': 'License grant clause'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: 2.1 License Grant. Subject to the terms and conditions of this Agreement, as of the Execution Date provided that the Initial License Fee as defined in Section 4.1 of this Agreement is paid as of the Execution Date and, IMUN hereby grants, and shall procure that each of its relevant Affiliates shall grant, to Forte (i) an exclusive, royalty-bearing license (or sublicense, including the right to sublicense solely as set forth in Section 2.3 and elsewhere in this Agreement), under the IMUN Patent Rights and the IMUN Know-How to the extent specific to the Compound and the Product; and (ii) a non-exclusive, royalty-bearing (as set forth in Section 4.3) license (or sublicense including the right to sublicense solely as set forth in Section 2.3 and elsewhere in this Agreement), under the IMUN Know-How that is not specific but is related to one or both of the Compounds and/or the Products; in each case, to make, have made, use, sell, have sold, offer for sale, and import Compounds and Products in the Field in the Territory during the Term (collectively, the “License Grant”).
Label: | cuad_affiliate_license-licensee |
5 | No | {'index': '5', 'text': "Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.", 'document_name': 'PAXMEDICA,INC_07_02_2020-EX-10.12-Master Service Agreement.PDF'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: | cuad_affiliate_license-licensee |
1 | Yes | {'index': '1', 'text': 'Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.', 'document_name': 'INGEVITYCORP_05_16_2016-EX-10.5-INTELLECTUAL PROPERTY AGREEMENT.PDF'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: | cuad_affiliate_license-licensee |
4 | No | {'index': '4', 'text': 'Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.', 'document_name': 'Microgenics Corporation - Collaborative Development and Commercialization Agreement.PDF'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: | cuad_affiliate_license-licensee |
0 | Yes | {'index': '0', 'text': 'Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.', 'document_name': 'CardlyticsInc_20180112_S-1_EX-10.16_11002987_EX-10.16_Maintenance Agreement1.pdf'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: | cuad_affiliate_license-licensee |
9 | NO | {'index': 9, 'text': ' 1.\tSubject to the other terms and conditions of the License Agreement as herein modified, Licensor amends and restates §4 of its License Modification to grant a non-exclusive license to Licensee to use Licensed Trademarks in connection with medical instruments that are tissue emulsifiers and/or aspirators for use in liposuction. ', 'document_name': 'Licensor Licensee agreement b'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: 1. Subject to the other terms and conditions of the License Agreement as herein modified, Licensor amends and restates §4 of its License Modification to grant a non-exclusive license to Licensee to use Licensed Trademarks in connection with medical instruments that are tissue emulsifiers and/or aspirators for use in liposuction.
Label: | cuad_affiliate_license-licensee |
5 | No | {'index': '5', 'text': "Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.", 'document_name': 'PAXMEDICA,INC_07_02_2020-EX-10.12-Master Service Agreement.PDF'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: | cuad_affiliate_license-licensee |
8 | NO | {'index': 8, 'text': ' 1.\tLicensor hereby grants to the Company, and the Company hereby accepts, subject to the terms and conditions of this Agreement, an exclusive, non-transferable license for the Term and in the Territory to Use the Licensed Intellectual Property solely within the Licensed Field and, where it relates to the development and commercialization of Licensed Products, in accordance with the terms set out in Schedule B to this Agreement, (the “License Grant”). ', 'document_name': 'Licensor Licensee agreement a'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: 1. Licensor hereby grants to the Company, and the Company hereby accepts, subject to the terms and conditions of this Agreement, an exclusive, non-transferable license for the Term and in the Territory to Use the Licensed Intellectual Property solely within the Licensed Field and, where it relates to the development and commercialization of Licensed Products, in accordance with the terms set out in Schedule B to this Agreement, (the “License Grant”).
Label: | cuad_affiliate_license-licensee |
0 | Yes | {'index': '0', 'text': 'Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.', 'document_name': 'CardlyticsInc_20180112_S-1_EX-10.16_11002987_EX-10.16_Maintenance Agreement1.pdf'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: | cuad_affiliate_license-licensee |
10 | NO | {'index': 10, 'text': " License Grant. Subject to the terms and conditions of this Agreement and the due performance by Licensee of Licensee's obligations under this Agreement and in reliance on Licensee's representations and warranties set forth in this Agreement, Licensor hereby grants to Licensee an exclusive license under the Licensed Patent for the Term in the Territory to import, offer to sell, and sell Licensed Product.", 'document_name': 'Licensor Licensee agreement c'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: License Grant. Subject to the terms and conditions of this Agreement and the due performance by Licensee of Licensee's obligations under this Agreement and in reliance on Licensee's representations and warranties set forth in this Agreement, Licensor hereby grants to Licensee an exclusive license under the Licensed Patent for the Term in the Territory to import, offer to sell, and sell Licensed Product.
Label: | cuad_affiliate_license-licensee |
10 | NO | {'index': 10, 'text': " License Grant. Subject to the terms and conditions of this Agreement and the due performance by Licensee of Licensee's obligations under this Agreement and in reliance on Licensee's representations and warranties set forth in this Agreement, Licensor hereby grants to Licensee an exclusive license under the Licensed Patent for the Term in the Territory to import, offer to sell, and sell Licensed Product.", 'document_name': 'Licensor Licensee agreement c'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: License Grant. Subject to the terms and conditions of this Agreement and the due performance by Licensee of Licensee's obligations under this Agreement and in reliance on Licensee's representations and warranties set forth in this Agreement, Licensor hereby grants to Licensee an exclusive license under the Licensed Patent for the Term in the Territory to import, offer to sell, and sell Licensed Product.
Label: | cuad_affiliate_license-licensee |
9 | NO | {'index': 9, 'text': ' 1.\tSubject to the other terms and conditions of the License Agreement as herein modified, Licensor amends and restates §4 of its License Modification to grant a non-exclusive license to Licensee to use Licensed Trademarks in connection with medical instruments that are tissue emulsifiers and/or aspirators for use in liposuction. ', 'document_name': 'Licensor Licensee agreement b'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: 1. Subject to the other terms and conditions of the License Agreement as herein modified, Licensor amends and restates §4 of its License Modification to grant a non-exclusive license to Licensee to use Licensed Trademarks in connection with medical instruments that are tissue emulsifiers and/or aspirators for use in liposuction.
Label: | cuad_affiliate_license-licensee |
2 | Yes | {'index': '2', 'text': "For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.", 'document_name': 'ArconicRolledProductsCorp_20191217_10-12B_EX-2.7_11923804_EX-2.7_Trademark License Agreement.pdf'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: | cuad_affiliate_license-licensee |
6 | YES | {'index': 6, 'text': '2.1.2 CAR Field License Grant. Anthrogenesis hereby grants to Celgene and its Affiliates a non-exclusive, royalty-free, fully-paid up, worldwide, license, with the right to grant sublicenses, under the Anthrogenesis IP to Develop, Manufacture, Commercialize and otherwise fully exploit products and services in the CAR Field. The foregoing license grant shall be non-transferable and non-assignable, except as provided by Section 6.4 of this Agreement.', 'document_name': 'Anthrogenesis IP agreement'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: 2.1.2 CAR Field License Grant. Anthrogenesis hereby grants to Celgene and its Affiliates a non-exclusive, royalty-free, fully-paid up, worldwide, license, with the right to grant sublicenses, under the Anthrogenesis IP to Develop, Manufacture, Commercialize and otherwise fully exploit products and services in the CAR Field. The foregoing license grant shall be non-transferable and non-assignable, except as provided by Section 6.4 of this Agreement.
Label: | cuad_affiliate_license-licensee |
3 | No | {'index': '3', 'text': 'Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.', 'document_name': 'ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement.pdf'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: | cuad_affiliate_license-licensee |
8 | NO | {'index': 8, 'text': ' 1.\tLicensor hereby grants to the Company, and the Company hereby accepts, subject to the terms and conditions of this Agreement, an exclusive, non-transferable license for the Term and in the Territory to Use the Licensed Intellectual Property solely within the Licensed Field and, where it relates to the development and commercialization of Licensed Products, in accordance with the terms set out in Schedule B to this Agreement, (the “License Grant”). ', 'document_name': 'Licensor Licensee agreement a'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: 1. Licensor hereby grants to the Company, and the Company hereby accepts, subject to the terms and conditions of this Agreement, an exclusive, non-transferable license for the Term and in the Territory to Use the Licensed Intellectual Property solely within the Licensed Field and, where it relates to the development and commercialization of Licensed Products, in accordance with the terms set out in Schedule B to this Agreement, (the “License Grant”).
Label: | cuad_affiliate_license-licensee |
2 | Yes | {'index': '2', 'text': "For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.", 'document_name': 'ArconicRolledProductsCorp_20191217_10-12B_EX-2.7_11923804_EX-2.7_Trademark License Agreement.pdf'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: | cuad_affiliate_license-licensee |
4 | No | {'index': '4', 'text': 'Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.', 'document_name': 'Microgenics Corporation - Collaborative Development and Commercialization Agreement.PDF'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: | cuad_affiliate_license-licensee |
2 | Yes | {'index': '2', 'text': "For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.", 'document_name': 'ArconicRolledProductsCorp_20191217_10-12B_EX-2.7_11923804_EX-2.7_Trademark License Agreement.pdf'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: | cuad_affiliate_license-licensee |
6 | YES | {'index': 6, 'text': '2.1.2 CAR Field License Grant. Anthrogenesis hereby grants to Celgene and its Affiliates a non-exclusive, royalty-free, fully-paid up, worldwide, license, with the right to grant sublicenses, under the Anthrogenesis IP to Develop, Manufacture, Commercialize and otherwise fully exploit products and services in the CAR Field. The foregoing license grant shall be non-transferable and non-assignable, except as provided by Section 6.4 of this Agreement.', 'document_name': 'Anthrogenesis IP agreement'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: 2.1.2 CAR Field License Grant. Anthrogenesis hereby grants to Celgene and its Affiliates a non-exclusive, royalty-free, fully-paid up, worldwide, license, with the right to grant sublicenses, under the Anthrogenesis IP to Develop, Manufacture, Commercialize and otherwise fully exploit products and services in the CAR Field. The foregoing license grant shall be non-transferable and non-assignable, except as provided by Section 6.4 of this Agreement.
Label: | cuad_affiliate_license-licensee |
4 | No | {'index': '4', 'text': 'Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.', 'document_name': 'Microgenics Corporation - Collaborative Development and Commercialization Agreement.PDF'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: | cuad_affiliate_license-licensee |
8 | NO | {'index': 8, 'text': ' 1.\tLicensor hereby grants to the Company, and the Company hereby accepts, subject to the terms and conditions of this Agreement, an exclusive, non-transferable license for the Term and in the Territory to Use the Licensed Intellectual Property solely within the Licensed Field and, where it relates to the development and commercialization of Licensed Products, in accordance with the terms set out in Schedule B to this Agreement, (the “License Grant”). ', 'document_name': 'Licensor Licensee agreement a'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: 1. Licensor hereby grants to the Company, and the Company hereby accepts, subject to the terms and conditions of this Agreement, an exclusive, non-transferable license for the Term and in the Territory to Use the Licensed Intellectual Property solely within the Licensed Field and, where it relates to the development and commercialization of Licensed Products, in accordance with the terms set out in Schedule B to this Agreement, (the “License Grant”).
Label: | cuad_affiliate_license-licensee |
6 | YES | {'index': 6, 'text': '2.1.2 CAR Field License Grant. Anthrogenesis hereby grants to Celgene and its Affiliates a non-exclusive, royalty-free, fully-paid up, worldwide, license, with the right to grant sublicenses, under the Anthrogenesis IP to Develop, Manufacture, Commercialize and otherwise fully exploit products and services in the CAR Field. The foregoing license grant shall be non-transferable and non-assignable, except as provided by Section 6.4 of this Agreement.', 'document_name': 'Anthrogenesis IP agreement'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: 2.1.2 CAR Field License Grant. Anthrogenesis hereby grants to Celgene and its Affiliates a non-exclusive, royalty-free, fully-paid up, worldwide, license, with the right to grant sublicenses, under the Anthrogenesis IP to Develop, Manufacture, Commercialize and otherwise fully exploit products and services in the CAR Field. The foregoing license grant shall be non-transferable and non-assignable, except as provided by Section 6.4 of this Agreement.
Label: | cuad_affiliate_license-licensee |
1 | Yes | {'index': '1', 'text': 'Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.', 'document_name': 'INGEVITYCORP_05_16_2016-EX-10.5-INTELLECTUAL PROPERTY AGREEMENT.PDF'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: | cuad_affiliate_license-licensee |
3 | No | {'index': '3', 'text': 'Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.', 'document_name': 'ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement.pdf'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: | cuad_affiliate_license-licensee |
8 | NO | {'index': 8, 'text': ' 1.\tLicensor hereby grants to the Company, and the Company hereby accepts, subject to the terms and conditions of this Agreement, an exclusive, non-transferable license for the Term and in the Territory to Use the Licensed Intellectual Property solely within the Licensed Field and, where it relates to the development and commercialization of Licensed Products, in accordance with the terms set out in Schedule B to this Agreement, (the “License Grant”). ', 'document_name': 'Licensor Licensee agreement a'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: 1. Licensor hereby grants to the Company, and the Company hereby accepts, subject to the terms and conditions of this Agreement, an exclusive, non-transferable license for the Term and in the Territory to Use the Licensed Intellectual Property solely within the Licensed Field and, where it relates to the development and commercialization of Licensed Products, in accordance with the terms set out in Schedule B to this Agreement, (the “License Grant”).
Label: | cuad_affiliate_license-licensee |
1 | Yes | {'index': '1', 'text': 'Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.', 'document_name': 'INGEVITYCORP_05_16_2016-EX-10.5-INTELLECTUAL PROPERTY AGREEMENT.PDF'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: | cuad_affiliate_license-licensee |
9 | NO | {'index': 9, 'text': ' 1.\tSubject to the other terms and conditions of the License Agreement as herein modified, Licensor amends and restates §4 of its License Modification to grant a non-exclusive license to Licensee to use Licensed Trademarks in connection with medical instruments that are tissue emulsifiers and/or aspirators for use in liposuction. ', 'document_name': 'Licensor Licensee agreement b'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: 1. Subject to the other terms and conditions of the License Agreement as herein modified, Licensor amends and restates §4 of its License Modification to grant a non-exclusive license to Licensee to use Licensed Trademarks in connection with medical instruments that are tissue emulsifiers and/or aspirators for use in liposuction.
Label: | cuad_affiliate_license-licensee |
8 | NO | {'index': 8, 'text': ' 1.\tLicensor hereby grants to the Company, and the Company hereby accepts, subject to the terms and conditions of this Agreement, an exclusive, non-transferable license for the Term and in the Territory to Use the Licensed Intellectual Property solely within the Licensed Field and, where it relates to the development and commercialization of Licensed Products, in accordance with the terms set out in Schedule B to this Agreement, (the “License Grant”). ', 'document_name': 'Licensor Licensee agreement a'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: 1. Licensor hereby grants to the Company, and the Company hereby accepts, subject to the terms and conditions of this Agreement, an exclusive, non-transferable license for the Term and in the Territory to Use the Licensed Intellectual Property solely within the Licensed Field and, where it relates to the development and commercialization of Licensed Products, in accordance with the terms set out in Schedule B to this Agreement, (the “License Grant”).
Label: | cuad_affiliate_license-licensee |
9 | NO | {'index': 9, 'text': ' 1.\tSubject to the other terms and conditions of the License Agreement as herein modified, Licensor amends and restates §4 of its License Modification to grant a non-exclusive license to Licensee to use Licensed Trademarks in connection with medical instruments that are tissue emulsifiers and/or aspirators for use in liposuction. ', 'document_name': 'Licensor Licensee agreement b'} | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: Supplier hereby grants Bank of America a nonexclusive, worldwide, irrevocable, perpetual license to: (a) any patents related to or necessary or desirable to use the Software to the extent such patents are now held, licensed to or hereafter acquired by Supplier, for the purpose of allowing Bank of America and its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their rights as set forth in the Agreement), make, have made, enhance, improve and alter the Software (both in Object Code and Source Code form) as necessary to conduct Bank of America business in accordance with the terms and restrictions or this Section; (b) any Copyrights now held, licensed to or hereafter acquired by Supplier in the Software for the purpose of allowing Bank of America and its Affiliates an permitted assigns to install, copy, use, execute, modify, distribute (as necessary or useful for Bank of America and its Affiliates and permitted assigns to enjoy their fights as set forth In the Agreement, produce derivative works from and<omitted>display such Software (both in Object Code and Source Code for ); any (c) other Intellectual Property Rights or Supplier in the Software as are necessary or useful for Bank of America, its Affiliates and permitted assigns to install, copy, use, execute, modify, distribute, enhance, improve and alter and copy the Software (both in Object Code and Source Code form) for the purpose of conducting Bank of America business in accordance with the terms and restrictions of this Section.
Label: Yes
Clause: Subject to the terms and conditions of this Agreement, Parent hereby grants to each individual member of the SpinCo Group, on behalf of itself and the other members of the Parent Group, and shall cause the other members of the Parent Group to grant to each individual member of the SpinCo Group, a non-exclusive, worldwide, perpetual, irrevocable, fully paid-up, royalty-free right and license, solely for use in the SpinCo Field, to (i)<omitted>use, reproduce, distribute, display, perform, make improvements and exploit Intellectual Property owned or controlled by Parent or a member of the Parent Group and currently used in the SpinCo Business, and (ii) make, have made, use, sell, offer to sell and import any goods and services incorporating, embodying or utilizing such Intellectual Property currently used in the SpinCo Business.
Label: Yes
Clause: For avoidance of doubt, to the extent that any of the licenses granted by the terms of this Agreement include any right to sublicense, such right to sublicense shall extend to Licensee's subsidiaries and joint venturers.
Label: Yes
Clause: Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.
Label: No
Clause: Achaogen retains all rights in and to the Achaogen Patents and Achaogen Know-How.
Label: No
Clause: Notwithstanding any other provision of this Agreement, each party's total liability in respect of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party's gross negligence or willful misconduct.
Label: No
Clause: {{text}}
Label: | Does the clause describe a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?
Clause: 1. Subject to the other terms and conditions of the License Agreement as herein modified, Licensor amends and restates §4 of its License Modification to grant a non-exclusive license to Licensee to use Licensed Trademarks in connection with medical instruments that are tissue emulsifiers and/or aspirators for use in liposuction.
Label: | cuad_affiliate_license-licensee |
Subsets and Splits